var title_f24_48_25344="Retinal periphlebitis sarcoid";
var content_f24_48_25344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal periphlebitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph of the fundus shows periphlebitis in a patient with sarcoidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Tolentino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25344=[""].join("\n");
var outline_f24_48_25344=null;
var title_f24_48_25345="Cutaneous changes of Stevens Johnson Syndrome";
var content_f24_48_25345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous changes of Stevens-Johnson Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized eruption of lesions that initially had a target-like appearance but then became confluent, brightly erythematous, and bullous. The patient had extensive mucous membrane involvement and tracheobronchitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 3rd edition, Fitzpatrick TB, Johnson RA, Wolff K, et al (Eds), McGraw-Hill, New York 1997. Copyright &copy; 1997 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25345=[""].join("\n");
var outline_f24_48_25345=null;
var title_f24_48_25346="Lung cancer clubbing";
var content_f24_48_25346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Clubbing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Side and B) top view of nail bed hypertrophy causing a distal enlargement of the fingers in a patient with lung cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Midthun, DE, et al. Clinical presentation of lung cancer. Lung Cancer 1996; :421. Copyright &copy; Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25346=[""].join("\n");
var outline_f24_48_25346=null;
var title_f24_48_25347="Striped fibrosis with CyA";
var content_f24_48_25347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing \"striped fibrosis\" in cyclosporine-induced nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD8AYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3RQFAA6AYrlp5rfXP7UsYleG6tScE9yO4rZ0wS29kI5n3uvTvxmnSW0UU0t4saiV1AYjgsPQ1VNqnJ9+jO6m/ZTut+hzGj3jmO1WZgyyDHmL2I6qfQ1bvrO4e4We1xGVPCt1NM1mFoXkRXSKO6GeV4Eg6YPal029LWo+0swnC84H3veu53f7yB6krv99TW/T+vuNIainmCKePE7LgKo7+1XrW5At1MudwGCAMkVybW5urlrpJ2RwOAe1bdlqMkcAAhUqvB5weKwq0Ul7py18PFRXJ8zQlmL7XjRsHu44P4VjtFLYanI8yh4pgZA5H3T6VsW15FJGGwwIGQCO1VZ9Qt7p2hALIBg5GOvpms6fNFtW06mVJyi3Hl06mVqs6zQRyxshMThiByTWgbhJ4FYgdMhiazPsHlx3Co26N+gxjaKi0VmMUtvKSWjOK6nCLhp0O104yhddP1H3c062ToRmOR8Ej061LpkjzIwSMJbJ93A6n1NQ6lHLLthhXG07qnsma1g2SDDIuDt7iqduTTcqVvZ6bsfeQXaX8chJNu+CGz90d8ircFwCxUx4UH7wrOnvm1CA28HmHHRyMAUNbXFrpOz7RvlzkKP4VrNwukp6MzdO8VGej2/4Jea3t3c3aLiXoxzwaWSMsY3RgFO0uSenrxWHawhm2y3DqOMKDnP19q3b21K2CiEr5YGNigc+/rmiceRpXFUj7OSjzEskkcUWYNxkH6026u2jVJFBO84wRwDVLREknZwzBYV+UZ5INS6zm0srg5DbUJHscVnyJT5XqzP2cVUVPdiPfxvG0oZRuOMg9xTLDMjTFCMM2T7VkaXaNP4bg3N865YMe5z0rS0dQlsAykNn5hW0oRjF2OipTjTUlF7OwzWX8uaB5E+UON3pjvxS3tgn2uIqx+zyAPHnoe+M+1R666vG8bdAM8dj6UraiJtLhtpIWJjAIdTyMVUVLli4lRjPki4+j/wAx1m8+nlnwHibPQcitSynS433MU+1eNykjrjpWR/aUEU8cEsyM0g3KCQCR7dj9KfLb2M7loJPKcDjsc/SonHm1lp5kVIc2s1ZvrY1o5YkuHmbajyHAJHAPrTor3azQXA3SA5Egx8wrITTTKw+0TMy4HGeMj1rMlNw85hugIGBPlsV2kEHjHqDSVGMna5Cw8Ju1zqknitTugdW81+R0ArN18qusWxmkBBHAA6VnxwpbOJL2bcinPXjNMSS13S3Rm8xQc5YY21UKSjLmTuaU6ChPmTvp27jtbVTcQovBCMf5VBDI+M8An9cVW82S8mkmb5d64UdNq06GT7OsaSHIDBTjrk56flXUo8sUmdqhyQUXuilqul2tzJLNNEQzAAlTjNN07SVt1Q2vCH5mLtyTWpqbRQQySylRGgBx6n0rkH8RXqXxn+z/ALjoExnH5VpFuS0O2hGviKfLB6Lu/wADtdoBAzxgU8F4ImCcscnJGM1gabr9relV4jl7gnFb8bIMMGJYDOO1ZSi1ucdalOk+WaPPbSS91HXLqK9uJkijbEqbyFPPSvQ4tIsTYbTYRtaAYbEYP6/jXG+JJFsNYW+feIZV2SNEOVPPPp3rRuPGmlR6eqWss8ny48nbt3N057U6nNJLlO/FwxGJ5JUItRstu/X/AIBz4e40PxfHbafM0sTMFVHbjB7H6c16KJVLsY1GAPmbjIzXP6f4ZY6hDqOrSI98/wC9WBThIx257mt8JFLvVS2xeCB0Y9amcoyObH1qdWUXF3aVm+7E1p0nt7aK6YxxrMrhh2x2+hrO8dRY1jTb+FcGKZIz7hsYrWvoree2tpL6O4drf7qxNnefcVTuYLm+NyNRVYw+3yUQ52Y6E+/Ssqdk0+1zhwslTqKfRXXrfQtW0Rg1BBLKco+772Seauavdm7uIgGYQjnb6msLesQmN1MYrnO750+XI9G9KhNzcX0EqRI8jyAIjBv3aep3Y/Sm6d5KT6AqDc1J9OvT1I9VuU1XXbOwt1JERE87joAO31rsrWzF7YySSuIw+QrY+6PWud0XRotPhkwSZpOZHY8n2HtW6snnabHbqQ2eduPTtUVndJQexOMmnywovSPX8WylPcLYwEW14ZCpw3ycEdPxrJlsEjuoTblUuXPmylR6n3rQmszbSqb1Mw7uI0GMemfXmjX4FtXihjRwzR+YZQeAB2pqaja3UdOSTSi9XfX+uxesWt7m4u5Wi3XNpGAu88Nkctj61h3GqT3EKG4Rd+75cDHHbir3hdvtEpt7kK8qg8g/Me+G9xmsjWLaWPUbiF23tFhi2Ox5xRRUfaNMqjSiq7hLol/SNa0Y6ckMjgF5VL8jgDFa8t00yxSxQs6ugOQAayINUtUFhDeW7SLKcIw/g7V0USxwoEWXAHYYxWVZ63ktTjrytK8lqNSZ7XT0XaGkGBgnNOv7/wAnTPNdcluKiluEt5/JYAJgksB0wOuah1K5gtdFkuG/eQrzg85Pp7VioJtNrdnOqfNJabsparONR0+yjQc3DBvm4KheSakFvFfqGlR0jAADL7d65uyhfUbix1JrkwKm4tCDgbT0A9v511dtqEG8J5yPgfKo/nXTOLpq0TtqwlRXJHdXMe/uDojoJY1ltSwHmqcFc9CR/Wrun3TS3kiGPKgbs9vrmoZ57d5buOeB7uNvlDAEhT6VnaebrTZnjtvMlsj91JFIZfYHuKvl5o7am3s1Up6r3vz/AMmdJeaqtrcQhoSYWOHYVDr1s4Ed5YfOoGSoPGKiXUbOWJ4pEaNmAyJFxVV4xDIfsdyEVuChb5TWUIcrTWj/AAZz06XJJO1mu+zHpqkc5ERR0Y4yCKpXD/Y9TSUcB+GFWkayslxvDS46qQTn2otdPn1WdpJIyiHkMRW65Y3e0Toi4QvLaJtW8UcilwGGP7vBJ/HtTIWgV9rRksTjJ5qjbzNaym2uwRIPulu49qS8mlA/cR7yDxz3rm9m27XOP2TbtfRl+1Ispbm3MYC7TKpx1B61LYR7lk88BnIDKMfw1k293qbusk0MPAIIbjipbma9vDG1vMiOvyEJ/KiVN9WvUJUZXs2td3ci1uyWaaNoflyx3qTgGnXiolnawSTkSLwr5wSfT3qwbeaML9oYM4znjrWZ4stVvI7WK3I81W3g56YrSDu4xubUWpzjBy07kdtPNb6iInJTk7iOAw7H0zWlHGL7Vo7OVi0Ozz5VJ6gH5R/n0rHur+F7SHzg4uUIyhU/PxzUUbXlpcC4Vwtwyk8dEHYfStZU3LVaM6JUZS12drfPuXVtbrw880c5Mti8jPCw58sE5xVefUnim3wOrR49cD8a2/DusNqFg8OtxxxzDseVceoql4gbSorYLbmPef4QMkiohJ8/JUjr+BlSm5VOSrB83dbMy0d7p9zdHbIGOtbNtDHEqAL8xHJPSuWjvJ4LgSxQuY8YxtPH04rfjv1kjBZJY/8AeQ4FbVYvZbHTiKU1ZLYk1bSLa7t0ZURnOQOM7f8ACm2W2Cza1mt/nGNrH5s/4VbivbOWNTEzZXoTkZPeqszHzhOwHl5xkHpWMeZrlkcseZrkmSWs0G54pi4YcAIxxmnSxQMpEin5hyXJbjtyaoRNLJctIsLEOdqsR0HrV6S+tJpPskUrebtwdx4z0xTkmnoVOLjK8b/5GbLpzzK0az/u4zkZOSpqmbL7LP8AMd8Z555BNdAIytissWVuUBX5jncR1/CsaeYYVX+ZmPAXqMVtTm5M6KNSUmyfb5KbjGctjkc4pqYlZQU24bIJFZY1e0STa9wu8dsk4om123S3bbIufQt1PtV8rN/q9V7RK+tTLqGsRWEJPlxsDJjuSeK7waRp1naM80AEflh374A9K5fwRYRxb9U1Fv8ASLuTEa47Zxu/pXZajfR2KjzedyliOuVHtXJiJy5lTgceY1WpxoUm7R/F9TmLuPw5q0OVtNrKOGxg4Ppiq0Wg3OmRCeyulnt2ORFM2Dn0DfnW3IbS93JbwKkcZDBYQAWb0/KpFubEtHZXCzQycugk+Ut64NNTlFWV/R6kwxFaEeRXa6p6mC93BcQDz7cu3KtE2MjHXNUk8F6VLIJ1t2T5gwAY4A9K39WtY7bUIZQnyTfK4x0PYj8K1SsRtmjMTYxhdp7e4qpVbJOPU0+uTpJOi2lLzMRz+8Qw/M+NoOeBTtBjf+zUkuoytwzsWQ9evX8sVrXhgihWGHnkHdXJa54jXS4JQYybgDC8YH1pRbqKyJoxqYn3Ka3OmClVTLYDHqfSoNRe286O3hvIYrlU2eUzkMT1yPU/WsLwn4lg1m2aG4liivUJ+RjgSDsR71oyafb3d+t7LEouEHyMeMD19M0uS0ve6Cq4edCo41dGiw7byVlRWbbj/eqdtwhEcRXyl/hXHymoL8x2m2a4IjgDD7x7n3qO1uYZ5Jhby7+OT7VVrq6FyuUeZLT8C04yESNju4zk1paS0dlpEr4EkkLMG9etYDXYWeNVO4r8uByxNa0IbEu4NA5HI7sOwI71nVh7tmY16b5UnsVXuftaJ50ZDTFjtB5AzToXmnuxFfm3FqMb2Y4bgY/EVDdSz6bJC11B5wXJWSP+orOm1G3nYyXZaRsHy41U4U01Dm+HY2hSc17q08tfuNmTUv7P1STbboIIxtIGd+P73uKpxg3JuppFO27PBPXA4qSGG41C3SSeMoIwF2MMlgO5J6VBqlvexXlo1hghBiSNhww9QaIRjF26kxUYvlXxdfkWtOYz2cUQjG63UhjjuDzUzT3JY4h+XsR3FY0z3dtdkqUWOU7iF6A45FPhkvyGMNwRGTkfuw3H1qnDqVUpW9/SzOs8kNYyQTKuZEwSG5/yKxNc0y4/saS2t3eXedzk4rXtQLq8R942YJKjrn/JqPTbW+s57qO6uBNBIcoD2GeK5YycHe/nY4IVHRnzJ6rWxheGoIP7FVWj8ySP5Tu6g5/TjtU0m1rowWyCORlwWA+6vf8AHtUmpW7Wuo24t2IW5b94g6ZHfFNZ1S61CZFIIJQf8BrqT5nzLqdzlzydRfa1/ErCcaezRKcsBwg9fU0+2mvXIn5kj/jROwpukWUl2pu5B+7DY5Oc1uaW6WN7LbOqrFIMox746iirOMbpK7CtUjC6SvJb/qZ7mJz/AKTbsFYcFgMVA8FuoDWkyjvsf5l6fmK6IQRszKEDxtnB6jGegqnN4dt9u6MsjZ6A5rGNeK3djnhiYL4m0RaRc2UTrDdW8cMzH5WZRhvxroo3UggYGDjFcXtCS3EVwWe1h6u475rFhlmudZ+zJcyi2dA6OXPAGcg89uPzoqYZVHe46mDjWblzW/E7PxG2lyqEu7yCC4H3GL8isey8uRFWLUoAhJ+9nHH19a5hdMuYJ5479re7gkAYII9xJ7deldbp+nxWahDDHtI+X29sVryKlDl5rm3s40KfKpN9ths91LG4jRluw3B8lTgfjSWEhgEmbWYh++e9XJrlIcIqNsb5sLjimtdTLGENvId/3c1N7q1iL3jbl/Eh+2T3CoJXECA4yQd31pke2OfAYEtkCQjg+n0qxNLPHEDJAFU9AxpsapcI3ybCefemmkttATSW1kWNMs4LmB3uYvMZWKqT2qneW6xXDwRZ2r8x47e1SafePpkpiZWdDycnr71lapPf/wBsw3CuBE4KlcdCcYohGfO9dOg6cJuo9dOgrR+fMyom7byxAx3rd05UtImeKKFWbqSvP1qMBLW3GFAx1xUemR3F/I5WRkUD7rD+tFSXPHXRIVWfPF30iirJqby6o1rMDvbHO3p6Utxcot79lM37wdQD19q27q0WO3E0iJ5y8Z9q5Y6WJNaS9inzIxwEPTOMZzSpyhPVaJfmTSnCeqWiNlLNZY2yix5GeBioZZXjEUNzGDCvAdF4/GrkzzweVCqBp3HJHTnjrSXojhh2XBLkrlgBnFSpO+pMZu6vqMspUimlkmcCNVL4A44rP0O10vUdSur62jdXXgtnCnNJZOPtphd1ZQnGec8cH60+7nh0ixdjsVH5YDHLew96txabUXqzV05czjB6uxD4i1NbKAhSJHb93DCo5/Csm28NzajIbjUZ/LCgYtVchh7lqu+GtOu7jVG1jUIiqFAYVc/dHYj3rUu7oReIIliJJZD5ikA9xV83J7kNzolV+r/uqO/V+fb/AIPcanh/TbaxYTRIUVdwI6AelcxJ4asZdQ36aymGQfLkHj1HtXoLXEcUJe4CCNiRtPcd6gjhsNm6zi2HOCMHg5ycCsqeInG7d/0Oejj69Jt3ev3Gdb6dHDfWryTsVjQYiVByw6fhVfxsJGjjucHCp0x3rfJiikBCDf0Uk8mue8SiRT5Tn5bqTCjPOPXFFKTnUTZGGftK8ZSMXwtqjW9zNDLOnmXCb4nxgZ6EfWtrWbKZr7Rru4w80MgDkdOe5qjd2SGbyZ4Q0aNnjhlPY1Zntrp4v3F3MD2XeSDXRJJyU0ehUlCVRVYaX3+635Gl4muI3ngijcGTO5VXnbjqTT9Nn3SRZf5pIzuJHANY9pBPbznfFvkZTucnJ+hqRJb1Uu0jjZjKAsbDAEYxz+NZumlDlRyzpRjTUIu/mXVguYzCt28JAJIaM8EeteeeN9Mmj8thMZjcSYiiIOQB/OvQIwbe2ijwW3DDOW6e9YBRpfFlyJhua0s98I7ZLYzWlOVnc7MvqulU9r/Km/X+mzkrjwhqlvZrdLCFdfnG0/MvfNdd4c1+bXbOWFoTHd2iKrkH7/vWtpstzcW8wxllP3GOSBjnNY8dgNL8WWlzbnZDextFKqngSKM05S5vi3R0zxn1yEo1kuZaxf4tfcQ+L9Quc2FrMALdgScjB3A8c/Squl6itpdxluccN9DXTeIbWK600oyFmUbxkdx6GuLu4VjUSlSQwxxWtK0oWLwbp1aKp2tudpc2k73CT2JCueTkfrWg9/IsqG8QNKqjcUPAP41keHbw3GiZl3O0RKkg84FX7aSO7mLxhjg4DSD+Vc0462fQ8qrBpuM18Oh0P2iFiquVBIDAHnrVecbrnZDBHlR1AH61Sfy5CQvmbxgbj0NY91cy2M8NvE4muZAcIpwze7HsBXPCj2OSlhuZ2i9TpIEQ2jtJcBUUnMf8xVYW7XN7vjkQoRgKzcqKwHsb27zLNqDRSqMhIUG36ZPWsyHTL6CNpba/ud+4FvMIII9RWsaS197U66eFjr+8V/RnR/2DJGMRTKYurpI2ST6CmrpiBR5U7Ip527yMGsjQdVmur2Syvgi3Cnh1HBx1rontWXaFnUfKMg+tW+aDtJhVVWhLknIp2F+UJLHYQOfeibxI1uxLxGUL0wcZqreW20IyqRyyuAOM5qnFZG4yJMeVnOfb0rX2VOXvM1VGjP35rQ2tMvpLy6N/cogGz91HnlR/jTA5+wXLuW3szk8dcn/69QKc25t4VIaMd/1xTtLdrmxnhlAEm7A4/wA+lQ4paryM5QSvJKyVvuL3hK9V4WtZQMA4UjpWk8DpI9vLtPzb0f0rFtI4f7StbfzdpUkvs4zjpXUQxYg/eNvwxIDjJxXLiGoz5l1OHFNQqcy6kUUpZ1VFLA4yo42j/CrshIbrwDkZqBytqjyBRnHAUVDZXbXjuHAzngAYIFcrXN7y2OJxcveS0RkXIV724tZFcF8tnHBFU4tLt5NUtbZmYRFHLENgkgDAq/r7vDqtqqOSrqQVP55zSWgDeILEScny5CufXA/+vXYpNQ5l2PShKUYc6drxf5MzFtPs3iGS0J8yNo8r1yPx/CtZ4PLAdS5IGPmaoruIf8JO8iDAjiAwOgqxK0sxMKAFV+Y45NEpN8r8gqVHPlfkrkEVuxuVD4MbgYwa0WiMbtFICc4Ckc4H1quk6JiNl8pxnBpfNlkdnDbSByW/ixUS5pMwnzSepYlhDgQMWfI5JP61n3VsbUpIJCSWC47VZ80oHaR/32QCPanzKz2zvIuVYZXHYgUotxfkKDlB+Rk3H75kZFcvHnzFPPHciubkjuJvEEUgjYw7lCvuJAA68fl+VdQ925iJjQnPB9ffNU9DVXuWnlUmNThFA6HHJrrhLli20d9OThBtrY05CzNDDEBI7nHPp3NdBbwx2sWFUKOM4rmNOus69gnEKnAx6n1rrM54x8uM57VwYm8bRPLxl42j8ylqsyrZsfvbsfSsy2ig2IdoyH4bacgVYlnkmgZVVAqNgE9+aRJikkggi3EAEDrzTgnGNiqacIcohYSQXAwGxkr61Rh+zXiKxlwRjkEg1pzyLNatdKrJgEEoMFqytOEMasZvmkJyeTkHtWlP4WzWn8LfU53xLeppdzNLhmYkKgHc44qv5japq9hFO22IqJGT34rWnjhuC9xLEsimYsqt6Yx/Ss3W4pbeaDULYBjG2GCf3a9CDVkup7GHd2o9bWv52OyvGmj2m3GUyF5z0xWNc4s7trnCNNjaoz90ev51NJrUl59iMDJ9kIHmcjr3zWXPfJd3IKyqsUcoVSx4Nc1GnJaSRw4ejNO0l6myylrZVvsg7yQyr95SM1ZuCRpgm01y6uRh164zzisVJp8PLq99AIFO5U3ZYHtjHGPaoJNanmtvs2hxDyY8nexxnPWh0pNq3/AFHD1KjTjt17F43sEFvHc6nKPtERwEB5Y54NU4JJdV1RbuYFRGNscZH3fUnPfpVPRFuv7Vd9TjEojG6Lj5Qx7+9asarCsj7wZmOWyfzrVxUW7bnS4RpXUdX39exPJKLu5kYkF1+XgcUK0sk6wiJVQDcHB7jtSxRwDcYY9qN175Nc/421WTTNIAhYrdykKhHPHeoSu+VEUaLrVFSh10KviXxZ/ZV+lvAqTMBmTB+6M8D61o2fiVNTtkGn29xPIQNyrEQEPoWPFZfhPw3ahftOph7i6lwQGGQK62G3leGVII/KtU4O35Rn1q5uC0tsdmKeEppU4Ru47u9k/l/wAMUo7iK+BQb4bhB80L9R/iPes7VVbT7221CKIzOgMcoU53REenfmk1O6+wC3nwAbeQq5GSdjHHOfpmuksbK21e2mtbpisikMjr1x2I/wAKUpKC5nsc7qKhFVbe67pr8H+hR0rVrC4V3tLiKMspVwxCn8Qazbq+i1PVLSG0PmQ2jmaWRDxuxgAHv1JNdAnhHT4Yp7i8EV1MRy5jArKZFgs53toliVUJRVAGR61NOVOTbiTRq0JScqV29tfP8x97eIscallUEgBnOPwGawtWsZxIzWflmEncctwBXPQaRJf2Rv8AUbpw7PtiTr+Jro/DWr2qslnqJWIxj5TJ0bsOa6Lci06HpOgsMm6MuZrdW/q5ueH4EtbCGIEjeTltvc+tWNTuRp0yRzoREejjpms/QNTnuzcGZABFIYSBgq2OhGKvak8Fxsi1KRPLGTGo4NYST59Ty5XlWvPVPcWK/tpI96XC7Bglh2rE0G9tbzxPq90sqtFFEke7OenXFcL4xsmttb8uxuJVtJcBTuIxnt7im6NfpogaKdcqRh4wcFga0VO97HuQyqPsJTpSu5LRfNP/AIB65aC3a83sz7W4cAHJ/Cqt/qVvZzsFhkKt0Ruw6ZrCt/FmhRaSI7OeSORsblkUluO2f8Kgn8S6fPanyoJ72ZSSiohOwe5+tZqDb12PJWAxDesH21MTxhqDQeII7mzymxhjaeTkCu10PW4rrTYXuifPA2vz0NeWxQX+uaviCFywbdjGNv510tto+oxq6tC+4OckDqa6OWMlZnu4zB0fYwpTklJL5na7d1q5BZpUO45OBjvio1cGJFHHzZznk1amKxwSl23ZX8T24qpGgFtGww8Xt1rOLufPxd1fzIoocayG3FlZOQOxx/8Aqq9Zxco2f9YzxMM8g9Qf50yzPkl2QbpipIDcDHuat26Qy6Q0rOiXO/eE7Kw7fjUTkRUnbT0RRmsZLSdJ4nDqo27j8uK6exl3QRhJUdBjkn17CqMYhntxLKyhCPm3cnP0o0S5itIWsZVMYLlo3b+IVz1W5x21RyVm6kLW1X9fgbMyeYSrHKDoKbAY7ckIoDDnA71bSSFpWjUqXUDI64FUbpY7MSSRj5uwJ7+lccXf3Tz4Pm9xmJ4kZ5WjVcickcj+ED39arX87Whsb1M+bFKFYnuG+Uj9a1ZXMsT3DwgyYz9KwdfvFuoYIXBUBg7f7q130tbRtoethlzcsLaLf9TTdn827ccHIJYdhT5fMa182JysqHt39jWTpt+15D5+NsErbMg+/H+fetaWLMRVGVmlILYOOKJLlaTJlHlaTLDQtLAkyqwYjJLjIHrU7TefDtkU7lX5Sg61ZecSQ+SuFK/KVJ4NUrdiBgo2ANrcVzpuSuzkTcldrYatqIcTGRpBKMbCcbT1zVq6P/Es8tQMDBPNJYiPEqzOAUb5CT261MbVLhWkifnpvHOcVMpa+90IlP3lzdDChIw+QD85/nVTTosQyTK5QpIw46GrmnKHlwRw0p69xmoNOlRLeUFA+ZHYL6812XtdI9G7Skl5HQeG1RtJjfClmJLHHJOe9O1OQxSRLHn1IX+tS6VLB9hQxbI16kDgA1DAUMk0jAzoxwDjJGP6VwPWpKTPLetWUminNaPFLGMOqsdwUHP4GooriWOUorONxAcY7e1XPPluraWRwuIgSExz+dQGAyvDLhypGSF7Gtk9LTOiMtLTJvENykOnpFE2wScKw6ACudgtZIYg0gA85wjBTnOTyf8APrV3WZ/OYQIHZgON3H6UydilpAXzlXU/lW1GPJBLudFCDpwS7j763MG+KFSv90HrUNtm4Q+dHl8ZYlcZpNXv421OG0tizzSJuZv7oA7/AJVJKzGMJkupwQc4wDVxvyq+5cG3FX3OX1fS5Ld5WtCyo5LbU7GqY0SS8hjW4lljaMZABwVP1rrrltyqVzjoTnrWRf6hBZXFtDOxDTvtAUZYjv8A0rphNtWPSpYupypLfuVLbSIx5W+WR8dUkO7n19q2xF5MAZUxF6KOn1p0Xllg8YbB6AjkjHU1MufKMZUPGfQ4qJybMKtaU37wiKRKrlsjGCfpSRx7ZEVRkEli3fJqSDMb/MCecYPNU7nXdMt7p4J7qKJ0HIfC1m79DGMZzdoK/oSWNxcTT3Akh8sK20Zbr71Q1G2W+8Q2sc4EkVpCZdhH3mJx/hVdPF2ki/SCKVmWUgb8YVat6tNJZ3kOpwRiaMKYmCjOVPOfwNWk0+x0xpVaVTWPK2nbp0NaF3uIpmWJYXU4DYxuA9qvw3DW1g9u6mR2xuYVxFr4pSG6L3any8kbipBNRXHis/2gZrOG8ljY/KDHweOmazdCT0aMnl1eT5XHT+upe8a3KmwW0Eal3ALMByAO2atWEht1gEs7RyFRy56DA4qDTdLuNTY6jqqss5YbYgOFA/nSazBb6l4jWIvss4CFYZPzvn7v+NapxS5PvOhezUVQvtdt76jrzxCJLs2kUzCEkKz5wpP1rRDPLG0OFy6Nn2yOKgW3DxXUN5b28kSg7Y41xt9MYrO0u6uEvZIOZI48BZG64PQE/hSSi1aKM1GE4/u1a34+ZV0NSAkU7RxpG5Lb8DGKsXGm22rX2y7jhkiQ/KUO3C9RV3UtPhmizcLibPDoev1rjbK31azmmlMRMKt1J7eoA61dubVHXSh7ZyrU58sv62Zet55fCt9dW7rJLbEhl9AfXNU44dQ8R3ZkaXYYyBknGB6itj7Fdayq/aF8q3bHzE5J9PpWzp8VvpIAgt1nB4YMf4unWm5cqv1N54qNJOSSdV9f60K2o+GrPVUgWSWSOSFcZTofeq48DaeLeZXLzSN0kbgg/WtxLiC5uRErCKdACEVsjFWJJ5Fu0hMhffyBjpWPPJ7M81YzEwSjCbS3OUh+Htj5ALNOz5P8QGa29KtLbRofs1vGR9eSTWvJLLDbkyAsvQcY/OsKO+gfXYxcnbFkAnsKcXKSd9hvE4jFJqrJyS1NK2FvBE83l+XO4y/GC1RieRyWIZATxyRketX/ABTqdpBZwR2qo0hOQ390Dr9ay4We5jEyxthufmYg1FNuS5mjmpXnH2kla/cpXBSaYMkrPJJxk9MHNP128istE3WwO+NgreWcH3z+nNZlro2r3txGIJSkZXAbjGPX61oW3g+aSfyry6llgyC4z972reThHeWx3y9hTceeotNbFGzv9Z1aEW9tGhPbYuSB6kngVrQaXqkKgX8tuhQffLElh6YFamofY2H9maWDAIWCbkOMtjp71dGlTzWcEGoSFpQM5yecdP8AJrCVeyT2T+84auPT+GKin5amS8N3aSFJ4U+zSqCCjZAPqD/jVs2/n6bIu4N5bfKSec1syR+TbDJ81QoUegFY1zbfZ2WeFvLRmAJP8J6A47jtWcanP6nPCt7XyZPp149qFSWQef8AxHH6ZqCeW8u0WCcN5iz79+OAvaqgJEvmSeXIDJyM/dYH9KvPNdMT5WxSOuPmA/GqcbPmS1KcOWXMkrhc3ogaUSnaEbGc/e+lczq++9jcRzBJZeOPmKj0A9a6WHToR+8un8+Q9Wfp+AqeVUQr5aBRjqOKcJxg9C6VaFJ+6rsxtI0trbTILUylY0AIjGMZHqfWrdvBItwD8ryYwB1zn+VXHkJAWNcyYxtHcVoaNavC01zdKF2jAB9upqZ1Wk5MyqV3GLk/uJXWO2hVJVJlHAb3xSadPIkMqEFwq5HHT1zVSe7eW4Z3x5WcKAeadeahZWUMfmXiRNMRGFP8THtXM4u1pdTj9nJrlau2MBWW4EZfMbEkqK0op44kligGURCwzVeztY4ZEmuE+YH5MjJBI5qPV5I7KxkdE/eyfIOOKTtOXKglapJQRR0X5WSSR+ADISfYE1nadbsghklfEZYSv9OpFXbl2isEiDZaQhOmOvWmwxguYXOS4IReTXX3l3O5PSUu/wCn/DnRWYhns8whij8gEYH1qOCaOzMkcwIcnqBmr9uFW2jVOFVQBxjtWIEN3d7pG8vJyTjjj/PeuGFpOV9jy4Wm5X2EtN20pGDsL/N6gVbiuRHdbGkRVA+4etWW2Wtq8rtgIDz6iuZgkkluGuTlQwwB6itYx9rd9DeEfb8zexekjeS7lJ+bOdntUGqRPFYFZV5JCr7k9Kz5tS1GK4kMdtiNThWPeoF0y/13Yb2+MSgghU7j0HvXSoONpSaSR2xpOFpzkkl95e8tUiYqQTggt0yPUmqZ1C2tUBuJolRD8rM3WsnxrePY6cLZZCDJkD1IBrnNF8KtqNr9qvLnygeEDnkmt4wTjeTPTw+Dpype2rztFvtuegxhZ4kngKtE+drK2QT9awb6b7LfQzMuG8zbtdScD1BrMSx1DwrqFrJcTmTTppNsip91Se+O3auiurK3vLlZ5NzsONhfKD3xTSSd73RnUpqi7wlzRez/AELcMgbk/LvG7cDj3pfNj8l8OGcDkg9MH1rlb3VNRvdek0zRUgKwAF3k7/lXM69FrujvM00/mJcgo+w5UZ7e1LlR00ct9q0pTUW7NLqdhP4x0izLgzPLIvAEa5z7Z6Vk6H4ffUJH1G4iWSW5csscnJQZ4GD3xXKeF7OKfVLf7U22MMM5717hocVtZ3bzOTjGFPX+VTOThHmtqbZkoZbFwoX5pLV/ojAufCVqQubeJGK84XH4im+G7eaKxksFO97edoiDzuU8j6cV0us6gFBnjjbag4B461y/h7VHgu576RVZZJc7egwBjNTCVScG2eXSrV61GXNrs16/8Mal2tqkAtp4AcDGGXjP40+12+SphEeAAFwMVdutYsbqdRKYg2N+GPOKvWltY3bAREA852+lZuo4x95M5JVXCHvxaKZljgtpWgkaWSQZwRjYMdK5XSoFu4HuXnCATncuBnPHetm+8y01AwGINCW4kPX6emO1c5rdtNpVy09mkrW05JmiAzsYdx7EGtaaVtHudWGpqUXFPWVmvO3Q7O5t44XU28iuWB3MB+VcZHqif8JlqNq7gKwQKp4ywHOKUeLraK1iS1ZSQnLMK46ZpNQ1b7Zaqd4bg5zk1dKk1uejgMvmlP2+mlrvvf8A4B6gwJym0CTAwR0P1rOeS5W7tYjEpgDFJFPU+/vRpl+LsXEgwPKPlOAeMjrWvMRLbM0OcjBPrxSem550k4PlZWspI72/NsmbaPJWONBwcetR3UsSrNYXELNI3AMYxuGetS6HJvnfy1UTDkHGTjHNaOoRDJMYInOF3HqB6fjWcnyy5WROShU5WtDnpmfSVhuPsGG4QNnnFa+iyPBZS39wMTT5CBjyi9quX1kbnTVEqtsVgN30xVA3n268mtfI2xpIYkfPVgMnjt1pSnzomVWNSFrddfQs6lIl9pEbqwZlQqV6ZOfvCuZtbd7y7kEa7/L6jPLVa1VZbMMSAip83BJzzxUug20ptZZbaRYp5SMHPJHtVwXJC50U0qNGUovfYvahYW8+mQxSr+8iUbyOOR2FZCz6vc5eFHjUHbtI6Y9ORxjFdRELhYcXREko/i6kDPGT3NSPaznawQ4YZ4rONTl3OJVnazZSvHijv7OCCRodjCOTaucHqvv+NX7m8WG7Fs8p8yUiMEjgEjj9Klu4bFr6OYrm7j6Pjj2BqzHFYJftNJHCbtVyxOCy1hKasm09jklU0TauLY6RDZIJG2yShslz1NX1TzW3Sr06e9U21SxMDSGYCNDzjnrSDXbLC7pgAxwpP8X0rnkqs3dp3OaUa09Wm2X2hTnJOKypPKvLO4jjkEu8Fc1JJqlvPK8cTbivBHrWfeSpp+nzSRoBI67Vx1yegxV06clvuaUaU7pPfSxk2cEd4IzDGdwRfMIPU+lXhLJAfs+0R/3d3TNM0yI2NikYbDY+fPGe9Ptn+3MWKkxJwpI5Jrsk7t32PRqO7f8AKi5a6YGLm7kDFs4UHhT7VLLpxjt1dpCegwTVSfzYol89CAWGMHrz3rW80XYTCny15+auecpqzvocdSVRNSvoQ+QtlE8wOXxwT2qKCI3a5ikLr/EpY4NLqdyUKxoFkRiN3NaGmDbb5CKik5wPpWcpOMOZ7szlKUYc73Zi3VqbbAcbffOQax/EXhCfXn02e0ulWOBxKyu7YfB5Ugdf6VpavqitJI7KGCZCqD1waNH1KaGOeKFA4DZXPat3GpyX6nXF1oRU46SNi4fzX8lZCAvykdRkViahvOpRRFsqg3Kp71ct7plmU3KDfJn7o7+9VbyQvqdo3Q4KccdKKUXGVvIijBwlbyYy8LT3llEBsO8vk+wq1bW4/tqJppACqn8argGXXFAwQkJOc+9OtpEXV8TNtGeHNW72suxrK/LZdvzOjuTJGEdZBsyMggVH5kU0RdkIJHzYpby1SaP5nI44HrUMWxzkE4AwV7VwRStc8yKTjcp6uzT2siwBwIjjCjIFVYbd7WwE9y4Xjjcc9a2nSVGLAKEcBW3d6wb+38y5/fArDEeRuyK6qMrrl6HXQlzLk6DWm3jNw+C2MDGetc1dWWo32qWkdrNsii7g4xzk/nmui1Hyo7drhTtTZwqnI9ua5vR5s3UF/fO0KRudyDuOcCuyl8LaPRoaRc4/0yLxvp0aR2d07SMVkCSf3evX25rZk0kSQ2skJjG2LaM9gccj3puuTJdwXFsqMLSRSdwx06j+nNcz4c8Roqpa30gSWNwqO+cEA9PyqlzuCOtU62Iwytry9PJnS3VjJJIY72KT7OY9sm7+L3FcqNXu9Ma5tWxKbc4DsOSvauul8S2ks4ikuUkgyVzuyQMdfpXIlf7R8T3N3Cp+yEFSTyDxxVUuZ/EjXARlaSrx0tf5/wCbLPw4YXGoarM2d0jA5Y1va+kaSpJLESHOHJBP04rkPIvdDv3m04GW2ZvmCHnHWr2peKNUmkB06ylNvjDM6/M3riiUHz8yNcThamIxHtaLVml1tbQxvGGkPaXNlLaAwLckDk4CtXR6NH4i020c/aLK8iUAKu47j9D/AI1QuribXo9OtVtZ0jWYNK0i4Ckda6qNotPjWBF2RLlef4jmiV7WZeJxFRUYUaiTet769dDDjvtWljmtmtJIVcHdJIwyvrWdcbtVhWw012W2thunnz1PoPWuo1Fi0BXKshV1OD6LnH5VieALWObSrhM4eKdi6uOvpRzJK9jKlVjGlKrGKTjb8eruGmeG9LvrWZke4eZFwWZ85PbFUdN1LUfD2tQWl1K5tXbYrN2z0r0nStMSaANGq24djkIuOPauT8d6DIVvlQq22Pz1cnBGB/8AWrKNaMpODZhhswVaq6Fd8yffp0ujro5k1C0ZHPzuMfTNYen6VrUayQ3UaSwoTtk3Y3Dt+lZvg/VhrGkiUBluoCEkI6k44IrutH1JLm0zdyKjodpAPB96xm5UU3BXR52IhVwTlBLZ6rt6Hl/iLwpFIshggeCfOSR905/lUXhjw3PY3H2y4ly6j5VHSvWb65tVdCNmM/M2e2K5m8vrGW+kgtZ1LAHdxwfxrWnXlNao7qGb4irS9k1ozM0Sxt9Pgu0hUgTSeaQxzhj1rXd4kRkUAPsI2/hWejJEcsSW4C88mor6/tEuQ02UkC4OTkVo1zMzlTc5FfR9cj0+8Msyjc52DdwM11OpgSra3dsjHzhhgD90noa4O/txId8Y3wueGU1pQ3d7aWUSGRyCvy454pTpKTU09TbEYVTlGpTdnsb39oaha+emoPutydq5XjHYiotRkg+xme1VBcyrxIvDH/I71h38s99bxrdiUuhzhTiss+IooYJYIoneW3BLIRy3sD+IqVRMY4NRipPe+vY1bsznSttydzuQCM5x+NdDD5VrplvOqrvCAAnoPU1mWpTUNDilWIp5i5O48g+h/GmWd39jlWPVWPkEYjxyA1VNXVl0HOPtKfLHo9u509mVfypRny2AbAqa71G4jl226nYB3OKyLvUrFYkWCZWPVUU5yPSqkV1qMkSGLT5GQDAZnUEj6Vz+y5nzSX3nCsM5e9JffoXLHUNkoW9iKy5GHI4IH9aIoLeHUprsXiSIWY7ehGeuT3FYTx6zaQrcTst3Bk70Iw3PpTYNX0+dZAIxbzA9H6itvZ31j+B2SwfP70NV5f1dHQmGwggxbyqqO/zgtnAx1FU7xNIYxNcSskKY6KSM+uR3os5IIkaYSQ7GHGw4qGb7FcFw7suRkbm6/Q0lG27ZlGir2lexJFqWlW0m62aYMxxvckoM9wPfFWb5pXvrQTyF1ZzweMEDIrLs7W0ClET7Q4zsdj8ygcjjpwa1CBcarEilS0WJJWHTJHT602lF3G4RhJtLvuWbi2uLnEceNp5Y9a2bWBYooAibSvDAfzqncXYsQpckKeBgZqZ5JDbm4YZMjkY/2RXJNykkuh59RznFLZFjUJYZIhGFDvnJA7Ad6riWURlYMSRIMZPBpbm3MdtFMFEZPBGfWqgWVEfa37tDnrw1TCK5dCKcY8tky7bR+dATwN3qM4rQs4lihZVYliOSxqjpiu+mSyLwWJZMLg/kaLR2uIOd4AG0gnkms5rmvroZ1E5XV9Eznp7cS3Ujsdg3Ybaf6VmlL238RtNHcrHZRxBzGy8yDOCPqOtbd9ZQwzyPNN5ZI3DZ2P8AWsnUvNktrMKxSZpAAWGNynOf6V6EGpLTY9ihJPbZq2qN6+gCeTNEyyxsPMT/AGh6Vn3RaB5Lq5cRLjIAOQPanQxXcFisMM58tRmMbQdpzjHsKhubfzLZSwaS5ByspOckdB6AVMFbRsypx5XZu/QdpMjz3N1Kcg/Lge3PFaOlKLl7qW6cGBDgZGOlZPhxmkLO4ZWZfmBA4Pp/Ort3aIodpJGS2HzMo6UVFq43sKsk5ON7bG4l8s37qDiHpu9fYU6R4rG2LsMhASPWsnTl83iDOwdM8cUmpSTQMgk2iNsglyQAMdK5nSXNyo43Qjz8iZJrGqvPYRwxjbcOAzAc1RggkWzw7nLHdu9DV6yhtXs4XjVkZhhg3UetYfiLUJI0EUDAAffOccf0roppfBBHXh4KT9lTVtSvdssnnBJFwSGlkzheBxWNLqttezxwR29zNFG5YvEudxxgVk3WozakyaZEixwtICZP4mHufSu40hrSBFigRV8sGPcq9fX611NciPXrUo4WCVRXb2X6v/IrLqCxwAXNhcQQbNhZ1yoHv6VnSadpmlwyXwtftBddwBOV5Pb2roNRge4CrGBNFzkZ29f8KyPD1w1rqb6NcxiaMn5QOcDuv61ClpdHNTqNwk6WjWrV91/wAs49O1C3hnGnxDdkYC9PWrH2e3gMcpj8mGI+YFzhc+ue9S3t/p9vcS2tmQ6xnDpg5QDt/Ssbxtf741MmI432rFCvOF6kn3NOLcmklox4fnrzjDWz/rYz9R1eSWYPblobEsyq6jLPjqRmtGbzdEshc/bZZBgSBZACCvv6H6VupZ2kmmwJFErQhQyACpbu3trqwaG7jDRFNrE9gaTqbWRTxS5lHl92+3X/AIcqWV7HdBJ4TGVBDBlOcZ7VYCpPqaSXSmSL7zk9WJ9q5KDwhqVleOuj6gqWkmGUsCWGOnFX7HwvfiKYXOsSszE4CdB9c0ny73NKtHDq8oVVb0d9ToL2G1WZfsysEbna4+6fbNcrosv9h+LLyC6Zkt747onb7pPof5Va8NSXMg1GC8mVltJQm9h83PTPtW3fWEVzG8csayA8DcP1o291slNYdyo1HdNWf4NMu2OvlJHsISjupOwucYxXO+Lbm8vrsafazbru4XE8ijiJKr2Xh4W1+qJrJV5eI1BBYZ/2jW7JpljYIbRr82803Pyrl2PuTzWfLCErrcwgqGGqc8Xd+j+9/wCS6mV4d0waLazQW7OYj87zPxk9MVqXeCtqLSb93LlWcHOQKo6jYrb6bPaWd00kknVmPC5+nTrWq+lR6Poumxx3Hnyox3uR97PfHpmm2tNdyatZzmpyesv8upmuywXSRfvJBJ/EzZAFV5LSHzZGhRIy37ySQDoKm1K3muXgW2wBuBJ6exq7o1hHJJeWt1u2OrRk46en41bfLG5tKahDnvqENnbQRRypIZRKdofOMe31z61DeaF9v0lXuFKzyBgyZ7Doa3Leyh0/T4rdG83YxdncYyT7VYhcSn7uXPGSeBWHtXujz/rVS/OmefaVH/ZjT2skjySMPk8wfmDVx7hzEpxtYEjHtVrXBYXGrW6I7LKW2EsMZxxWxpPh2Bp5Dc73ROFGe9byqpLnkejLEUoQVSS/rYo6bavcWpm8slyNvPHFUpdPgs7qZvsyFpcAnnJA569q7XVb+10WxHmMqnA2KTj8647VpReFVkleJWO4EcH1rCFWU9dkcuHqzrttq0WT215C00sZRIElGREpJx7/AFrL1HxBYiVIZWB8sEPhNwH/ANeuM1aae8maaK4cDzCiqOwHHXvWjpeiE6X9oupjsnPyqBy2O59AK6VBJJs9tZfQoRVSrL5HY6TJp9xEtxbmFIt3TGD+VaNzqRWYrG6qq8YHSvNrvS5dM8mWCVjA7dK6+wv0ntUeTliP7ue1KVNPXc5cTg4K1WD5ov8AAsQpAulw2dormO2JQK77myeQdx7D1qzrFvFb6bbyPb280wwHZhx9eOatgWl5ZxzSxiONTgBRjJz0qWOBZzvjJxEeUP8AIj8qz5rM8eMnDVOxmy6Dpk3lTmIxQSoCAG6Gqr+GFklH2ORxb4z8zd63bqPzhH5riOQKybducofb8KkuklVI1hUmMDscc9iaSqSXU2jjK0Ptfqc1e6VdWULyLzIi7twPFaGjgXFr56gYkbdleDmtSaaVY5BMFeJELMOoJxVDw2VOmjopznaO2RkVTm3G7NJV51KTct00a+n2sF5er9pdpBHwEzgA++K27q2Vk8ofKp5G3sKxNE+ypNclc/aC2Cuef/1VryNIISmVG44HrzXDW5ufc8jEc3tEk9EZlzOikRs5ZR8qoW/rU2n25uj8jN5OMMCOh9qz9V0qWQ2063LKkf3kCcMCMYNa3hiNobaaNizESZyf5fhV1Go0+aLLquMaXNB6k+qajBpkUUWCWf5VUdh6msWS9vWVljWFI+gBHOKgvFM+s3E0h37GKqc9B7VU1A3XntbWjP8AKq7nK9SevPoBWlKjGKXc2oYeCSXXdti388MKbryXcQNqxrycmshLyXU9YgtXHliHhfMb7px1J9a0LbRk3eZfSmVs5wOn4+taaQ2mw7YYwT0KgYrfmjHbU7PaU6atHV9+3oGpXH9mWLfa5kijZNquOcHHX6VnaSLr+zl/tG9iurgSEo0Yx8uOAQKuXWjpPavIirIqYYwvko/4dqrzpb38CzacRbzxDDwDjp6VEOWxhTUXs/Vk5jeKRrmJ0Ziu5414xzj86uWt2moBkMYUngqTWFp8JivzcTHezqFdCcZ/+vV6wt/s+pSkuFTO7bjJpzjpruVUgrO+62NeC28hWWEHI565rNiu7wrP9oj82PBOwr0x2qzcBzPkbgOCpDYA+oq0Io2QKOQ3ByeKxTS1epzJqOstbnKS69dSP5KKkKHuFJIrJ1VTNppkikLTBgXU4GQelbWt6eLZzKrbwDnAH6VHIvlJarbwQ+QcSbQcEkjvXbFxVnE9ilOEeWdJaHn119utruGS3hkZ15AVDyO9all4luLG6E2oWDhcYAI24PPNd5earFHslVkEmOURc/UGqOq3Om6zbFLiJ4ouglKY2n60+dy3Wh2PGxrqKrUbrv1RnXPiyKSzMsI2EJ8qg8ls/wCFWfCKymU6q4HnytuTI/zxWW/hextjHPLeo1u7qqAHl2Y4ArsYbf7GxgEQTyl6DnP0qJcii1HqcmIlh6cHChrzb37djFt7x5NZvre70yyhuiA32mBD+9HXnNZ3i/Rbq9Y3EThkSMYUNzwO1dHIPszlzFIFPII5xx0NchqU93cTymIyAnhQp6GqprXQMBGcZ89NpWMPT7vxDY2CTRCQ2cLFsnso6g+1ereE9TttRhhl2ArMgIB/UfzrzDxzcarYeBn8gSB2KrM+7LImPmb8eBgetXfCNxNo/h+2nuLa5SO5USCGb5TExPHPoRyKwqSVSbpdTbG8mMg1yqMltbqv8z1C40lheiG1l8uF+eB936VBqVpFp6lIGZzjLlmyfxrAtPE4Ee9mmjXHyt947uRj3FZWs665s5oHZjcTjYpXr83BJpRpVL2bPKw+Hq1KihzX/rdmBpHii3tNY1Nb/P2W6Y52jPIPHFS3fj5/tkgs7VXthgLvJBPvXPa94em068WKNXlDYKsF61mTQTW52uuGxnGOla2le7PtYYHB12qu91/TPQ9O13Rr2JbmVktbtDyjSEc+orYuZmvSk0bLOD/Huzken+fWuY8JeD4dW0r7bezGNXJCKo5NaL6XP4ZgW9sblriwRwZopFwyjpkUXV9zxq9LCqq4UZe8naz29Ezam1GzslVpp0jkJ6YxkUxvEek/uY3vsLIvAJ+77GsTWIItV1VHkw1vFb+cCAfmycDIqK/0u2voJIILOONwg8qRQcuafKjBUcMuVVW036aHUafdTPrb2qxK1t5ImWYHgjOMVbswY766hAO4/MCT1Bqr4Mnt73RIJpE23ccXksfoav3Fu0zpJBIEkQfL7j0NZPVtHn1PcqTpy0toOs3a5mmtZQ2wDLOemB1pmoXHlwWstjKrxK5LFe4pP7TiBa3u7fYkgKvKvY1UvngitVS23iFW5JH3iewFTGLvqRGEnUV1p+Bi+KrhJ9VtbuCWONY8neBnJ/qa7XwDcz3mnSzTt82/+IYOMelcfPprErKsKmP+83P0rqPh/KPKntZGzMH3fVaK6XsWl0LxsYvCtR6WMv4jaS2o3MMEsrCKXaQQOFwaydfRhaxN5q4hyMA5JwMVtfEmXULS7tpLQl4u4C5IPrWYsC32n7pwMyp82P60Un+7i3sXgZr2cJPocT4XhjmvIIpVJ55APpXoGp3Gn2XkWsqHYRtyOwrj/DESW3iHyXIxE7IrH8+ldhrlnDPMuGAKjJwM+9b1LXSZ6uZShLEx5r2sQaobS501reP5wqGVOxArG8O7/wCzhlcneeanuHgXTmu8NG0YMaKD9/k1o6Bb+TpcKk7cjODTj7sWjmhPkoS7X0NCTW7G4dIkikVEG7IwpXt0NJBEbiVG0+6kKBs/fy3XndUtyLdptk8QEr8DzACD9DUJ0+GOX90r2cxHJRsBvxqUklocLhStomvxOiFuJg80g+ZAML/jTjbzy6TdJOfKaT7hJ+7XMS2V2JT5WpXCSjsWDA0+6/tm5h2T34cJk7Ujxn9etYuk9LNGDwt7WmvxK93rUVnazWzMZrl08pQmWH1NWtOBtZLbzVKQOoUnP8QHQ/nUel2dvawMbgp57HLPt5qHUbtobq0tTDIyTE4YcheOD/8AXrey1ijql7NLkht1ff0N6zuBBqUWQdhyuT1I7VtXeJgknJWPkrnk+9cy5ae2hkRdzj72O3rWhpty0oKzSpHEflx61zVKd7SXQ4K1G9prdG2LgSWvlQKCw9TTLFnS5labr/dWnW6QrEVtV3spxgf41Rac21ziaHEoIDNkk4P865lG94o4YxUrxiv8yJtKul1CS43IbaUkkd1ou2CKQBk+mO1XLuUzxeXEXQnkYHH41UW0uDby+YWLyHqOorWMm7ObN4zbs6jDSLc3Zfzt21XyYyOo7VfiskeOUYAG4/dPQVXt7uK2jUKrrgEE5xn61dg8pbQupPTcSOeetZ1ZSvcyrSndvZdDEllaOeS0lG13TGR3FYt3pkiQK9udksQ+UqeW+taM14by+jaPaQQCTjkCrF7J5dlKQm51BAUda643hbzPQpuVJxstXuYIvpDFE0qgsCACP61o2c5aWORTksME+tZdnd2ttpjS3mJbWdxHIu3Jjz0OBz7UzUZX0k2/2WPz7eb5kZCeh54+lbNcz5TpqKLk4Wsb8d7DdySIgdWViuW6Ejrioo3mura4jhJ3x4II60unmI7nCFJmGWU54J74q1piNZNIW/jPNYO0U7HHL3E1bUxhNdfYQtyqmYk4HcAetZeoyK0cAVmiwpY+nHUVoeI70ENHb/M55OBzXPwWFxLsE0h+fODjlc10wWl3oenhqdoKctDbiiFpBa3rRLc25JEq91wM/nWppszXNrKEQeRvICxDhuM//WrFuZLrT8WyF5AWyTjAPHpVPxJq37m1t7W2lswoPmFTgOaTg5Gaw9XESWu/4HTyeHtD1FYVuQkN3EwlHkuMqwPykgcZpb2O+iP2hZI7pQ+0E/IW/pXly3z28/zu6Hr5ik8mu98Ja4t+i2GoT5BbfFLn7rD1NTOnKC5r3NcTl9bDx9pzc68+3l/w5bt9TWcvHIxhnQAFH+9n+tV57cQuzCP5sjJrX1iztrWNPtMSzwsx+bHzZ+tY8t5FYtL9pdjaxru3OOQvv9DRCaesTlpTUlzU0S/MRGXjEig5z6elP1e4+3RxI9rG0WNrFxkMPTFOu5raG3EkbjZjdnPAFcxGZ9XvlE8s9vBk7FjO08DqTTspe8bUoKf7yWiRqSaPDdwosVxLGinHlA5C/wCFWU0y1s7iEtAZZOvmscnNc9FoUwmlOn3Fxa3OC5JcsGx2bNa+keJknItNQTyLwHYc9C1N83Q2nGcouVCXMuvR/wDBRvvFFcSJ5keXHIBHSs688O6fdM7SQDzHBBb0zWk2VmyHYk88dhTLW5yXTaXdmCLk96yu0ro8+FSpD3qbsUfBkQ0zT1CxtKkcsq4z0G7Gf0qHxbcFtJvA8Wxro+TFHn7zE4FONnqUd5dG0uEgjeQ+ZEybtrdypyODWbrenXDGOaMyXd8hzGsjBVBPGcdBinZOXNc64KEsR7eUlrr19fTcl0hVW8uIrsA7bZAccZw3b9KvJOIbffaxqHVGEaEdSehxWPIksVhbmWS3TVYs7gJPlYZ5Un6frT5NYiij3XMBtQ6fJIrB0J+vY05JvUupSlV9+Cvf+tvMjt7k6fqL+cVFndlipK4XeB8w9s1saTrEFzpsNxtWKFh8ozggD6/Ssu4UeJfD0sMTDzYWEkZHqB/+sVwr6frN0qWqwyvHF91V6Yp8t1rudVHCQxcf3kuVre/4M7q2NzM8ohlW7gDMVO8b8t2/CtKO3S4th5jS+cMAL06V5Ik11ptxuhkkhnQ4ODg/Q1uTeM7+e0SKEeROcBpF/i9/ahrWyOqrk1VSToyun17f15Hba/cvp+kecwLKmMDNYfhvxQ8c6XAjVZMkHae1ctPqWqzQPFPPLJE55DDPNVbBbmCZdiNsZgCSMYFXGGlmdNLK4RoShVs2z3VdWg1O2R4nVx/WuV1CG4tNSab94IQnybVyuc8g+nFZvhtpIppUSQEEeaAfXvXbt4j02KwWK4SQTSJtKBc5bp1rnlH2TtFXPmq1B4OfLTV0cPcR2aarftKdhmRZY2GR83Q4qzba/b/Y0+0xs00LDDdnHYn3rRSKBpVhMeQo3KSBgH05+tRG009buKeeIYDBmUdGwfSt7pqzO/2tOatUTdv0X6mfFpd9rciXt3ELeyZv3aYwCPpW7mVfkRXIT5fTpT7/AFN9U3WmmrttUO8MflwB/wDXrGS/kiyokxg889+9Sk5rVfIzvUrJXSVtl2X+Z0UI/tLTwJBhhyG9COhpomu3sw80ACquGEh5OOMite1htLaEx27tIFX7xOcmmagGaARxAeY/yqOxJrJTu7JHl+2TlZLS/XoYsM8swZRsQfd3nn6YNT3t09pBE62rTKJdszJ1H+1Vq1h8qaS0k8ttmAcDGc1SuLxLCN2mb5FbaR3I7VStJl29o7R3J/lLxNMoKMNwI4z6ZrNvdZtLaVrZ7popipwT0APvXPXviaR7sG0i326cbe5FWNLjS9nudS1KyDRug2REZ4HBNa8nLrI9D6l7GPtMRtb8Tf0w/KJbCVZ4SCGXcOT6ir+2G4jkO3ZIOGzwQaxbnR2tc3mioAyjdJbDhZF9AOzVStdbaOUvdWc1kc5DOp2nno3HFTbm1iZew9t79J3/AD+a/wAjsdC1X7IHiu1fP8OF6jtitiG9huLiXdEU+UE7xzisC11JL2IXCvFkZA2c4yelNt7qU6i8N1MpWRPlYD/PpXLOipNytZnl1cMpylK1n1On2weWSCBGeQSc5qC4ugGVYSG7k5zgVRtrmO6jK7v3cTY2r7etEziG4mZQNrjoDislSs7M5lRtK0tye/mgdV4ycFs9OMVl3Mt3Na+XAdkYHzHuQe1VZbq7uYwjw9Pl69q0pIna3R0LKo+8eOv9a3UFTSudcafsUr/5kdnHHHbbIkxIQN3rWTq0czzO0M5WIKeQeBx3HX8q0bySKEqC5BYgE9xzU13YXEUZuAsRjk4KdyDVJpO76lRlyy5m9ziPDfhu6uZ7kLfsinqNuR9evSurhs7q2t47a4jjuI4v9XKh2kc+hqeytbm2tpDY2QSORsli+Nx/GoLmTUXheVUVMNjZ1J9Ktyc5bqx0VcTVxM7ya/D9NSOeW4eYThxJIvGGXa2P61ENSa5BQb1bocdasx3gliVbuPynxwCD0pJi1rILmIeZHgbgTnimtNGtRK3wuOvQn0/T1G52QBipwfWs7E+Zrf7BuLgbJ9wAQg9+a0p/ENyUbytMyu0KGLdjVBRNPbzwXGY5cb/lP3PrUx59XMiHtdZVPLr/AJMz4ptRXV/JKrNEcEA4B/A+lJ4ltTJOYoY3eM55Izg9xmrOnadNHbebc3bTRBT5O1cMh9c9fwqzbjVVtw6RPc2J5UNw+P61pzWd0dEaqjNTjZW07f0yVvh/pl7pCYMqzvGCHz0OPSvLreO60jWHtZPllilMZ/kP5163pniy3MqWAOLjGFSQbSPb3rzvxkAdWuJZivnHDZHGTSw7q80lU2O7Ka2K9pOjidU1dX/rY9a0+GHUvD8MTHzNq7CT1yK47xHZR5igKMUmElvLvbJf5eK6H4aXLXPhtTID5iyHJI656Gsb4jW724ge03eZ9pR+D6nB/Suai3GvKn5ni4dOljJ0G+rMW+nhn1SCzcEWcCq0igcM3GB/Wuz0PSre7druYKVBwExjj1PrXJ6ItjMnm3aLJO8rSgHoDngfpXYaRexQBvP+UcknHGK2xHNy2ib4+U1Hkp9NP8x2pxJBOQiDy24J615t8TYY7aW0vIF2S/xEcZwa7i+120kuG86dY1XoW6Y9TXmvjG8vtffzbC0mksI8qjhPvepAooqUUrnZklKoq0ZS0S3v+RLcePpktYVtoUknZB5hYYw1JpHi2+tLO4bVbSS6jY7o3VcBT6E9hWD4S05L7VljkH3Typ+tevw2X7ki2tk+zgfPuPFW7JXZ6mYPB4N+yVO99Xrb8TL8Oa4NY0aa5ZBFsYqQDnkDINRXF0JY1ihjdi6l3b+6M96ytNA0zxHe6ZGAtndoZkGMYYDtW5pl9bW8zG4UASkJnPOMf/XoatsjzMRTjRlKdNaOzXz/AMv0NDTrZb7QZJIIkhnI/dhgBvAPOM+vPNZbaKl5pGYovKuCSHSQfLIPcevvXe6XZxGPe6q+fu5HQU/UdPR4S8Cqki88DgjvXJ9YUZtHiwx8qdSyfU8W8PXsnhrUpre8Rvs0mVQt/Cw7H867lvsc1tHHHKI2lAbJH86z/FmkwXgRpciOQhWZeCrdmH6isnSg1lI1tqMrBrdgFAAPnofukfSut2krnu4mUMVT+sR0l1X4XMvx7o8VpFbyx8schyOlU/Bltah/Ou7bzichc4wuO+O9afxH1CKWO0htssCN7cdugq74KvbaLQoUaONpVkfBPUd6q75bne61WGWJ93+B1lrBiB0aFXVeQQmRg1i61bATwxi2Ty5MBtqcEn3rpYr6SPS2jiGfOOQ3dQapTMkcMzXE7BY13HHt6fWsIyaZ89TnNSbWmpznhewMN9dvcMVihk8sMOQQCc1py2tvNJywDo+UB5G2maNDM9o812GjS5nZ/Lx0B6VetlVYrlGtgk0QxE3XeprSbs7nXiavNUbb8tDEvr6zjkklvHlVCcBIl5P19q5SG5ll1LrNLbknYWUrj6dcV0GqadK1pJcocmMFsf38Dr+dXPD1pDcWVvPLFIk8ijcCcgVrFqKbZq5QUU1J27DfC2ptdwzxQoF8slRI46Dpk4rStdEguoFm8/zt2fnUgA1h6xfLpbG10pI0lnzuYLVWLUNVtl2Qw70POVXA/AVLg5ax0Ljha0o88Go3PVTp9rsdrEhWfkJ05pun2dxCpmv1TERLKq8496y4ZfK1EGR5EjOAMHqa6eBttu+8l0Iz09q4KvNBWve583W56Ste9/vMi5uLOBBMigyzMQxPXNcp4sszPaSgZ/eJgHsGHT863p7NDJAyOuAx+U9R+FXbxYGt2i2AnGMkdq2hJU2ranZQqrDzjKN2zzbwSsTRusyL52SGDdQR2rt3hU2seIV3r90Y6VzGq6I9jeC909tswOd38LD0b/GruleII55PJvle3uT2k+6x9jXTNOXvRPUxkXiX7elquq7f8A6FLe4MIkt4TIR99ARmkZWa2mhTak5T5VkHGfSmWMDws8iM0IPH3sZFSz26SMpmB3HOHUnNc7etjyW9bXOQ1HTpNNuoZoUaKG5YJJHxhJPX0wa6W3ht7myjDkl1Oc4wwPeodX0x9QtvJSRQTypz90jkH61QsbsT3P2DUofst+F6seJMdwe9a35o76o7nJ16alf3o797dzWZLexK4lWKMDDbm60LJHfHdbyMyjgbfT3BrBjtTNrMSXg8qKEHLEcOf4TV7T9KjNyywXphdj1POfQim4pK7Zlyws5OTv6GtG6iVIi48w9u/wBamuJsRAb1jMZzgjP4msDSLWS08QXkVw7O23O5znjNbGokGF2QFjj0zWcormSMqtOMZpJ3219RzKt1cQztCjxhcliOMeorVLmaBVO/5ei9foae8KyaZbyRR4KqDtA/pVa3mVS2X25OenT2rmcudadDilL2i06EpDvKsLBflGTt7/hTtNTzrqVtgwnGTSRP5kbglWkAPz+o/wAmiFGjdVtrjBbls81L2aIezWxm+LMSvFbrCPNJBLf3QaoTyiKMQCMbFwr5JySewrS1mOa0tftU0oY7uCFzz6VWtoluwLqWMeYPusBzXTTaVNdl+Z20pKNKPZfmYN3JKLhreNuIznOe30rQjRtjXM6SDahWQgc+tQWkCXGvzsSPl+YemRWpY6rbyXctrbyl7gOQ4x1Nbzk0tEddaTSSgr2V2SStbzaJClnJwrqzbTtOM88/Sud8QXEvmxXMd9NBBG+ETnJXIPT8xW2222vnsnRBCWEkffbz8wFVvEP2eAac29GEc5bGMhR7+1Z07JrzMaMVzpau92vuuVLiWObUZr9YVV4UREYr14ySPzrjfFqG61iGKFhJczskYAGMdv511IlS5863tyWmLbhx8vGKg1TSrnTfEOnalcxRSIJVk3x9wMcfWuiLUdOvQ9bB1Y0Kmu6TsvloegeFNI/sfTxAZ5JWOCxbgZ9hXO/EFXe33oSHDoRz2zXcpMjwCbohXdzxxXnPjG6XUImmjJ+Sfy2TODwpx+debhXKdZzkfP5dKdXF+1nvfUg0bSbc2tpeM77igPl54JI61D4i8Q22mSmynhmk3jB8scj3qzp97Db6FaTS5KIuxu3NZN/fWV/4n0u4ggMvylHVhyOeP8+9d9nKWp7FGnGeIl7RNpXf3HK61qEeqyW1hpodhI48xmXbu9B+FemaeFtYordVVCqhVUew7Clm0+yedCYkVogShIAIPqKSeytzd/amWWS5RcRBT8vTrSbTQYjFU6tONKnGyV/vZxGt2M+g+JDqyRA2c7gkKMbCepIrsBqoELRWzsfMXO3GQT2q3KkV9CsE6+ZFNGQ6sPumuci8Oy28rRR6nLDaLnaoUZHtu9KNJKzLlWjiYRVV2lHy3X+aKW97nxTbSFM/Zxl+Ogx3rqdBgsHt0uLqESTLKzxrngdhn8qp2lnbW1tLFafMzZLMxy2cd60vDNtbLYStJvknhc4UHg+nFKq1y6GWMqRlSsr2Vl67/qbegRSC7MrOcNkew9q6NsAEnpWFY3TWRRbiM+VKN6Mo5X2NSX2rRM624YRmQ4BfjI9q82rCVSd0tD56vTnVqXS0Oc11JDpV0AOCCU59+KwZNKk1W1tD5ggvbbA3EZyPQ+ord8SiWO2ktgfmncBR6dya5yHUk0y7FvM7vOcZC5bAAwAa9Gldxuj38KqjgvZ76v8AIsw6OLVrltQ23RnURsxQBdvoB2rJn8L3WnXAm0S62ISC0b/MAa6Ww1Wy1F/LEqux6p0I9sVHDIF1F7ZZWd42ZsHG0pnjHv2q7u9mbRxVelJqXXdNafcUbefWmkaNdRhlu4lLm1aHYNvscVMYby7P2m/8u1iU7niXJzjpk1utHE8wmjEf2kps3n7wU9qLqNAib0DxqQWHqKlSS6HOsTd/Ck/Jf0v1MrXLp4tL80qYk2+Yr4xnPSsEz+ILuz86GIrERuyPvMvqBWv8QtQS6tIfKUpbmVYmBGDio57Q2mtRawNTZ7aNBDFaKuB93GD7cZoi7RV1qb0qvsaEZuCu299bDfDl7LeyPaXJRnjXg4x+lbl7Hssy1un71eBiuL1JZ7HVzqCjyo3ckegYdcf4V2trP5qbwRiRQRz3pyW0kRio2kqsF7r/AKZyF5ereWd99riEZgmWOFmHzyOOTj25xXXW1wsdtCrgKdg4C+1cZqc4l8UojjaluwbB7nNdP9qtZiXYyKxPIABqJ3sjTFQUYQjLrr95t3SSbHSJAZQRtB9frXQ6dOn2QFiFIOGHoa5afzpL+1SMsfmycdxW9DHDKQkfDA5OD0rlrxTikzwsTBOCT9SPUII4tQaR12oy5DY/ipkcKyq9yrBkUZOT+tXbtRLAwmcnA6Y4NUzaQ29pLIrOI1AbygcZPpiojK8Ur67GUJ3ik3rsc/e3X2oGJWMXOMjvVaTTEiaOJ1E8cucgjNarQjUWRmEsKrxsIx+PFLbXNtb6w7XMqqII/lBPUnr+mK7eflXur5HpRqOC9xapbHOT+H0dGZri5lgHKw+ccfSltlm0e8is5riRtPn4jaQ5ML/3SfQ1qTNc3yymKNUty5MeeCe9QXJ+0WskN5EqlhtcE547EGrTb0Z1xrTkuWo7rt28/X/hjaY/uRkhXH8fTNYWveVeWzxyIfPVPMjlXgqQcAg1TttTu7G3FpewSXVvHxHNH94r2De9WbnW7STS5kthhnGxVbgilGm4vYzhhqtKacVfXdHJ6hqd7d6fp6kHzJAy7h3wf/1VYh1vUNJeBdQgZtigI+Ox9a0ra2VPD9lPImRDOJCR6E4NdReLDcTbJFjdD/eXqPQVrKaWltD0a2KpQ/dumnG7/Pp8mYGn6uupXTapbSZZBslj6HHrW3YX5uJfLnUR8Hbj09ayNa0VIWju9HQQXC8Mo+5IP7rVreGryC7sGdoxDIGKtHt5U+h+lYz5XHmSPOxKpyh7WktNrdV/Xc6Hw7qEd4JlAIdGxj0FT6rZJ5Ek0fyy5B55B9qxNNuoNO1UqoCicc+5roLu8RI8uyqpweec1wVIuFROGzPGrQlTrKVNaMzLKJ1vApXaOCzH361sSWMLYKAxyDo68EVQ1GSV9ksGMDHQ/wA6E1aXgzweUg5LZyDSmpztKJM1UqWnEr3sb30Zt7m4H7t+VxjOOmap30kkUQFqQewA5A98VDq9xhWeJmWSVsnH8QotpY4g6SbHYLlsnmuqMGop/gdsKbjFPp2M/wANXUU8+orIzLLHL82F/WrGj6PHp/iW81GJjLb3ADBsfdJ61iWcsdtql5LIJYobojbIi5wRxWodXW0ytvM2xD+7UdG7nIxW1SErvl6nbXp1FKSpbSSX5fkxmuOV1GzjHMhYlSD+NXdUgjGjm4yAJhzxzWRa30eo6rJM6N8sf7vI6H61qTzyXGneQ4DKvUAYptNcvkTJOPIu25hWTQx3MUtvJjzE8vA9R3/HityYw3dridZ/MJyqqflDeuKwNHuLYX32OREFwrFtoznBP+eldNPeQCQQxhd54znODVVG01oViJe+rb9yzqF80OmQQyup3jYozgH6msGSKJ5IYY1y2/c5Zs8AY/rV0mKNj9tiBmjcGIHkhvWud1K4uJ9WhSMg3EjYPYAGopQtsLCUG2+XTdlFoDbRzRTMpj3n5d1S6I9rZ6gJnP7wgqgz0rbtNMsGleO4kaSUfe7AHvTpdM0u4Wd9n2dIDhZt2dzfT0rV1Y7M7pYylK8ZX13aLUc3n5KqxlCk9uRmq0+sWcWXWVsqdrKozt9axZ01W0eSO3uAi5Iztycdsf571c0i0m05La5ubWOa3chZWIycf3qTSSuZTo06ceeTuuiQ+38SwrvWKCbaOj7TnP8AhWgl9Z39uwjlG4/LsYbeak1FLy31hJLRoRbHAUFRgg9c+lZ/iK3tzI8lu0cepRr5rJHxvTPUCoTjJrzMYSo1ZJRTjfre/wB+hUlWe11VCm4nK5LHoOmK01ujY3pliwV6PH346UlvL9s0sXPBnQ7WXuT61XMJnYOX3A9Se5qtJaMqMFrGfozornWVvDB9kuVjAPzjAyR6YNUdVvbGa3jNxKPtEeRtiOcg/wAqxY9PhnmMaT7cjoeRmtL7MFtvJlVPKi5yBjP41mqUI/CYvDUabXKzM1jWEaJJsSNeyZ2jsij/AD1qHStPU2hlv1cyOTJjH45JqC1khvr5JVQi1ZljU5x8oOWP516VoCWd7YSTRxhw7FSGHIx2p1qiow0R0Yyv9TpKMVZ9f8jzaIWNrrtrdpujt5kdTvXG0ngc+lb1/ppUQalagldoR9nXOcg4q9qfhm3RpkwvlTIQpJ+6T7dKxdG1SRLKbS7sYlhIjbnk46Gmp86UoP8A4Yj2jxUI1IO7ja/p/Whn65qLR6xvgOFAG4DvXS2N/BcQRgyIzMozjnFcdrEJGqwiJ9zO2PqKt3Vols8I0mZhcuCGI5VjxwRWkoxaSOuvRounBN2dt/8AM39X06K9spbZ+AxyGA5FV9F/0jQUDDzGVij55IK8fypul6jNJbgSfJcREiSPrhhVHQb2S31O7tGG4TOZRj+HPUVNnZowVKp7OUH9nX/Mu6q8Q0VLZ4lZZ3IHy9CPT3qj4QneWxlt5UbdBIYw2fSrurrdwrF5K70XLM3ofWqHhF9ltetK2HErM+enrS+wx0tcPP1RQ8TQGx1GLUWUso4kGOD710WnhLq380WZG45+914FJdGPUbVVX5oZVOT14/KqMFhqFmnk2eohYh0BXOPxqUrqz3LnJVqcYydpR9dvkdigZCLiNVeRRgbjjArcs7mIqHYbGZQcVgGRQm7y2aLHIBxmh9RSRIYYFI3fMTnkVzTpOoeFUour0NeW/t0yGbDkfd6Gn3UKXunSGMHzWUqoPUHtWbqMMEq7ggLlOCOq1V0e+fTJp1vJJDGeVB5zUKlePNDdEKhePPT+JdCta3txE62lyG84dasnSrcpI8x3O7ZYnrnP8q0dQWHUNP8At9kmZocuFC/M2O1c/f6pKtjC0kZ8ybcCSCAAB/Ot4yc/hVn1OiNRz96Huvr6mrdXKR2gWMAjtiqN2vm2XmlcSKc4/wDrVXjmGjCKKTNzJcDzAD0Uf41c1m4jjs2deHkGBVRXK0l16lUlaSUVuypqixWltbXFuA8kg2vH14NYt3bW85ZpozC+fm6jJ9609Kt50gWaX5lVxvOeVXsR6jNa9z/xMNHiZo4gsjHewA6Dv7ZrXn9m7b+Z1Kv7CSitddzlrHWrZg1iwVocGMqwweauabeo7CB1aSa3bZkDqvYn+tF9p+k2Vutxft5RIAMmOck4H51QvLO4trpLrTm3OB8uf4x1wau0ZbHR+4rXjDRvv3OqlEUzy5YhxglOx9xWBA7af4xljBXy7uDzSmepBx/KhfEVvJbYu4bi1nK4ZmTjPoDWTZG51nX4Z4FKw24PzE571MKbSfNsKhhpwU1UVo2e+3l+J2NxZR391BIJDgHJHT35qTUby2v52tIpCWVCN2euKdBpl9LD5kbIJAOGVuT9fWsWzWKwvZBPCElcnLAVjGKk9HexwRjzv3ZX5TZ0EXFpbXKuxYjBXNEk8t7a4uPl529MZqZbyGG1chh838RrmfEd1HcSRG3nYsvUAf5+lKMHObdhQpyq1HLl1NyC3CEF3yEU7c1zutanYR3AdZJPObg7eaj1CbUbqxaYhliUBflGPxNFgnlRW4S0AlBH7wjOSa6Ixt7zO2nGFKV6ju+y/wAyXTddhW3MU4EcanKbh976U+1ulmmcrEhU56jmquq/ZptUAhwWUksnvioY1uYRmKM4PQkdRWqirXS3OpU6co80VZs3IRHHZXMyoo8tegHVj0p2mv5toJjEUK5BBzhvcU3TR5kfkzxkEndz7dKtSStFC5IYKufmAGM/T0rGW7RwTvzOKMnUJbCa/RoiUulU7XXj86u2apeWjC4/d3SklWU4Bx0Jrz27une6aeJsuWOefu88cVsfZNUjtPtkcsiyOPqPpWsqelrnqVcvjGMU5Wfn3OmhZ4N0925IRS2e5FGkRxTyC+um23EhJVTgADOKyfDdzNcxtDd4keQY256Gtq1077XbhJ7gQy2hCsnQkdjWc/dvfQ4a/wC65ovR7fL/ACNVLEXnmJGgVZCNzAYJI6c1Sns1hP2f5RIZDu8xsEn1Ht7VbN9Lp9sXRSASEz1A461ja9pl3q9p9qhmEczjGG4yPY1jC99Xoeerp67Dta+0yRyedG+VwT5fI28fl0qSeOS/W3+ySusBAAUd/wD69RWF1Hp1i1tc3JuJMEEbRtHsM9adp96tgWR1IiIMkRQ5xjtWjTtotjralOnottv1NOAR3Je1lRh5GCCTjIqlfwac2v28kqsbpo2hR1PABHQ/nUVtaXGo3r31tcqiLlWjkXBH49xVqyW1t5lWYRPcx/Mp67OKztZ6M5L6vlOc0zSIJ3lguXljuraQ4Ck8+/FM1Q3Zkt9Lgmxcyvgsp6J7mtTR7tzq+o3SBSC2wN296TSYjfapdXSsC64gU4/iPORW7bTbZ6/O4VJVJ9En82ZN7p8Ftqkem2+oXk17tyQq8J6EmrFprkguRp2oLgqMPIfT/HmupgWW0uZY5UZZjGyhic5bHBrz6/txKCWlHnOpbIPRvSim+fRjwtT6zeNbXs/10L+jxrFHcQp+9W3lx8vBKnmui8P372lwsdmW8piWkVvX3/CsTStPJ0+0vNNnAuWhAkjY5VyOx9DS3l9c20S3F1bvalhtaRXDKPr3onFTugxNFYibitXt/S/yOy1LWxPd2tnBbSt55YCRRuCEDPJrjNOVm8U6gkhwzR7sn1BrR0TU7ayV3lnfzGUBlK5/4EDWHLeGDxOLuQH7LKCu4DOKilS5LxSMcFhpU1Ugo20/HcZqsPleIbV5WeOGXo45ANdPo1xa77qGISie3bMnmJtPP8Q9elQanZ/b7EwEYWQ7o3X+FuorM03UZJiEviyanAPKRmGBInofWqkuZF1YvEUlJbx0fp0f+ZrXmj299IpkjPzliZ4/lbJ7tjrisO3tH0a+mm3BxGuAW7muktn8mzknumMMS8nJwDXF6prlxLeSbIzJG67QNuR7UQ5np0LwirVVKnF3iXtQ8UPcae9nD81zIACVGAav+FtLZNMuYLwsrXGd3rzxVbwzpotrR5rpFMsvzjI5B9K6YXMUaBZiAccHB64onaKtFCxE40oOhRXq+7Mu6uLbQrOG1i+coAgXqSP/AK9JHfau6BrbS2ETcjI61R0qHzvF0r3GyQKN6Fuc8Zrso5bl9xEbtz1VeKib5elzCu4YdKPKpNq7b8yC3vERXgnzlOAStR3L21pD50IBbgDnqTWUtzeWNwI5o0vMnbhM8VZvNT0qbf8AbbZ4XwflK45/lRyWd1t5GDoSTvFXv2/y3NnTmNzDHM2QCMYx+FN1CSFZ0jnKbh0DYqta3jPYW9y0LxROvyccr9arTW0N9dLOkrEqRvXpkA5H61koPmu9jmUHzcz2J7S7fSr4mMFom6pjj8K6BLqN4yRCm1j9wjis64tAzozAAoO4p8k8SJtZlzjOBWdRRqWaWpnVUatmlqTXUqSBGmggZx93KZxXMa2zXd8kSsAinoOMc1LdanMLwqFPlDGBjOc9azNQlaO6ZyGCsevpXTQpOLO3B0HGV1ubtubSTT4lm+QgkAs2OhxgjsKw9JivZdRupLGcLZB2BCtleOwrRkvbG70+M3trudBgOPvN6VW0zVpLeOSIaUUgOQoX3PemlJJ6F041oqdo797fgb1zb6fPDHHfwmVwwK7hkbuxqbUy80BVUWPyzyB8ufT8qz9MvgzRyzwOFGQqDoKrzyXNxduqNticnIcY4rJU3za9DlVGSnr0JIr3TxarBfLjsC4G010ujWmnpaAWhTaw521xWoNZyKYtsjuuPunlagknsLayM0N+8ZbI8pgdwb3A6VVSjzrRtXNauElWVotq/wAztbW+toLxkSX90ny8nqfWuX8U3UOq67DDZuoMSszn+8emK5nTJjqWGinZZt33SOM5rV063mEd2jrsvJVI8zbyp7j/AOvVRw8acue+pv8AU4YOpzt3laxUaOTftmlwhI27jjj2qxHpMw1WHykZ7cEN5pPy47jFaEdrBBpw88NKYeVA/g9ie9Qy6ru0+K4Vkjg3FSxAOSOw/lWjm+g5V6lTSOhvySRpbMDsMY7dqx7/AFIR7GMa7+qhiQAB6e9NgvLu9bzYo/Js1Tk4yT64q5pOlfaraS5iTZCi7h5gySfYVmlGmrzMXCNFNzdmUNO0m1kvWvlUrG/zbWPetdmj6RgFl5wo6VPdadHa2q3Bd5EYZzu6fhWXaXkcsnm7QrAdBxuH+NHN7T3lsJS9quaOqRoLjzA5Ic5AOByBVTUhHFG534EjbthPJx3/AEqTTnku3f7JEXlViGB9PrVbxCjC2ZLi1IlU53bvujv7HvRFe/YIR/eKJw0FvbnW541UmDdvOBXoFpcW89nLEI9scYx65z0Ncv4XMSzMzJklyFJXOR716Po9nDNpyyNbjbIeFHHFViqigtTqzfEcskpdLHnep6ZJZ51CzU8NuO09hXUSQw6tpUV5aPsvlRTx0f1BroNYjtdNs/tBi3RghGXtg8Vxfh6cQm6kgUCB5XAXrgZ7VnCo60eaPT+rGEMRLFUvaLeL0ffyZOmo3KIUnt4jgc7XzWbrGqz6j9njjBRY2J2djWppunwWEE180peSUkKrNn8hTo9NEkTXE6tnlzsXr3rVOCd7GilQTblHb8zAGmzXh8x3VDnOTTDY6hGMR4mjibcAOT74rorcXF1p9wNPtR5kYDbCc7h6D39qWC3vWtFvVia1bBEkUikDjjI9M0/a9DRY7Xl09Bmna1CljHbPbSWskZxhU+9+NUr0yajNIYITaRNwXcYZv8BW2rwmON3j6jJLDvUVxcJMHRAqoOue9RGyd0jnhKMZc0IW/Qyooo7OPy4juGMD3/8Ar1gaFrCacrWjF4pjcMxKrk5xxXQmO6vtTWCCLbAAFd8VBrvh+2j1NFM5WcjcGHXPvWvNFvll1O2FWnJSpVXrJX+46PS72bUdOFxeIyOmQoYYJriLxo5LyQhVjkJPB6/iKssusgGFX3KO+f1qfR/D80btNfENK4JJB5qYwVK7Jw9KGEUpymtdkh/h62Wy02ZpBiTJIGeB71Frthe6vpJSFgkSyAkshww7DP1q5ZW0kOkMl4+2QufmY9B/+utGTxBFd2RsYI0Dsu0kcA47ilJyveKuR7ao6vtqau7/AHHCaRqG6UxXJWIodpBPYcYFWNbaIywWsZ3G4Zd5z0GecVa1/wAMrcH7RCwhuTg5PT61i3Wn38F3HJdOjsVzknoPatlZ6nr05UKslVjK3l5npFqsNuIgDuXaBjPp0zWTrOhG5BlgZY7nOUJJzyc1zdjd6jOpMQkyP4gPujtWrD9uSQu17MLoABYnUAMKz5HF3ued9VqUJ8ymrixaDdtOkupzlolOSgOc8d62LaG288PFb70UcEDNNuZ/tdlDOpcBjtZSMfWulVdOs7JJUdYwAOVPzZ+lZVKjildas48Tiqllzb7WWxhWRjnklOPkx09Kgmfz44RlQwDKBjHfkGrEESIzvEhAyXU9iKR4UaN9uCWHDU3uTeNzlLK+Fr4hfYBnoe+BXe2GpXkNuEEKSLnIZuDivOrnw/ewXXn27hgBuBBz+GKu2Pi6eC3EVwqeYhwd45HtV1KSqLRXPRxmEjioxlRtK1rnZRwx7nlKMnO/acHJp0VrDewM7ICrZGGHeuU0vWLsNIrssgyR84zV5tXukIEbIi9cBeKh05XsmebPC1IS5YvUoQy39jqZtoZGMQbDRnkLXUppsl0FkizC2MnaKyLQh52dlBYLnPfmuz0lQ0IByd3BqcTUdNXW4sdXcEmlr18zH/s7U5UyboeV03dyBXPtdIt20SSCZlbBYHrzXV61PJHZGJGwpLL+lcrpFhBDbmRVJkfG5m5J4p4eTcXKQsLNyi5TSt5EyB2DbVdjx07VV+zXsl4ZJTFHbA5zI2QR9KL2d4o8xHYcHpXMXc8pcgyuQOgz0rpUW9j0qGHlV1i7HZ2d7pqozyMGYMVVewHSqN3N+73W92i/PvGByfbH5UvhnT7aWDdIm4sMkE8Zq1qul2ttFDNCpVyxHXjgD/Go0UrGFT2VKbjd/gKL2b7FBsVlkPDttzzSzaRJdAbp5Ul65dsEfhWyiKLdpFUAhQQB0z9KoX91LCImVvmZgCSOtZRm27Q0OeFV3/dqxClh9m1GERIdgQZcnOWxzWTexsJ2W7t0kdmA5xjPrn0rqdNbNpdysA0iHClhnFQXMMXlyTNGrSY6nmiNS0mmZKrNTeupy8NnbpqouLM+XahBJjPKnuK37u/yVlidBF/fK7ufeuXiUTOzvnPoDgVaktI8xRguEYDIBrplTUrXPUrUPacvPLVI0prqa7dUsACzffLfdqGbRi8CK+ZZM/u0HCD8Kum3jtLDEC7cA4PeneGppJYHaR2Yg8ZPSsm+VNxOR1fZq9Pp95PAt1BpjWtykasehHcVsaQJbAyfOZI5ORFt6cetYXiP5fsu0kZYg4JH8Oah0+5lubCXzXbKRqAQTnkVhKHtIepySj7WHrudDe3jSWxmuoRDbRncw3bsfXHSqsP2G52C1gE0cp+Vh1X39sVxMlzNFFIBKxDIVYE5DD3ra8DXMkdmwU8ecFGewI5xVSoezg2mWsNy0JVIvZ7HUaNIumXNxHMpCMwBfA49Cf5VT8VXMNyJpI8tDFGQzjoT7UmvZju2RWbDR888nmsaclNNdFJCbS2PUjpU0qSlJVerJoUVKar9XYreDYB/YbyyxlpRJs2nqOOv416bDJFb2cRZlRAoxXCeFnE9/qEciIU2I4AyOR/+qt2/YvaOucBPu4/CscVH2s+UzzFe3r2el3f70hvjfUIR4dutpycZGRXKaG8R0KN0Urlck4/OneOrh4NFt4I8BJXG845I9KTTEVdNghUYjJ6V04emoU7Lud2GoRpYRW6y/ItySQS2MRgkV1JOcdQf8ael3LDdW9q8uxD94HjFTXFnBHpDlE2lmXJH1FZXxWP2W00m3gwiSudxHU9O9HMm1DvcKEVWqRo/zN/lc1tK1qzn8RXNvbyuluu0AkcFuhIPpV3U2vtPS5+2XKy2ki/u1/iz2Ncp4Dtkm1Z2fdwuMA8V3F7BHLdLBIu5FjJGeTnisqqjTqJeRz42lToYhRWySuc/FGtxZo4OWC8jPOal0yCMHEnKlduG61YihSOWUrkbWIA7VDdyGC4JiCj5QenQ5rVyveKKc3K8V1Hi4l0udRD86MSADxz71XtbG3kkvNTuZDJOeFzkAeoFaU4FwAZFBKjI9qq2qC42+YTtSQgKOlQndX69TJNSXNs+pV+0RmcB1MbO2M0nlT2+sNubdbFdyn1PpU2q2kXlvweGwKqNM8th+8O5om2hj1Ix3rVa2aOhLmSa2ehPDaJrl1JvcC0TjJ6Z7k1h32jW1ooltbti+/8Adt2HPSul0O3jfw7CuCPMjyxHU0XIW00YzxIheLATcuQtSqjUrLbYSxU6U3GD0TtYyI7u4Ez2+oIVmjGAwHDZHH86zdY095LeS8csCsYAU9AKvapcST2NtdSH987FWI7jrVvxA5Ph1m4BVFXjuNw61rflt5nTTl71OSVrsz9Nsru20a3uLHzZJxujniUdyfT2x+tXb2xvr0xfa4mjlMYKYXkEDpmtfwk7DUymflZmYj32iul1qJfsxlHEikAEfWuWrXcKvLbfqefiMXOnifN/qcBocTz2NxbOwXa+9O/B5x+FX7KxZYys0u45weKoWLsuvXCKcKT0/wCBEVpgldRYAnGOn4VvK93b1Oqu5czs99SaIhZVTa6lF4HUEVRmMav8zE5JIWtJoUGCBgk9QaXTrKGTV4mdd3JOD04rNSSvI54zUU5PsY9pfJ5zxycbh3H61JPa2nmElImzzkrirniW3httQLQRKjMeSB/n1pmj2MV1aebKXLljnBq4yTiqi6msZpwVWOlz/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Focal areas of interstitial fibrosis and tubular atrophy (right side of picture) in cyclosporine nephrotoxicity that, on lower power, would produce a characteristic striped appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25347=[""].join("\n");
var outline_f24_48_25347=null;
var title_f24_48_25348="Dobutamine: Pediatric drug information";
var content_f24_48_25348=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dobutamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"    see \"Dobutamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/35/24115?source=see_link\">",
"    see \"Dobutamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dobutamine Injection, USP;",
"     </li>",
"     <li>",
"      Dobutrex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous I.V. infusion: 2-20 mcg/kg/minute; titrate to desired response",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"      see \"Dobutamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous I.V. infusion: Infants, Children, and Adults: 2.5-15 mcg/kg/minute, titrate to desired response; maximum dose: 40 mcg/kg/minute",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W, as hydrochloride: 1 mg/mL (250 mL); 2 mg/mL (250 mL); 4 mg/mL (250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 12.5 mg/mL (20 mL, 40 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Dilute in dextrose or NS; maximum recommended concentration: 5000 mcg/mL (5 mg/mL); rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration (mcg/mL); administer into large vein; use infusion device to control rate of flow",
"    </p>",
"   </div>",
"   <div class=\"block uicn drugH1Div\" id=\"F14471791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1000",
"     <b>",
"      mcg",
"     </b>",
"     /mL, 2000",
"     <b>",
"      mcg",
"     </b>",
"     /mL,",
"     <b>",
"      or",
"     </b>",
"     4000",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1000",
"     <b>",
"      mcg",
"     </b>",
"     /mL, 2000",
"     <b>",
"      mcg",
"     </b>",
"     /mL,",
"     <b>",
"      or",
"     </b>",
"     4000",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F162007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Per manufacturer, do not give through same I.V. line as heparin, hydrocortisone sodium succinate, cefazolin, or penicillin.",
"     <b>",
"      Incompatible",
"     </b>",
"     with heparin, cefazolin, penicillin, and in alkaline solutions (sodium bicarbonate).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, mannitol 20%;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate 5%;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alcohol (ethyl), alprostadil, amifostine, amiodarone, anidulafungin, argatroban, atracurium, aztreonam, caffeine citrate, calcium chloride, calcium gluconate, caspofungin, ciprofloxacin, cisatracurium, cladribine, clonidine, dexmedetomidine, diazepam, diltiazem, docetaxel, dopamine, dopamine with lidocaine, dopamine with nitroglycerin, dopamine with nitroprusside, doripenem, doxorubicin liposome, enalaprilat, epinephrine, eptifibatide, etoposide phosphate, famotidine, fenoldopam, fentanyl, fluconazole, gemcitabine, granisetron, haloperidol, hetastarch in lactated electrolyte injection (Hextend&reg;), hydromorphone, inamrinone, insulin (regular), labetalol, levofloxacin, lidocaine, lidocaine with nitroglycerin, lidocaine with nitroprusside, linezolid, lorazepam, magnesium sulfate, meperidine, milrinone, morphine, nicardipine, nitroglycerin, nitroglycerin with nitroprusside, norepinephrine, oxaliplatin, pancuronium, potassium chloride, propofol, ranitidine, remifentanil,  tacrolimus, telavancin, terbutaline, theophylline, thiotepa, tigecycline, tirofiban, vasopressin, vecuronium, verapamil, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, alteplase, aminophylline, amphotericin B cholesteryl sulfate complex, foscarnet, indomethacin, micafungin, pantoprazole, pemetrexed, phytonadione, piperacillin/tazobactam, thiopental, warfarin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Bivalirudin, cefepime, ceftazidime, drotecogin alfa, furosemide, heparin, midazolam, nesiritide, nitroprusside, pantoprazole, tenecteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, dimenhydrinate, heparin, ranitidine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Doxapram, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in various parenteral solutions for 24 hours; incompatible with alkaline solutions, do not give through same I.V. line as heparin, sodium bicarbonate, ethacrynic acid, cefazolin, or penicillin; compatible when coadministered with dopamine, nitroprusside, potassium chloride, protamine sulfate, tobramycin, epinephrine, atracurium, vecuronium, isoproterenol, and lidocaine; pink discoloration of dobutamine hydrochloride indicates slight oxidation, but no significant loss of potency if administered within the recommended time period",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term management of patients with cardiac decompensation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F162009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       DOBUTamine may be confused with DOPamine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F162006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Anginal pain, hypotension, increased blood pressure, increased heart rate, increased ventricular ectopic activity, nonspecific chest pain, palpitation, premature ventricular beats (dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, headache, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Slight decrease in serum potassium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (isolated cases)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Cutaneous necrosis (isolated cases), local inflammatory changes and pain from infiltration, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Mild leg cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dobutamine or any component; patients with idiopathic hypertrophic subaortic stenosis (IHSS)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypovolemia should be corrected prior to use; infiltration causes local inflammatory changes, extravasation may cause dermal necrosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent drug; must be diluted prior to use; patient's hemodynamic status should be monitored; contains sulfites which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13314045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, heart rate, CVP, MAP, urine output; if pulmonary artery catheter is in place, monitor CI, PCWP, RAP, and SVR. Dobutamine lowers central venous pressure and wedge pressure but has little effect on pulmonary vascular resistance.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors, causing increased contractility and heart rate, with little effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     - or alpha-receptors",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: 1-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 10-20 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In tissues and the liver to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25348/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practices (ISMP), \"Standard Concentrations of Neonatal Drug Infusions,\"",
"      <i>",
"       ISMP",
"      </i>",
"      , 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, \"Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25348/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25348/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Subhedar NV, \"Treatment of Hypotension in Newborns,\"",
"      <i>",
"       Semin Neonatol",
"      </i>",
"      , 2003, 8(6):413-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25348/abstract-text/15001113/pubmed\" id=\"15001113\" target=\"_blank\">",
"        15001113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13243 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25348=[""].join("\n");
var outline_f24_48_25348=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161958\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058084\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442333\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058078\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161937\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161922\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058088\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471791\">",
"      Usual Infusion Concentrations: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471790\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162007\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058081\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058087\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162009\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162006\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058092\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058077\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058076\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299223\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161931\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161933\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314045\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058083\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058075\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058090\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058091\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13243\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13243|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=related_link\">",
"      Dobutamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/35/24115?source=related_link\">",
"      Dobutamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_48_25349="Mechanism of dissecting aneurysm formation";
var content_f24_48_25349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Mechanism of dissecting aneurysm formation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 561px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral and cross-sectional schematic view of the carotid artery.",
"    <br>",
"     (A) Aneurysmal dilatation of the vessel related to a hemorrhage between the media and the adventitia (subadventitial dissection).",
"     <br>",
"      (B) Communication between the arterial lumen and the dissection cavity or disappearance of the hematoma may lead to the formation of an extraluminal pouch or a fusiform dilatation.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Guillon B, Brunereau L, Biousse V, et al. Long-term follow-up of aneurysms developed during extracranial internal carotid artery dissection. Neurology 1999; 53:117. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25349=[""].join("\n");
var outline_f24_48_25349=null;
var title_f24_48_25350="Prurigo nodularis 3";
var content_f24_48_25350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A prurigo nodularis nodule showing periferal hyperpigmentation and central scale.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25350=[""].join("\n");
var outline_f24_48_25350=null;
var title_f24_48_25351="Procedure for intrauterine insemination";
var content_f24_48_25351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Procedure for intrauterine insemination",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/48/25351/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25351/contributors\">",
"     Elizabeth S Ginsburg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/48/25351/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25351/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/48/25351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25351/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/48/25351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrauterine insemination (IUI) is a procedure in which processed and concentrated motile sperm are placed directly into the uterine cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IUI is used to treat infertility related to a variety of causes, as long as at least one patent fallopian tube is present. It is also often used as an intermediate level and cost-effective intervention prior to proceeding to in vitro fertilization (IVF) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/1\">",
"     1",
"    </a>",
"    ]. Some common diagnoses in patients who undergo IUI include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ejaculatory dysfunction (including sexual dysfunction and impotence)",
"     </li>",
"     <li>",
"      Severe vaginismus",
"     </li>",
"     <li>",
"      Cervical factor infertility",
"     </li>",
"     <li>",
"      Male factor infertility",
"     </li>",
"     <li>",
"      Unexplained infertility",
"     </li>",
"     <li>",
"      Stage I or II endometriosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IUI is useful in couples with severe sexual dysfunction since coitus can be avoided. Its advantages in cervical factor and male factor infertility are that sperm bypass potentially hostile cervical factors and the number of sperm that gain access to the uterine cavity is enhanced. In women undergoing ovulation induction, randomized trials have reported higher pregnancy rates with ovulation induction combined with IUI compared with ovulation induction alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/2\">",
"     2",
"    </a>",
"    ] or with timed intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IUI is contraindicated in women with an active cervical, intrauterine, or pelvic infection. This would be in the setting of a recently documented or diagnosed infection, or if there were concern at time of IUI, such as purulent discharge from the cervix or recent exposure to a sexually transmitted disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cumulative pregnancy rate after IUI generally ranges from 5 to 20 percent; the reported range varies widely and depends upon multiple factors. Lower pregnancy rates may occur when there has been a longer duration of infertility, female age is over 40 years, or in the presence of severe male factor infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. Higher pregnancy rates have been documented when ovulation induction was combined with IUI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/9\">",
"     9",
"    </a>",
"    ]. This increase in pregnancy rates appears to be due to an increase in the number of mature oocytes available for fertilization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], but multiple gestation rates were also increased to 10 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DOCUMENTING OVULATION AND TIMING OF INSEMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Natural cycle procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural cycle procedures are an option for patients with ejaculatory dysfunction, vaginismus, or cervical factors. Ovulation should be documented prior to proceeding with an unstimulated, or natural cycle, intrauterine insemination (IUI). Several methods are available, the most cost effective method is the use of over-the-counter ovulation predictor kits. These kits perform a biochemical evaluation of urine and are available in both mechanical and electrical options. A serum LH level that is greater than approximately 20",
"    <span class=\"nowrap\">",
"     mIU/mL,",
"    </span>",
"    depending on the assay used, suggests an LH surge. Urinary levels typically increase approximately 12 hours after serum elevation. Most home ovulation kits detect urinary LH levels of 35 to 50",
"    <span class=\"nowrap\">",
"     mIU/mL.",
"    </span>",
"    Ovulation usually occurs 24 to 36 hours after the urine LH surge is documented.",
"   </p>",
"   <p>",
"    Basal body temperature, although helpful for analyzing ovulatory patterns and in guiding couples in the best window for intercourse, is not helpful for determining timing of IUI because ovulation has typically already occurred once an increase in temperature is apparent; therefore, the window has been missed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Controlled ovarian stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled ovarian hyperstimulation is commonly used with IUI in couples without sexual dysfunction who have infertility that is unexplained, due to mild male factor or attributed to cervical factors or early stage endometriosis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    citrate is the standard first-line therapy; if unsuccessful, injectable gonadotropins can be the next step [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/12\">",
"     12",
"    </a>",
"    ]. Randomized trials have shown that IUI with ovulation induction results in a two- to three-fold higher pregnancy rate than IUI alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/13\">",
"     13",
"    </a>",
"    ], although lower than in vitro fertilization (IVF) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"     \"Overview of ovulation induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;We commonly utilize one of three approaches for ovulation induction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       Clomiphene",
"      </a>",
"      citrate 50 to 150 mg for five consecutive days, beginning cycle day 3 or 5 with urine LH testing starting cycle day 10 to 12, depending on the patient's usual menstrual cycle length. Follicular monitoring is at the discretion of the provider, however, not typically performed. Once a morning urine LH surge is documented, an IUI is performed that afternoon and again 24 hours later. This is our first-line approach for most patients. There is no evidence that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"       human chorionic gonadotropin",
"      </a>",
"      (HCG) administration in clomiphene citrate IUI cycles results in higher pregnancy rates than urinary monitoring of HCG [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       Clomiphene",
"      </a>",
"      citrate 50 to 150 mg for five consecutive days, beginning cycle day 3 or 5 with serum LH testing starting cycle day 12. Once a serum LH surge is documented, an IUI is performed the following day. We use this approach in patients who are known to be ovulatory, but are not able to identify the LH surge from urine kits.",
"     </li>",
"     <li>",
"      Injectable gonadotropins (recombinant FSH) per provider dosing beginning on cycle day 2 after ovarian suppression is documented. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of ovulation induction\", section on 'Gonadotropin therapy'",
"      </a>",
"      .) We commonly follow serum estradiol levels and ovarian follicle size with transvaginal ultrasound. Once at least one follicle has a mean diameter of 15 to 18 mm, 5000 to 10,000 units of HCG are given as a subcutaneous or intramuscular injection as an ovulation \"trigger,\" replacing the biological LH surge, with either one IUI performed 36 hours later, or two performed 12 and 36 hours later. It is reasonable to begin with injectable gonadotropins (including IVF [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/14\">",
"       14",
"      </a>",
"      ]) rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      in older women or those with diminished ovarian reserve [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimum minimum size of the leading follicle (15 to 23 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]) before HCG injection and timing of IUI after the injection are controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usefulness of performing a second insemination is controversial and often dictated by practice preference [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Randomized trials suggest no significant difference in pregnancy rates when IUI is performed once at 24 or 36 hours or twice at 12 and 36 hours or at 18 and 40 hours after HCG administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of a GnRH antagonist to recombinant FSH during controlled ovarian hyperstimulation may improve pregnancy rates and reduce the incidence of premature luteinization in women with some types of ovulatory dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Use of GnRH antagonists may also be beneficial in preventing luteinization when delaying IUI over the weekend in practices with staffing restrictions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/30\">",
"     30",
"    </a>",
"    ]. In each of these scenarios, a GnRH antagonist is added to a controlled ovarian hyperstimulation cycle once the lead follicle is 16 to 17 mm in size to delay luteinization, thus allowing for additional follicular development, especially if monofollicular development is present, or to delay IUI until a more feasible time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=see_link&amp;anchor=H14#H14\">",
"     \"Unexplained infertility\", section on 'Gonadotropin injections with or without IUI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SPERM PROCESSING AND INSEMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Semen collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A semen specimen is best produced in the morning and after two to three days of abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/31\">",
"     31",
"    </a>",
"    ]. Ejaculate is collected into a sterile cup; this is imperative to minimize risk of uterine infection from contaminants. In general, lubricants should not be utilized, as most are toxic to sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. If necessary, the man should be instructed to keep the lubricant off the head of the penis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sperm preparation techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is critical to prepare the ejaculate prior to insemination in order to separate the sperm from prostaglandin-rich prostatic secretions or seminal fluid, which can result in uterine cramping and, rarely, anaphylaxis when placed directly into the uterine cavity. In addition, sperm preparation maximizes the number of motile sperm for the insemination, removes cellular debris, and concentrates the specimen.",
"   </p>",
"   <p>",
"    Two commonly employed techniques of sperm processing are the swim up method and use of density gradient centrifugation, both of which utilize culture media, such as Earle's",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/62/30690?source=see_link\">",
"     balanced salt solution",
"    </a>",
"    or Hams F10. The swim up technique layers the culture media onto an ejaculated sample which has been placed in a test tube, and centrifuged, then incubated. The motile sperm will \"swim up\" into the media. This layer of media is removed with a pipette, leaving the dead or non-motile sperm and debris in the bottom of the test tube. The motile sperm and additional media are then centrifuged and the pellet of motile sperm is resuspended in a tiny (usually 30 microliter) droplet of media for evaluation and insemination.",
"   </p>",
"   <p>",
"    Taking advantage of the higher density of motile spermatozoa, the discontinuous gradient method suspends the semen onto two layers of varying percent density gradient solution. Historically, Percoll's solution was utilized to maximize sperm recovery; however, it was withdrawn from clinical practice in 1996. Multiple alternative agents to Percoll's have been introduced and found to be comparable in their utility. The centrifuged specimen results in a pellet which is again diluted and centrifuged, and the resulting pellet is resuspended with Earle's media, then utilized for insemination.",
"   </p>",
"   <p>",
"    The percentage of motile sperm recovered after processing is generally higher with the density gradient method than the swim up technique, possibly because motile sperm may be trapped in the pellet after centrifugation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/34\">",
"     34",
"    </a>",
"    ]. Therefore, we prefer the density gradient method in cases of oligo- or asthenospermia. However, a systematic review of randomized trials comparing these two techniques did not find a statistically significant difference in pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend that a tiny drop of the processed sample be evaluated prior to insemination to ensure that an adequate number of moving sperm is recovered. If samples consistently have less than 3 to 5 million motile sperm, pregnancy rates will be less than 1 percent per cycle and in vitro fertilization (IVF) is the appropriate course of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Inseminate parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) has published widely accepted parameters for semen analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/36\">",
"     36",
"    </a>",
"    ]. The following parameters were derived from men whose partner&rsquo;s time to pregnancy was &le;12 months.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Volume &mdash; mean 3.7 mL (5th centile 1.5 mL)",
"     </li>",
"     <li>",
"      Sperm concentration &mdash; mean 73 million",
"      <span class=\"nowrap\">",
"       spermatozoa/mL",
"      </span>",
"      (5th centile 15 million",
"      <span class=\"nowrap\">",
"       spermatozoa/mL",
"      </span>",
"      )",
"     </li>",
"     <li>",
"      Total sperm number&mdash; mean 255 million spermatozoa per ejaculate (5th centile 39 million spermatozoa per ejaculate)",
"     </li>",
"     <li>",
"      Morphology &mdash; mean 15 percent normal forms (5th centile 4.0 percent normal forms)",
"     </li>",
"     <li>",
"      Vitality &mdash; mean 79 percent live (5th centile 58 percent live)",
"     </li>",
"     <li>",
"      Progressive motility &mdash; mean 55 percent (5th centile 32 percent)",
"     </li>",
"     <li>",
"      Total (progressive, nonprogressive) motility &mdash; mean 61 percent (5th centile 40 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These parameters are not very useful for distinguishing subfertile men most likely to father a child naturally from those unlikely to father a child without medical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In addition, difficulty exists in defining normalcy for post-wash specimens utilized as inseminate for IUI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/39\">",
"     39",
"    </a>",
"    ]. Similarly, the minimum post-wash total motile sperm count for IUI is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Although pregnancies from IUI have occurred with post-wash total motile sperm count less than 5 million, a post-wash motile count greater than 5 to 10 million is associated with higher pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. A total motile sperm count less than this warrants further evaluation and possible treatment by a urologist. Moreover, in vitro fertilization (IVF), possibly with intracytoplasmic sperm injection (ICSI), is often required to overcome severe male factor infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Insemination catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although catheter preference is often institution dependent, meta-analysis of six randomized trials showed that pregnancy and live birth rates are the same whether flexible or rigid catheters are used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/46\">",
"     46",
"    </a>",
"    ]. Many brands and types of insemination catheters are available. Stiffer catheters are easier to insert into the uterine cavity because they do not bend, but they are more uncomfortable for the patient and more traumatic to the endometrium, and thus, associated with more vaginal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catheters come in two main types: (1) relatively stiff single sheath catheters (straight or with a preformed curve) that cannot be bent and (2) curvable catheters with an external flexible sheath that will maintain a curve and a very soft internal catheter. We prefer the latter, as it is less traumatic and can be formed to accommodate the curve of the patient's uterus. An internal wire or rigid stylet may be used with external sheaths for difficult IUIs. In our experience, patients barely feel the IUI procedure with these catheters.",
"   </p>",
"   <p>",
"    Two catheter types are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef78723 \" href=\"UTD.htm?15/35/15931\">",
"     table 1",
"    </a>",
"    ). Costs vary, with the sheathed catheters and the inner wire catheters costing most. Some vendors will give negotiated volume discounts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     INTRAUTERINE INSEMINATION PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prepared sperm specimen",
"     </li>",
"     <li>",
"      Speculum",
"     </li>",
"     <li>",
"      1 cc sterile syringe with blunt cannula",
"     </li>",
"     <li>",
"      Disposable polyethylene insemination catheter",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Patient preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper identification of both the patient and sperm sample in the laboratory and the clinic is essential. Antibiotic prophylaxis is unnecessary.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     Povidone iodine",
"    </a>",
"    should not be used to cleanse the cervix because it is toxic to sperm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain fresh or frozen ejaculate for IUI preparation and processing (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Sperm processing and insemination'",
"      </a>",
"      above). Once processed, care should be taken to maintain the specimen at body temperature until insemination.",
"     </li>",
"     <li>",
"      The patient should undress from the waist down and lie on an examination table in dorsal lithotomy position with her feet in stirrups. Although not mandatory, consider asking women with an anteverted uterus to maintain a full bladder to facilitate straightening of the uterus. This is not useful for women with retroverted uteri.",
"     </li>",
"     <li>",
"      Open a 1-cc syringe and draw up approximately 0.3 to 0.5 mL of air.",
"     </li>",
"     <li>",
"      Attach a blunt sterile needle (eg, MONOJECT blunt cannula).",
"     </li>",
"     <li>",
"      Aspirate the processed sperm and its suspension media into the syringe. Ideally, the sperm is suspended in a small volume of media, no more than 0.5 mL, to prevent expulsion or reflux from the cervix and uterine contractions after it is inseminated into the uterus.",
"     </li>",
"     <li>",
"      Attach the syringe to an 18 cm polyethylene insemination catheter (flexible or rigid per provider preference).",
"     </li>",
"     <li>",
"      Insert the speculum for adequate visualization of the cervix.",
"     </li>",
"     <li>",
"      Without touching the end of the catheter that will enter the sterile uterine cavity, insert the catheter through the cervical os, through the endocervical canal, and into the uterus to a depth of approximately 6 to 6.5 cm. Try not to let the catheter touch the fundus of the uterus, as this will cause cramping and, in some cases, disruption of the endometrium and bleeding, which is toxic to embryo development. Consider use of a rigid stylet or abdominal ultrasound guidance if difficulty is encountered with insertion of the catheter. We avoid the use of a tenaculum because it causes uterine contractions and patient discomfort.",
"     </li>",
"     <li>",
"      Inject the sperm and then slowly withdraw the catheter.",
"     </li>",
"     <li>",
"      Sperm are present in the fallopian tubes as early as five minutes after insemination [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/48\">",
"       48",
"      </a>",
"      ]. We have our patients rest in supine or reverse Trendelenburg position for 10 minutes after sperm injection. Although there are only limited data on whether rest is of any value in enhancing pregnancy fertilization rates, one randomized trial reported higher pregnancy rates in rested patients compared with those who were immediate mobile post IUI (pregnancy rate",
"      <span class=\"nowrap\">",
"       16/55",
"      </span>",
"      [25 percent] versus",
"      <span class=\"nowrap\">",
"       4/40",
"      </span>",
"      [10 percent]) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25351/abstract/49\">",
"       49",
"      </a>",
"      ]. Psychologically, patients are often reassured by a period of rest following the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Postprocedure care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient may resume her normal activities after insemination. Increased wetness after the procedure is due to loosened and watery cervical mucus, it does not mean the sperm specimen has flowed out. She may take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    if she experiences abdominal cramping or discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are infrequent, especially in experienced hands. However, potential complications related to IUI include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bleeding or spotting",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Cramping or lower abdominal discomfort",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are also risks of hyperstimulation associated with the use of ovulation induction medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"     \"Overview of ovulation induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"       \"Patient information: Infertility treatment with gonadotropins (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrauterine insemination (IUI) is a useful technique for achieving pregnancy in couples with severe sexual dysfunction, but can also be useful in patients with other types of subfertility (cervical factor infertility, male factor infertility, unexplained infertility, stage I or II endometriosis) as long as at least one fallopian tube is patent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cumulative pregnancy rate after IUI ranges from 5 to 20 percent. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When IUI is performed during a natural cycle, we suggest use of an over-the-counter ovulation predictor kit to schedule the optimum time for the procedure. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Documenting ovulation and timing of insemination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cervical factor, mild male factor, early stage endometriosis, or unexplained infertility, we suggest controlled ovarian hyperstimulation with IUI rather than natural cycle IUI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Semen processing for IUI is not difficult to learn and can be adapted to use in clinical offices, but care must be taken to ensure adequate quality measures are in place. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Sperm processing and insemination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/1\">",
"      Van Voorhis BJ, Sparks AE, Allen BD, et al. Cost-effectiveness of infertility treatments: a cohort study. Fertil Steril 1997; 67:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/2\">",
"      Arcaini L, Bianchi S, Baglioni A, et al. Superovulation and intrauterine insemination vs. superovulation alone in the treatment of unexplained infertility. A randomized study. J Reprod Med 1996; 41:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/3\">",
"      Chung CC, Fleming R, Jamieson ME, et al. Randomized comparison of ovulation induction with and without intrauterine insemination in the treatment of unexplained infertility. Hum Reprod 1995; 10:3139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/4\">",
"      Haebe J, Martin J, Tekepety F, et al. Success of intrauterine insemination in women aged 40-42 years. Fertil Steril 2002; 78:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/5\">",
"      Dovey S, Sneeringer RM, Penzias AS. Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles. Fertil Steril 2008; 90:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/6\">",
"      Campana A, Sakkas D, Stalberg A, et al. Intrauterine insemination: evaluation of the results according to the woman's age, sperm quality, total sperm count per insemination and life table analysis. Hum Reprod 1996; 11:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/7\">",
"      Merviel P, Heraud MH, Grenier N, et al. Predictive factors for pregnancy after intrauterine insemination (IUI): an analysis of 1038 cycles and a review of the literature. Fertil Steril 2010; 93:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/8\">",
"      Harris ID, Missmer SA, Hornstein MD. Poor success of gonadotropin-induced controlled ovarian hyperstimulation and intrauterine insemination for older women. Fertil Steril 2010; 94:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/9\">",
"      Guzick DS, Carson SA, Coutifaris C, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. N Engl J Med 1999; 340:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/10\">",
"      Melis GB, Paoletti AM, Strigini F, et al. Pharmacologic induction of multiple follicular development improves the success rate of artificial insemination with husband's semen in couples with male-related or unexplained infertility. Fertil Steril 1987; 47:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/11\">",
"      Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005; 365:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/12\">",
"      Dankert T, Kremer JA, Cohlen BJ, et al. A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH for ovarian hyperstimulation in intrauterine insemination cycles for unexplained and male subfertility. Hum Reprod 2007; 22:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/13\">",
"      Veltman-Verhulst SM, Cohlen BJ, Hughes E, Heineman MJ. Intra-uterine insemination for unexplained subfertility. Cochrane Database Syst Rev 2012; 9:CD001838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/14\">",
"      Reindollar RH, Regan MM, Neumann PJ, et al. A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. Fertil Steril 2010; 94:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/15\">",
"      Zreik TG, Garc&iacute;a-Velasco JA, Habboosh MS, et al. Prospective, randomized, crossover study to evaluate the benefit of human chorionic gonadotropin-timed versus urinary luteinizing hormone-timed intrauterine inseminations in clomiphene citrate-stimulated treatment cycles. Fertil Steril 1999; 71:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/16\">",
"      Matorras R, Diaz T, Corcostegui B, et al. Ovarian stimulation in intrauterine insemination with donor sperm: a randomized study comparing clomiphene citrate in fixed protocol versus highly purified urinary FSH. Hum Reprod 2002; 17:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/17\">",
"      Matorras R, Osuna C, Exposito A, et al. Recombinant FSH versus highly purified FSH in intrauterine insemination: systematic review and metaanalysis. Fertil Steril 2011; 95:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/18\">",
"      Ghosh C, Buck G, Priore R, et al. Follicular response and pregnancy among infertile women undergoing ovulation induction and intrauterine insemination. Fertil Steril 2003; 80:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/19\">",
"      Silverberg KM, Olive DL, Burns WN, et al. Follicular size at the time of human chorionic gonadotropin administration predicts ovulation outcome in human menopausal gonadotropin-stimulated cycles. Fertil Steril 1991; 56:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/20\">",
"      Palatnik A, Strawn E, Szabo A, Robb P. What is the optimal follicular size before triggering ovulation in intrauterine insemination cycles with clomiphene citrate or letrozole? An analysis of 988 cycles. Fertil Steril 2012; 97:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/21\">",
"      Farhi J, Orvieto R, Gavish O, Homburg R. The association between follicular size on human chorionic gonadotropin day and pregnancy rate in clomiphene citrate treated polycystic ovary syndrome patients. Gynecol Endocrinol 2010; 26:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/22\">",
"      Cantineau AE, Janssen MJ, Cohlen BJ. Synchronised approach for intrauterine insemination in subfertile couples. Cochrane Database Syst Rev 2010; :CD006942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/23\">",
"      Osuna C, Matorras R, Pijoan JI, Rodr&iacute;guez-Escudero FJ. One versus two inseminations per cycle in intrauterine insemination with sperm from patients' husbands: a systematic review of the literature. Fertil Steril 2004; 82:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/24\">",
"      Cantineau AE, Heineman MJ, Cohlen BJ. Single versus double intrauterine insemination (IUI) in stimulated cycles for subfertile couples. Cochrane Database Syst Rev 2003; :CD003854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/25\">",
"      Bagis T, Haydardedeoglu B, Kilicdag EB, et al. Single versus double intrauterine insemination in multi-follicular ovarian hyperstimulation cycles: a randomized trial. Hum Reprod 2010; 25:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/26\">",
"      Rahman SM, Karmakar D, Malhotra N, Kumar S. Timing of intrauterine insemination: an attempt to unravel the enigma. Arch Gynecol Obstet 2011; 284:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/27\">",
"      Tonguc E, Var T, Onalan G, et al. Comparison of the effectiveness of single versus double intrauterine insemination with three different timing regimens. Fertil Steril 2010; 94:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/28\">",
"      Bakas P, Konidaris S, Liapis A, et al. Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. Fertil Steril 2011; 95:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/29\">",
"      G&oacute;mez-Palomares JL, Acevedo-Mart&iacute;n B, Ch&aacute;vez M, et al. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles. Fertil Steril 2008; 89:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/30\">",
"      Checa MA, Prat M, Robles A, Carreras R. Use of gonadotropin-releasing hormone antagonists to overcome the drawbacks of intrauterine insemination on weekends. Fertil Steril 2006; 85:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/31\">",
"      Jurema MW, Vieira AD, Bankowski B, et al. Effect of ejaculatory abstinence period on the pregnancy rate after intrauterine insemination. Fertil Steril 2005; 84:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/32\">",
"      Agarwal A, Deepinder F, Cocuzza M, et al. Effect of vaginal lubricants on sperm motility and chromatin integrity: a prospective comparative study. Fertil Steril 2008; 89:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/33\">",
"      Anderson L, Lewis SE, McClure N. The effects of coital lubricants on sperm motility in vitro. Hum Reprod 1998; 13:3351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/34\">",
"      Morshedi M, Duran HE, Taylor S, Oehninger S. Efficacy and pregnancy outcome of two methods of semen preparation for intrauterine insemination: a prospective randomized study. Fertil Steril 2003; 79 Suppl 3:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/35\">",
"      Boomsma CM, Heineman MJ, Cohlen BJ, Farquhar C. Semen preparation techniques for intrauterine insemination. Cochrane Database Syst Rev 2007; :CD004507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/36\">",
"      Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010; 16:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/37\">",
"      van der Steeg JW, Steures P, Eijkemans MJ, et al. Role of semen analysis in subfertile couples. Fertil Steril 2011; 95:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/38\">",
"      Bonde JP, Ernst E, Jensen TK, et al. Relation between semen quality and fertility: a population-based study of 430 first-pregnancy planners. Lancet 1998; 352:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/39\">",
"      Dickey RP, Pyrzak R, Lu PY, et al. Comparison of the sperm quality necessary for successful intrauterine insemination with World Health Organization threshold values for normal sperm. Fertil Steril 1999; 71:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/40\">",
"      Pasqualotto EB, Daitch JA, Hendin BN, et al. Relationship of total motile sperm count and percentage motile sperm to successful pregnancy rates following intrauterine insemination. J Assist Reprod Genet 1999; 16:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/41\">",
"      van Weert JM, Repping S, Van Voorhis BJ, et al. Performance of the postwash total motile sperm count as a predictor of pregnancy at the time of intrauterine insemination: a meta-analysis. Fertil Steril 2004; 82:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/42\">",
"      Van Voorhis BJ, Barnett M, Sparks AE, et al. Effect of the total motile sperm count on the efficacy and cost-effectiveness of intrauterine insemination and in vitro fertilization. Fertil Steril 2001; 75:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/43\">",
"      Miller DC, Hollenbeck BK, Smith GD, et al. Processed total motile sperm count correlates with pregnancy outcome after intrauterine insemination. Urology 2002; 60:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/44\">",
"      Huang HY, Lee CL, Lai YM, et al. The impact of the total motile sperm count on the success of intrauterine insemination with husband's spermatozoa. J Assist Reprod Genet 1996; 13:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/45\">",
"      Wainer R, Albert M, Dorion A, et al. Influence of the number of motile spermatozoa inseminated and of their morphology on the success of intrauterine insemination. Hum Reprod 2004; 19:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/46\">",
"      van der Poel N, Farquhar C, Abou-Setta AM, et al. Soft versus firm catheters for intrauterine insemination. Cochrane Database Syst Rev 2010; :CD006225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/47\">",
"      Lavie O, Margalioth EJ, Geva-Eldar T, Ben-Chetrit A. Ultrasonographic endometrial changes after intrauterine insemination: a comparison of two catheters. Fertil Steril 1997; 68:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/48\">",
"      Settlage DS, Motoshima M, Tredway DR. Sperm transport from the external cervical os to the fallopian tubes in women: a time and quantitation study. Fertil Steril 1973; 24:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25351/abstract/49\">",
"      Saleh A, Tan SL, Biljan MM, Tulandi T. A randomized study of the effect of 10 minutes of bed rest after intrauterine insemination. Fertil Steril 2000; 74:509.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7413 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25351=[""].join("\n");
var outline_f24_48_25351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DOCUMENTING OVULATION AND TIMING OF INSEMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Natural cycle procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Controlled ovarian stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Protocols",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SPERM PROCESSING AND INSEMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Semen collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sperm preparation techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Inseminate parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Insemination catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      INTRAUTERINE INSEMINATION PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Patient preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Postprocedure care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7413\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7413|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15931\" title=\"table 1\">",
"      Types of IUI catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=related_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=related_link\">",
"      Unexplained infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_48_25352="Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children";
var content_f24_48_25352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/48/25352/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25352/contributors\">",
"     Sarah D de Ferranti, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25352/contributors\">",
"     Jane W Newburger, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/48/25352/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25352/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/48/25352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25352/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/48/25352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1256643\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cardiovascular disease (CVD) is generally manifest in adulthood, the process of atherosclerosis can begin early in childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/1\">",
"     1",
"    </a>",
"    ]. For most children, atherosclerotic vascular changes are minor and can be minimized or even prevented with adherence to a healthy lifestyle. However, in some children, the atherosclerotic process is accelerated because of the presence of identifiable risk factors (eg, obesity and hypertension)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    specific diseases that are associated with premature CVD (eg, diabetes mellitus and Kawasaki disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary prevention measures to minimize the risk of developing atherosclerosis in childhood will be reviewed here. In addition, the primary care assessment to identify the child at risk for premature atherosclerosis, and by extension CVD, will also be discussed. Risk factors for early atherosclerosis in childhood and the management of the child at risk for atherosclerosis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link\">",
"     \"Risk factors and development of atherosclerosis in childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1258227\">",
"    <span class=\"h1\">",
"     PEDIATRIC PREVENTION OF CARDIOVASCULAR DISEASE (CVD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, guidelines from an expert panel sponsored by the United States National Heart, Lung, and Blood Institute (NHLBI) outlined two primary pediatric goals to prevent atherosclerosis and by extension, CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of the development of risk factors associated with atherosclerosis (primordial prevention) based on general measures that focus on adherence to a healthy lifestyle.",
"     </li>",
"     <li>",
"      Identification and management of the child at risk for early atherosclerosis based on the presence of established risk factors including hypertension, obesity, dyslipidemia, insulin resistance, physical inactivity, and smoke exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H3#H3\">",
"       \"Risk factors and development of atherosclerosis in childhood\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1258262\">",
"    <span class=\"h1\">",
"     PROMOTION OF HEALTHY LIFESTYLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of the development of cardiovascular disease (CVD) risk factors should be addressed in the pediatric primary care office by promoting a healthy lifestyle for the individual child, and on a population level through advocacy (eg, promoting healthier school lunch, smaller portion sizes, and increasing public awareness on healthy dietary choices). The rationale for these approaches is that an adult population with a lower risk burden of atherosclerosis, as a result of pediatric preventive care, will have a lower rate of CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2011 NHLBI guidelines, specific measures for preventing atherosclerosis were reviewed and graded based on the available literature [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/1\">",
"     1",
"    </a>",
"    ]. These guidelines recommend that pediatric routine health care supervision should promote and reinforce positive cardiovascular behaviors. Age- and developmental stage-based recommendations were developed using the health care supervision framework of Bright Futures of the American Academy of Pediatrics and are focused on the following areas to reduce the risk of developing atherosclerosis.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nutrition",
"     </li>",
"     <li>",
"      Physical activity",
"     </li>",
"     <li>",
"      Smoke exposure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from the Cardiovascular Risk in Young Finns Study demonstrated that ideal cardiovascular (CV) health in childhood is related to lower prevalence of CVD factors in adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/3\">",
"     3",
"    </a>",
"    ]. Ideal CV health was defined as the simultaneous presence of four beneficial health measures that included never tried smoking, body mass index &lt;85",
"    <sup>",
"     th",
"    </sup>",
"    percentile, physical activity at goal levels (",
"    <a class=\"graphic graphic_table graphicRef75748 \" href=\"UTD.htm?20/10/20653\">",
"     table 1",
"    </a>",
"    ), and diet consistent with current dietary recommendations (",
"    <a class=\"graphic graphic_table graphicRef78256 \" href=\"UTD.htm?3/49/3870\">",
"     table 2",
"    </a>",
"    ). In this cohort of 856 individuals followed for 21 years, an increasing number of ideal CV measures was associated with reduced risk of hypertension, metabolic syndrome, dyslipidemia (ie, elevated low-density lipoprotein cholesterol), and increased carotid artery intima-media thickness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1258283\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good nutrition beginning at birth has profound health benefits including a potential to decrease the risk of CVD by preventing or ameliorating obesity, dyslipidemia, hypertension, and insulin",
"    <span class=\"nowrap\">",
"     resistance/diabetes",
"    </span>",
"    mellitus. Several United States health organizations (American Academy of Pediatrics [AAP], the American Heart Association, the American Dietetic Association, and the United States Departments of Agriculture and Health and Human Services",
"    <span class=\"nowrap\">",
"     [USDA/HHS])",
"    </span>",
"    have issued dietary guidelines for children and adolescents that are consistent with one another and are discussed in greater detail separately (",
"    <a class=\"graphic graphic_table graphicRef79084 \" href=\"UTD.htm?5/60/6093\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=see_link&amp;anchor=H12#H12\">",
"     \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Dietary guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2011 NHLBI expert panel endorsed the",
"    <span class=\"nowrap\">",
"     USDA/HHS",
"    </span>",
"    dietary recommendations for children aged two years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, the panel also provided the following age-specific guidelines for a cardiac healthy diet for all pediatric patients from birth to 21 years of age (",
"    <a class=\"graphic graphic_table graphicRef78256 \" href=\"UTD.htm?3/49/3870\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In accordance with the World Health Organization, AAP, the United States Surgeon General Office, and the American Academy of Family Physicians, exclusive breastfeeding is recommended for the first six months of life and continued breastfeeding to at least 12 months of age. Breastfeeding appears to decrease dyslipidemia and obesity, two CVD risk factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=see_link\">",
"       \"Breastfeeding: Parental education and support\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link&amp;anchor=H20#H20\">",
"       \"Infant benefits of breastfeeding\", section on 'Adult cardiovascular disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Within appropriate age- and gender-based requirements for growth and nutrition, the total fat intake is limited to 30 percent of total calories, saturated fat to 7 to 10 percent of total calories, and dietary cholesterol to less than 300",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      However, fat intake should not be restricted in infants younger than 12 months of age without medical indication.",
"      <br/>",
"      <br/>",
"      Support for this recommendation is based on the Special Turku Coronary Risk Factor Intervention Project (STRIP) trial that demonstrated modest improvements in fasting lipid profiles in infants whose parents received counseling regarding a low-saturated-fat, low-cholesterol diet compared to those whose parents did not receive any dietary counseling [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/4-7\">",
"       4-7",
"      </a>",
"      ]. At 14 and 19 years of age, the group that received repeated dietary counseling for a low-fat diet had lower saturated fat intakes, and serum LDL-C (low-density lipoprotein cholesterol) than the control group [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Importantly, there was no difference in neurodevelopmental outcome, which effectively addressed an initial concern that a low-fat diet may adversely affect development. This diet primarily relied on fruit and vegetables, whole grains, low-fat and nonfat dairy products, beans, fish, and lean meat [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The remaining 20 percent of fat intake should be composed of a combination of monosaturated and polyunsaturated fat. Additive trans fats should be eliminated from the diet.",
"     </li>",
"     <li>",
"      The remaining 70 percent of total calories should include 15 to 20 percent derived from protein intake, and 50 to 55 percent from carbohydrates primarily in the form of whole grains.",
"     </li>",
"     <li>",
"      The caloric intake should match the growth demands and physical activity of each individual child. Estimated calorie requirements are based on gender, age, and level of activity (",
"      <a class=\"graphic graphic_table graphicRef52158 \" href=\"UTD.htm?18/60/19405\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Ongoing nutritional counseling for families with children with identified CVD risk factors by a registered dietician is recommended to assist in the adoption and sustainability of a diet that provides adequate nutrition and reduces CVD risk. A behavioral approach that engages the child and family has been shown to be the most effective method for achieving dietary change [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/1\">",
"       1",
"      </a>",
"      ]. Dietary counseling should be tailored to each child and family based on diet patterns, social setting, and patient sensitivities, such as lactose intolerance and food allergy.",
"     </li>",
"     <li>",
"      Other recommendations include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increased intake of vegetables and fruits, using models that have been shown to be beneficial in adults. Specifically, the panel provided a pediatric version of the DASH (Dietary Approaches to Stop Hypertension) diet, based on total daily caloric intake. This diet is rich in fruits and vegetables, whole grains, and lean proteins (",
"      <a class=\"graphic graphic_table graphicRef64935 \" href=\"UTD.htm?11/33/11806\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Reduce the intake of sugar-sweetened beverages and foods. In infants between 6 and 12 months of age, only 100 percent juice should be allowed, and the intake should not exceed 4 ounces per day.",
"     </li>",
"     <li>",
"      In children older than 12 months, if cow&rsquo;s milk is introduced, decide with the parents on the fat content of milk based on the child&rsquo;s growth, appetite, body mass index, CVD risk factors, and intake of other sources of fat and caloric dense foods. The medical provider may decide that low fat dairy is appropriate as early as 12 months. By two years of age, saturated fat should be limited to 8 to 10 percent of the daily caloric intake and milk should be provided as 1% fat or skim (",
"      <a class=\"graphic graphic_table graphicRef78256 \" href=\"UTD.htm?3/49/3870\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In children greater than two years of age, encourage the intake of dietary fiber in the form of naturally fiber-rich foods such as fruits, vegetables, and whole grains.",
"     </li>",
"     <li>",
"      A daily minimum intake of vitamin D supplementation (400",
"      <span class=\"nowrap\">",
"       IU/day)",
"      </span>",
"      is recommended for all children. No other vitamin, mineral, or dietary supplementation is recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link&amp;anchor=H23365817#H23365817\">",
"       \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Recommendations for vitamin D intake'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5129625\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, evidence demonstrates that daily vigorous activity decreases the risk of CVD and improves fasting lipid profiles. Although data similar in quality are limited in children, there are several reports that demonstrate the beneficial effect of increased physical activity and reduction of sedentary behavior on reducing the risk of atherosclerosis and CVD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Special Turku Coronary Risk Factor Intervention Project for Children, multivariate analysis demonstrated lower amounts of physical activity for adolescents (determined by questionnaire) correlated with increased risk of atherosclerosis by indirect measures (ie, increased mean aortic intima-media thickness [IMT] and decreased endothelial function measured by flow-mediated dilation [FMD]) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/11\">",
"       11",
"      </a>",
"      ]. Sedentary adolescents who increased their level of physical activity decreased the progression of IMT compared with adolescents who remained sedentary. In persistently active adolescents, the progression of IMT was attenuated compared with those who became sedentary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H235229608#H235229608\">",
"       \"Risk factors and development of atherosclerosis in childhood\", section on 'Indirect evidence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In another report from the Special Turku Coronary Risk Factor Intervention Project for Children, sedentary adolescents were at an increased risk for clustered metabolic risk factors compared with more physically active peers [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/12\">",
"       12",
"      </a>",
"      ]. Physical activity was based on self-report and the cluster risk factors were body mass index (BMI), lipid profile, and blood pressure.",
"     </li>",
"     <li>",
"      In a report from the longitudinal Cardiovascular Risk in Young Finns study that recruited children from ages 3 to 18 years, low physical activity was associated with accelerated IMT progression over 27 years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from the International Children&rsquo;s Accelerometry Database demonstrated that increasing time for moderate- to vigorous activity (MVA) was associated with better cardiometabolic risk factors regardless of the amount of sedentary time [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/14\">",
"       14",
"      </a>",
"      ]. Higher mean time spent in MVA correlated with reductions in mean waist circumference, systolic blood pressure, fasting insulin, and fasting triglycerides, and increases in HDL-C (high-density lipoprotein cholesterol).",
"     </li>",
"     <li>",
"      In the Dietary Intervention Study in Childhood, higher self-reported levels of physical activity were associated with lower systolic blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several small studies have shown exercise programs that improve physical fitness resulted in a reduction of CVD risk factors including lowering BMI, blood pressure, and arterial stiffness; and improving lipid profiles [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/16-18\">",
"       16-18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also evidence that physical activity patterns established in childhood are continued through adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the above evidence and data from adult studies, routine physical activity should be encouraged as it is associated with a decrease risk of atherosclerosis and CVD. However, the type and level of activity for optimum cardiovascular health are unknown.",
"   </p>",
"   <p>",
"    Based on currently available data, the expert NHLBI made the following age-based recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/1\">",
"     1",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef75748 \" href=\"UTD.htm?20/10/20653\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All children older than five years of age should participate in moderate to vigorous physical activity for at least 60 minutes per day, which is in accordance with the recommendations by the United States Centers for Disease Control and Prevention (CDC,",
"      <a class=\"external\" href=\"file://www.cdc.gov/healthyYouth/physicalactivity/guidelines.htm\">",
"       Youth physical activity guide",
"      </a>",
"      ). In addition, the activity should be vigorous on three days of the week, which is in agreement with the 2008 Physical Activity Guidelines Advisory Committee Report from the United States Department of Health and Human Services (",
"      <a class=\"external\" href=\"file://www.health.gov/paguidelines/guidelines/summary.aspx\">",
"       2008 HHS Physical Activity Guide for Americans",
"      </a>",
"      ). Examples of moderate activity are jogging or playing baseball, and examples of vigorous activity are running, playing singles tennis, or playing soccer.",
"     </li>",
"     <li>",
"      In younger children and infants, parents should allow for unlimited active playtime in a safe and supportive environment.",
"     </li>",
"     <li>",
"      Limiting leisure screen time to less than two hours a day in children. In infants less than 12 months of age, screen viewing should be entirely discouraged.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1262290\">",
"    <span class=\"h2\">",
"     Avoid smoke exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric health care clinicians should provide ongoing counseling on the benefits of a smoke-free environment for the child and family. Patients and parents should be informed about the addictive and adverse health effects of smoking, including the risk of CVD, for themselves and for their children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37081?source=see_link\">",
"     \"Prevention of smoking initiation in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/23/30073?source=see_link\">",
"     \"Cardiovascular effects of nicotine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1256953\">",
"    <span class=\"h1\">",
"     IDENTIFYING CHILDREN AT RISK FOR CVD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1262598\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening is common in regular pediatric care and is designed to identify conditions that, if untreated, increase risk of disease sequelae, and for which there is an available cost-effective intervention. When deciding whether screening should be performed, the test&rsquo;s sensitivity and specificity, prevalence of the screened condition, cost of the screening test, and the potential benefits and harms of screening and intervention must be considered. In pediatrics, evidence is often lacking from randomized controlled trials to determine whether or not screening and treatment are beneficial and cost-effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H2#H2\">",
"     \"Screening tests in children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data are not available to assess individual risk for CVD in clinical pediatric practice. Because premature CVD occurs decades after suspected exposures, and premature atherosclerosis is generally asymptomatic, there have been no randomized controlled trials of different screening practices examining risks, benefits, costs, and effectiveness.",
"   </p>",
"   <p>",
"    In contrast, there are large prospective population-based studies for adults that assess individual risk for cardiovascular events and guide therapeutic choices aimed at risk reduction (eg, Framingham or Reynolds Risk Score). This approach directly links risk factors to cardiovascular events and is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the paucity of evidence from randomized controlled trials in children, the following pediatric risk factors for accelerated atherosclerosis (and by extension CVD) have been identified through direct evidence from autopsy studies and indirect evidence using methods that detect vascular changes that have been associated with increased risk of CVD in adults. Screening for these risk factors is recommended by the AAP, AHA, and NHLBI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk factors and development of atherosclerosis in childhood\", section on 'Atherosclerotic changes in childhood'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H3#H3\">",
"     \"Risk factors and development of atherosclerosis in childhood\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity and overweight",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Dyslipidemia",
"     </li>",
"     <li>",
"      Smoke exposure",
"     </li>",
"     <li>",
"      High-risk diseases (eg, chronic renal disease, diabetes mellitus Type 1 and Type 2, and",
"      <span class=\"nowrap\">",
"       homozygous/heterozygous",
"      </span>",
"      familial hypercholesterolemia)",
"     </li>",
"     <li>",
"      Family history of premature coronary artery disease in first degree relative (ie, heart attack, confirmed angina, interventions for coronary artery disease, stroke, or sudden cardiac disease in a male parent or sibling before 55 years of age, or a female parent or sibling before 65 years of age)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although long-term outcome data are not available to demonstrate that identification and treatment of risk factors in childhood will reduce the prevalence of clinical disease, it is reasonable to assume based on data from adult studies that timely intervention to prevent (primordial prevention), decrease and possibly eliminate CVD risk factor(s) in children will decelerate the atherosclerotic process (primary prevention), and prevent or delay the onset of CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/2,19,20\">",
"     2,19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1262516\">",
"    <span class=\"h2\">",
"     Routine health care",
"    </span>",
"    &nbsp;&mdash;&nbsp;During routine health supervision visits, screening is recommended by the AAP, the AHA, and NHLBI to identify children with any of the above risk factors associated with atherosclerosis.",
"   </p>",
"   <p>",
"    Routine screening consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obtain history for possible smoke exposure, diet, and level and frequency of physical activity and inactivity.",
"     </li>",
"     <li>",
"      Review the family history for premature coronary artery disease. The NHLBI guidelines suggest that the family history for premature CVD be reviewed at the prenatal or first visit, and again at routine visits at three and ten years of age.",
"     </li>",
"     <li>",
"      Identify conditions associated with accelerated atherosclerosis (",
"      <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"       algorithm 1",
"      </a>",
"      ) (ie, high-risk diseases).",
"     </li>",
"     <li>",
"      Measure blood pressure, weight, and height.",
"     </li>",
"     <li>",
"      Calculate body mass index (BMI): BMI and BMI percentiles may be determined using linked calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link\">",
"       \"Measurement of growth in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lipid screening initially at 9 to 11 years of age, and again between 17 and 21 years of age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/17/281?source=see_link&amp;anchor=H235228239#H235228239\">",
"       \"Definition and screening for dyslipidemia in children\", section on 'Lipid screening'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1256961\">",
"    <span class=\"h3\">",
"     High-risk diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain pediatric diseases are known to be associated with accelerated atherosclerosis and premature CVD. In 2011, a risk stratification algorithm developed in 2007 for the following conditions associated with CVD in children and adolescents was revised into a simpler two-tier system (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link\">",
"     \"Diseases associated with atherosclerosis in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Homozygous and heterozygous familial hypercholesterolemia",
"     </li>",
"     <li>",
"      Types 1 and 2 diabetes mellitus",
"     </li>",
"     <li>",
"      Chronic kidney disease",
"     </li>",
"     <li>",
"      Cardiac transplant recipients",
"     </li>",
"     <li>",
"      Kawasaki disease",
"     </li>",
"     <li>",
"      Chronic inflammatory diseases",
"     </li>",
"     <li>",
"      Cancer survivors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this algorithm, management decisions (ie, indiction for intervention and goals of therapy) are based on the risk stratification of the specific condition and the presence of the following additional CVD risk factors (",
"    <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal fasting lipid profile",
"     </li>",
"     <li>",
"      Family history of early coronary artery disease",
"     </li>",
"     <li>",
"      Hypertension (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H6#H6\">",
"       \"Risk factors and development of atherosclerosis in childhood\", section on 'Hypertension'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased body mass index",
"     </li>",
"     <li>",
"      Fasting blood glucose greater than 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Smoke exposure",
"     </li>",
"     <li>",
"      Physical activity of less than one hour a day",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1256968\">",
"    <span class=\"h2\">",
"     Further screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of childhood atherosclerosis (and by extension the risk of CVD) increases as the number of CVD risk factors increases. Thus, further evaluation is recommend for children who are identified as having one or more known atherosclerotic risk factors or with an underlying primary disease associated with increased risk for CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25352/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure is measured on three separate occasions with the appropriate sized cuff. The age- and height-specific blood pressure percentiles should be determined using calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"       calculator 3",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"       calculator 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Accurate measurements of height and weight, and calculation of BMI. BMI and BMI percentiles may be determined using calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link\">",
"       \"Measurement of growth in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lipid profile. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/17/281?source=see_link&amp;anchor=H235228239#H235228239\">",
"       \"Definition and screening for dyslipidemia in children\", section on 'Lipid screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fasting blood sugar",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemoglobin A1C. The NHLBI guidelines suggest that abnormal glucose metabolism be assessed using a fasting blood sugar every two years in patients &ge;10 years of age with a BMI &ge;85",
"      <sup>",
"       th",
"      </sup>",
"      percentile, and two additional risk factors for diabetes. Risk factors include family history of type 2 DM, ethnicity with a high risk for diabetes, signs of insulin resistance, or conditions with a high-risk for diabetes (eg, polycystic ovarian syndrome). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=see_link&amp;anchor=H4#H4\">",
"       \"Diseases associated with atherosclerosis in childhood\", section on 'Diabetes mellitus'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnosis of diabetes mellitus\", section on 'Hemoglobin A1C'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      History of smoke exposure including both personal and second-hand smoke. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=see_link&amp;anchor=H12#H12\">",
"       \"Risk factors and development of atherosclerosis in childhood\", section on 'Smoke exposure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise, amount of screen time, diet, and sleep history. Obstructive sleep apnea is a risk factor for CVD and is discussed separately. (See",
"      <a class=\"local\" href=\"#H5129625\">",
"       'Physical activity'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"       \"Cardiovascular effects of obstructive sleep apnea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11092?source=see_link\">",
"       \"Sleep physiology in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5929?source=see_link\">",
"       \"Assessment of sleep disorders in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment, including non-pharmacologic interventions, is initiated for children who are judged to be at increased risk for atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=see_link\">",
"     \"Overview of the management of the child at risk for atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1257420\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric prevention to reduce the risk of adult cardiovascular disease (CVD) consists of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      General measures for adherence to a healthy lifestyle that would prevent or reduce the development of risk factors associated with atherosclerosis. (See",
"      <a class=\"local\" href=\"#H1258262\">",
"       'Promotion of healthy lifestyle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identification and management of the child at risk for early atherosclerosis based on the presence of established risk factors including hypertension, obesity, dyslipidemia, insulin resistance, physical inactivity, smoke exposure, or high risk conditions (",
"      <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1256953\">",
"       'Identifying children at risk for CVD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During routine care visits, we suggest that care providers promote positive cardiovascular behaviors and a healthy lifestyle to reduce the development of risk factors associated with early atherosclerosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In particular, pediatric care providers should provide age-appropriate information and support to children and their families regarding nutrition (ie, a diet low in saturated fat and rich in vegetables, fruits, and whole grains) (",
"      <a class=\"graphic graphic_table graphicRef78256 \" href=\"UTD.htm?3/49/3870\">",
"       table 2",
"      </a>",
"      ), physical activity (",
"      <a class=\"graphic graphic_table graphicRef75748 \" href=\"UTD.htm?20/10/20653\">",
"       table 1",
"      </a>",
"      ), and avoidance of smoke exposure. (See",
"      <a class=\"local\" href=\"#H1258262\">",
"       'Promotion of healthy lifestyle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term outcome data are not available to demonstrate that identification and treatment of risk factors in childhood will reduce or prevent premature CVD in adults. Nevertheless, it is reasonable to assume based on data from adult studies that timely intervention that reduces and possibly eliminates these risk factor(s) in children will decelerate the atherosclerotic process (primary prevention), and prevent or delay the early onset of CVD. As a result, we suggest that all children during routine health care visits be screened for CVD and atherosclerotic risk factors (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Screening consists of reviewing the child&rsquo;s diet, physical activity level, risk of smoke exposure, and family history for premature CVD; measuring blood pressure, weight, and height; calculating body mass index (BMI); lipid screening; and identifying any condition that is associated with accelerated atherosclerosis in childhood (",
"      <a class=\"graphic graphic_algorithm graphicRef54963 \" href=\"UTD.htm?0/45/726\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1262516\">",
"       'Routine health care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extent of childhood atherosclerosis (and by extension the risk of CVD) rises as the number of CVD risk factors increases in children. We suggest children with one or more known risk factors or with an underlying primary disease associated with increased risk for CVD should be screened (in some cases rescreened) for additional risk factors (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Screening includes the same elements that are done routinely for all children (eg, blood pressure, lipid profile, growth measurements, BMI) and the additional assessment for obstructive sleep apnea, diabetes, and insulin resistance. (See",
"      <a class=\"local\" href=\"#H1256968\">",
"       'Further screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/1\">",
"      Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/2\">",
"      American Academy of Pediatrics. Cardiovascular risk reduction in high-risk pediatric populations. Pediatrics 2007; 119:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/3\">",
"      Laitinen TT, Pahkala K, Magnussen CG, et al. Ideal cardiovascular health in childhood and cardiometabolic outcomes in adulthood: the Cardiovascular Risk in Young Finns Study. Circulation 2012; 125:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/4\">",
"      Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation 2009; 119:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/5\">",
"      Rask-Nissil&auml; L, Jokinen E, R&ouml;nnemaa T, et al. Prospective, randomized, infancy-onset trial of the effects of a low-saturated-fat, low-cholesterol diet on serum lipids and lipoproteins before school age: The Special Turku Coronary Risk Factor Intervention Project (STRIP). Circulation 2000; 102:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/6\">",
"      Niinikoski H, Viikari J, R&ouml;nnemaa T, et al. Prospective randomized trial of low-saturated-fat, low-cholesterol diet during the first 3 years of life. The STRIP baby project. Circulation 1996; 94:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/7\">",
"      Kaitosaari T, R&ouml;nnemaa T, Raitakari O, et al. Effect of 7-year infancy-onset dietary intervention on serum lipoproteins and lipoprotein subclasses in healthy children in the prospective, randomized Special Turku Coronary Risk Factor Intervention Project for Children (STRIP) study. Circulation 2003; 108:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/8\">",
"      Niinikoski H, Lagstr&ouml;m H, Jokinen E, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation 2007; 116:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/9\">",
"      Niinikoski H, Pahkala K, Ala-Korpela M, et al. Effect of repeated dietary counseling on serum lipoproteins from infancy to adulthood. Pediatrics 2012; 129:e704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/10\">",
"      Gidding SS, Dennison BA, Birch LL, et al. Dietary recommendations for children and adolescents: a guide for practitioners. Pediatrics 2006; 117:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/11\">",
"      Pahkala K, Heinonen OJ, Simell O, et al. Association of physical activity with vascular endothelial function and intima-media thickness. Circulation 2011; 124:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/12\">",
"      Pahkala K, Heinonen OJ, Lagstr&ouml;m H, et al. Clustered metabolic risk and leisure-time physical activity in adolescents: effect of dose? Br J Sports Med 2012; 46:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/13\">",
"      Juonala M, Viikari JS, K&auml;h&ouml;nen M, et al. Life-time risk factors and progression of carotid atherosclerosis in young adults: the Cardiovascular Risk in Young Finns study. Eur Heart J 2010; 31:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/14\">",
"      Ekelund U, Luan J, Sherar LB, et al. Moderate to vigorous physical activity and sedentary time and cardiometabolic risk factors in children and adolescents. JAMA 2012; 307:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/15\">",
"      Gidding SS, Barton BA, Dorgan JA, et al. Higher self-reported physical activity is associated with lower systolic blood pressure: the Dietary Intervention Study in Childhood (DISC). Pediatrics 2006; 118:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/16\">",
"      Farpour-Lambert NJ, Aggoun Y, Marchand LM, et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 2009; 54:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/17\">",
"      Tolfrey K, Jones AM, Campbell IG. The effect of aerobic exercise training on the lipid-lipoprotein profile of children and adolescents. Sports Med 2000; 29:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/18\">",
"      Janz KF, Dawson JD, Mahoney LT. Increases in physical fitness during childhood improve cardiovascular health during adolescence: the Muscatine Study. Int J Sports Med 2002; 23 Suppl 1:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/19\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/20\">",
"      Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2006; 114:2710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25352/abstract/21\">",
"      American Academy of Pediatrics. Committee on Nutrition. American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. Pediatrics 1998; 101:141.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16975 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-197.136.42.3-3357F5F93E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25352=[""].join("\n");
var outline_f24_48_25352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1257420\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1256643\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1258227\">",
"      PEDIATRIC PREVENTION OF CARDIOVASCULAR DISEASE (CVD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1258262\">",
"      PROMOTION OF HEALTHY LIFESTYLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1258283\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5129625\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1262290\">",
"      Avoid smoke exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1256953\">",
"      IDENTIFYING CHILDREN AT RISK FOR CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1262598\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1262516\">",
"      Routine health care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1256961\">",
"      - High-risk diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1256968\">",
"      Further screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1257420\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/16975\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16975|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/45/726\" title=\"algorithm 1\">",
"      NHLBI pediatric risk stratification associated with CVD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16975|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/10/20653\" title=\"table 1\">",
"      Pediatric physical activity for CV health",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/49/3870\" title=\"table 2\">",
"      Pediatric diet to prevent CVD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/60/6093\" title=\"table 3\">",
"      Dietary guidelines children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/60/19405\" title=\"table 4\">",
"      Pediatric calorie needs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/33/11806\" title=\"table 5\">",
"      Pediatric version DASH diet",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?35/14/36070?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/60/35782?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 3\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 4\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5929?source=related_link\">",
"      Assessment of sleep disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=related_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/23/30073?source=related_link\">",
"      Cardiovascular effects of nicotine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/281?source=related_link\">",
"      Definition and screening for dyslipidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18441?source=related_link\">",
"      Dietary recommendations for toddlers, preschool, and school-age children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40184?source=related_link\">",
"      Diseases associated with atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23320?source=related_link\">",
"      Overview of the management of the child at risk for atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37081?source=related_link\">",
"      Prevention of smoking initiation in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43096?source=related_link\">",
"      Risk factors and development of atherosclerosis in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11092?source=related_link\">",
"      Sleep physiology in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_48_25353="Hydromorphone: Drug information";
var content_f24_48_25353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydromorphone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/48/14086?source=see_link\">",
"    see \"Hydromorphone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/13/3289?source=see_link\">",
"    see \"Hydromorphone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dilaudid-HP&reg;;",
"     </li>",
"     <li>",
"      Dilaudid&reg;;",
"     </li>",
"     <li>",
"      Exalgo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dilaudid-HP&reg;;",
"     </li>",
"     <li>",
"      Dilaudid&reg;;",
"     </li>",
"     <li>",
"      Hydromorph Contin&reg;;",
"     </li>",
"     <li>",
"      Hydromorphone HP;",
"     </li>",
"     <li>",
"      Hydromorphone HP&reg; 10;",
"     </li>",
"     <li>",
"      Hydromorphone HP&reg; 20;",
"     </li>",
"     <li>",
"      Hydromorphone HP&reg; 50;",
"     </li>",
"     <li>",
"      Hydromorphone HP&reg; Forte;",
"     </li>",
"     <li>",
"      Hydromorphone Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Jurnista&trade;;",
"     </li>",
"     <li>",
"      PMS-Hydromorphone;",
"     </li>",
"     <li>",
"      Teva-Hydromorphone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F180641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F180611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute pain (moderate-to-severe):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     These are guidelines and do not represent the maximum doses that may be required in all patients. Doses should be  titrated to provide adequate pain relief. When changing routes of administration, oral doses and parenteral doses are",
"     <b>",
"      NOT",
"     </b>",
"     equivalent; parenteral doses are up to 5 times more potent. Therefore, when administered parenterally, one-fifth of the oral dose will provide similar analgesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial: Opioid-naive: 2-4 mg every 4-6 hours as needed; elderly/debilitated patients may require lower doses; patients with prior opioid exposure may require higher initial doses.",
"     <b>",
"      Note:",
"     </b>",
"     In adults with severe pain, the American Pain Society recommends an initial dose of 4-8 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Initial: Opioid-naive: 0.2-1 mg every 2-3 hours as needed; patients with prior opioid exposure may require higher initial doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Critically ill patients (unlabeled dosing): 0.2-0.6 mg every 1-2 hours as needed",
"     <b>",
"      or",
"     </b>",
"     0.5 mg every 3 hours as needed (Barr, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Continuous infusion: Usual dosage range: 0.5-3 mg/hour (Barr, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patient-controlled analgesia (PCA) (unlabeled dosing) (American Pain Society, 2008):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Opioid-naive: Consider lower end of dosing range:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Usual concentration: 0.2 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Demand dose: Usual initial dose: 0.1-0.2 mg; range: 0.05-0.4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Lockout interval: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Epidural PCA (unlabeled dosing) (de Leon-Casasola, 1996; Liu, 2010; Smith, 2009):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Usual concentration: 0.01 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bolus dose: 0.4-1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infusion rate: 0.03-0.3 mg/",
"     <b>",
"      hour",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Demand dose: 0.02-0.05 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lockout interval: 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., SubQ:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     I.M. use may result in variable absorption and lag time to peak effect; I.M. route not recommended for use (American Pain Society, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial: Opioid-naive: 0.8-1 mg every 3-4 hours as needed; patients with prior opioid exposure may require higher initial doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rectal:",
"     </i>",
"     3 mg every 6-8 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Chronic pain:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Patients taking opioids chronically may become tolerant and require doses higher than the usual dosage range to maintain the desired effect. Tolerance can be managed by appropriate dose titration. There is no optimal or maximal dose for hydromorphone in chronic pain.  The appropriate dose is one that relieves pain throughout its dosing interval without causing unmanageable side effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Controlled release formulation (Hydromorph Contin&reg;, not available in U.S.):",
"     </i>",
"     Oral: 3-30 mg every 12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     A patient's hydromorphone requirement should be established using prompt release formulations; conversion to long acting products may be considered when chronic, continuous treatment is required. Higher dosages should be reserved for use only in opioid-tolerant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Extended release formulation (Exalgo&reg;):",
"     </i>",
"     Dosing range: 8-64 mg every 24 hours. For use in opioid-tolerant patients only; discontinue all other extended release opioids when starting therapy. Suggested recommendations for converting to Exalgo&reg; from other analgesics are presented, but when selecting the initial dose, other characteristics (eg, patient status, degree of opioid tolerance, concurrent medications, type of pain, risk factors for addiction or diversion, etc) should also be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Individualization of dose:",
"     </i>",
"     Pain relief and adverse events should be assessed frequently. Dose increases may occur not more often than every 3-4 days; consider titrating with increases of 25% to 50% of the current daily dose. If more than 2 doses of rescue medications are needed within 24 hours for 2 consecutive days, consider increasing the dose of Exalgo&reg;. Do not administer more frequently than every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Conversion from other oral hydromorphone formulations to Exalgo&reg;:",
"     </i>",
"     Start with the equivalent total daily dose of immediate-release hydromorphone administered once daily. May titrate every 3-4 days until adequate pain relief with tolerable side effects have been achieved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Conversion from other opioids to Exalgo&reg;:",
"     </i>",
"     In general, start Exalgo&reg; at 50% of the calculated total daily dose every 24 hours (see Conversion Ratios to Exalgo&reg;). Titrate until adequate pain relief with tolerable side effects has been achieved. The following conversion ratios may be used to convert from",
"     <b>",
"      oral",
"     </b>",
"     opioid therapy to Exalgo&reg;.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Conversion ratios to Exalgo&reg; (see table):",
"     </i>",
"     Select the opioid, sum the total daily dose, then multiply by the conversion ratio to calculate the",
"     <i>",
"      approximate",
"     </i>",
"     oral hydromorphone equivalent; start Exalgo&reg; at 50% of the calculated total daily dose every 24 hours. (",
"     <b>",
"      Note:",
"     </b>",
"     The conversion ratios and approximate equivalent doses in this conversion table are only to be used for the conversion from current opioid therapy to Exalgo&reg;).",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Conversion Ratios to Exalgo&reg;",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Previous Opioid",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate Equivalent Oral Dose",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oral Conversion Ratio",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         <i>",
"          Approximate",
"         </i>",
"         equivalent doses for conversion from current opioid therapy to Exalgo&reg;.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Ratio for converting oral opioid dose to approximate hydromorphone equivalent dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Monitor closely; ratio between methadone and other opioid agonists may vary widely as a function of previous drug exposure. Methadone has a long half-life and may accumulate in the plasma.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hydromorphone",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Codeine",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.06",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hydrocodone",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Methadone",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.6",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Morphine",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.2",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oxycodone",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Oxymorphone",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.6",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Conversion from transdermal fentanyl to Exalgo&reg;:",
"     </i>",
"     Treatment with Exalgo&reg; can be started 18 hours after the removal of the transdermal fentanyl patch. For every fentanyl 25 mcg/hour transdermal dose, the equianalgesic dose of Exalgo&reg; is 12 mg every 24 hours. An appropriate starting dose is 50% of the calculated total daily dose given every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Discontinuing Exalgo&reg;:",
"     </i>",
"     Taper by gradually decreasing the dose by 25% to 50% every 2-3 days to a dose of 8 mg every 24 hours before discontinuing therapy.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F180630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/13/3289?source=see_link\">",
"      see \"Hydromorphone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Acute pain (moderate-to-severe):",
"     </b>",
"     <i>",
"      Children &gt;50 kg:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F180612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be titrated to appropriate analgesic effects. When changing routes of administration, oral doses and parenteral doses are",
"     <b>",
"      NOT",
"     </b>",
"     equivalent; parenteral doses are up to 5 times more potent. Therefore, when administered parenterally, one-fifth of the oral dose will provide similar analgesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Acute pain, opioid-naive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Use with caution; initiation at the low end of dosage range is recommended. For patients &gt;70 years, The American Pain Society recommends  consideration to lowering initial doses by 25% to 50% followed by upward or downward titration (APS, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V: Reduce initial dose to 0.2 mg",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10169504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral (immediate release), injectable: Initiate with 25% to 50% of the usual starting dose depending on the degree of impairment. Monitor closely for respiratory and CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral (extended release; Exalgo&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute): Initiate with 50% of the usual starting dose for patients with normal renal function; monitor closely for respiratory and CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt; 30 mL/minute): Initiate with 25% of the usual starting dose for patients with normal renal function; monitor closely for respiratory and CNS depression. Consider use of an alternate analgesic with better dosing flexibility.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F180613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Oral (immediate release), injectable:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Moderate impairment: Initiate with 25% to 50% of the usual starting dose for patients with normal hepatic function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment:  Has not been studied; initial dose should be more conservative as compared to those with moderate impairment; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral (extended release; Exalgo&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment: Initiate with 25% of the usual starting dose for patients with normal hepatic function; monitor closely for respiratory and CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: Use alternate analgesic.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilaudid-HP&reg;: 250 mg [contains natural rubber/natural latex in packaging, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 1 mg/mL (1 mL); 2 mg/mL (1 mL, 20 mL); 4 mg/mL (1 mL); 10 mg/mL (1 mL, 5 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilaudid-HP&reg;: 10 mg/mL (50 mL) [contains natural rubber/natural latex in packaging, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilaudid-HP&reg;: 10 mg/mL (1 mL, 5 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilaudid&reg;: 1 mg/mL (1 mL); 2 mg/mL (1 mL); 4 mg/mL (1 mL) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 10 mg/mL (1 mL, 5 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrochloride: 1 mg/mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilaudid&reg;: 1 mg/mL (473 mL) [contains sodium metabisulfite (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as hydrochloride: USP: 100% (972 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal, as hydrochloride: 3 mg (6s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 2 mg, 4 mg, 8 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilaudid&reg;: 2 mg, 4 mg [contains sodium metabisulfite (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilaudid&reg;: 8 mg [scored; contains sodium metabisulfite (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exalgo&reg;: 8 mg, 12 mg, 16 mg, 32 mg [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, controlled release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydromorph Contin&reg;: 3 mg, 6 mg, 12 mg, 18 mg, 24 mg, 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet, powder for injection",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F180643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11238289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exalgo&reg;: As a requirement of the REMS program, healthcare providers who prescribe Exalgo&reg; need to receive training on the proper use and potential risks of Exalgo&reg;. For training, please refer to file://www.exalgorems.com. Prescribers will need retraining every 2 years or following any significant changes to the Exalgo&reg; REMS program.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10168465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Exalgo&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM204267.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM204267.pdf",
"     </a>",
"     . Medication guides are also available at file://www.exalgorems.com.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F180582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"     <b>",
"      Note: Vial stopper may contain latex.",
"     </b>",
"     May be given SubQ or I.M.; I.M. route is not recommended (APS, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: For IVP, must be given slowly over 2-3 minutes (rapid IVP has been associated with an increase in side effects, especially respiratory depression and hypotension)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Hydromorphone is available in an 8 mg immediate release tablet and an 8 mg extended release tablet. Extreme caution should be taken to avoid confusing dosage forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exalgo&reg;: Tablets should be swallowed whole; do not crush, break, chew, dissolve or inject. May be taken with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydromorph Contin&reg;: Capsule should be swallowed whole; do not crush or chew; contents may be sprinkled on soft food and swallowed",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F180649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, acyclovir, allopurinol, amifostine, amikacin, amsacrine, anidulafungin, atropine, aztreonam, bivalirudin, caspofungin, cefepime, cefotaxime, cefoxitin, ceftazidime, cefuroxime, chloramphenicol, cisatracurium, cisplatin, cladribine, clindamycin, cyclophosphamide, cytarabine, dexmedetomidine, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin, doxorubicin liposome, doxycycline, epinephrine, erythromycin lactobionate, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fludarabine, foscarnet, furosemide, gemcitabine, gentamicin, granisetron, haloperidol, hetastarch in lactate electrolyte injection (Hextend&reg;), hydroxyzine, kanamycin, ketorolac, labetalol, levofloxacin, linezolid, lorazepam, magnesium sulfate, melphalan, methotrexate, methotrimeprazine, metoclopramide, metronidazole, micafungin, midazolam, milrinone, morphine, nafcillin, nicardipine, nitroglycerin, norepinephrine, ondansetron, oxacillin, oxaliplatin, paclitaxel, palonosetron, pemetrexed, penicillin G potassium, piperacillin, piperacillin/tazobactam, propofol, ranitidine, remifentanil, scopolamine, sulfamethoxazole/trimethoprim, tacrolimus, teniposide, thiotepa, tobramycin, vancomycin, vecuronium, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, gallium nitrate, hyaluronidase, minocycline, pantoprazole, phenytoin, sargramostim, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ampicillin, cefazolin, cloxacillin, dexamethasone sodium phosphate, diazepam, heparin, phenobarbital.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, bupivacaine, ceftazidime, chlorpromazine, cimetidine, diphenhydramine, fentanyl, glycopyrrolate, hydroxyzine, lorazepam, methotrimeprazine, metoclopramide, midazolam, pentazocine, pentobarbital, potassium chloride, prochlorperazine mesylate, ranitidine, scopolamine, tetracaine, trimethobenzamide, ziconotide.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ampicillin, diazepam, heparin, hyaluronidase, pantoprazole, phenobarbital, phenytoin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cefazolin, cloxacillin, dexamethasone sodium phosphate, dimenhydrinate, haloperidol, ketorolac, prochlorperazine edisylate, promethazine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F180581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate-to-severe pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exalgo&reg;: Management of moderate-to-severe pain in opioid-tolerant patients (requiring around-the-clock analgesia for an extended period of time)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F180651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dilaudid&reg; may be confused with Demerol&reg;, Dilantin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HYDROmorphone may be confused with morphine; significant overdoses have occurred when hydromorphone products have been inadvertently administered instead of morphine sulfate. Commercially available prefilled syringes of both products looks similar and are often stored in close proximity to each other.",
"       <b>",
"        Note:",
"       </b>",
"       Hydromorphone 1 mg oral is approximately equal to morphine 4 mg oral; hydromorphone 1 mg I.V. is approximately equal to morphine 5 mg I.V.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dilaudid&reg;, Dilaudid-HP&reg;: Extreme caution should be taken to avoid confusing the highly-concentrated (Dilaudid-HP&reg;) injection with the less-concentrated (Dilaudid&reg;) injectable product.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Exalgo&reg;: Extreme caution should be taken to avoid confusing the extended release Exalgo&reg; 8 mg tablets with immediate release hydromorphone 8 mg tablets.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F180639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, extrasystoles, flushing of face, hyper-/hypotension, palpitation, peripheral edema, peripheral vasodilation, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, abnormal feelings, agitation, aggression, apprehension, attention disturbances, chills, coordination impaired, CNS depression, confusion, cognitive disorder, crying, dizziness, drowsiness, dysphoria, encephalopathy, euphoria, fatigue, hallucinations, headache, hyper-reflexia, hypo/hyperesthesia, hypothermia, increased intracranial pressure, insomnia, lightheadedness, listlessness, malaise, memory impairment, mental depression, mood alterations, nervousness, panic attacks, paranoia, psychomotor hyperactivity, restlessness, sedation, seizure, somnolence, suicide ideation, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amylase decreased, dehydration, erectile dysfunction, fluid retention, hyperuricemia, hypogonadism, hypokalemia, libido decreased, sexual dysfunction, testosterone decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, anal fissure, anorexia, appetite decreased/increased, bezoar (Exalgo&reg;), biliary tract spasm, constipation, diarrhea, diverticulum, diverticulitis, duodenitis, dysgeusia, dysphagia, eructation, flatulence, gastric emptying impaired, gastrointestinal motility disorder (Exalgo&reg;), gastroenteritis, hematochezia, ileus, intestinal obstruction (Exalgo&reg;), large intestine perforation (Exalgo&reg;), nausea, painful defecation, paralytic ileus, stomach cramps, taste perversion, vomiting, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, micturition disorder, ureteral spasm, urinary frequency, urinary hesitation, urinary retention, urinary tract spasm, urination decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: LFTs increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site (I.M.), wheal/flare over vein (I.V.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, dysarthria, dyskinesia, muscle rigidity, muscle spasms, myalgia, myoclonus, paresthesia, trembling, tremor, uncoordinated muscle movements, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, dry eyes, miosis, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, bronchospasm, dyspnea, hyperventilation, hypoxia, laryngospasm, oxygen saturation decreased, respiratory depression/distress, rhinorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Antidiuretic effects, balance disorder, diaphoresis, difficulty walking, histamine release, physical and psychological dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F180585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydromorphone, any component of the formulation; acute or severe asthma, severe respiratory depression (in absence of resuscitative equipment or ventilatory support)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Additional product-specific contraindications:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dilaudid&reg; liquid and tablets: Obstetrical analgesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dilaudid&reg; injection, Dilaudid-HP&reg; injection: Opioid nontolerant patients; patients with risk of developing GI obstruction, especially paralytic ileus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Exalgo&reg;: Opioid nontolerant patients, paralytic ileus (known or suspected), pre-existing GI surgery or diseases resulting in narrowing of GI tract, loops in the GI tract or GI obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Suppository: Intracranial lesion associated with increased intracranial pressure; whenever ventilatory function is depressed (COPD, cor pulmonale, emphysema, kyphoscoliosis, status asthmaticus)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F180566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with  hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression:",
"     <b>",
"      [U.S. Boxed Warning]: May cause potentially life-threatening respiratory depression even with therapeutic use,  especially with initiation or dose increases; instruct patients on proper administration of extended-release tablets. The use of ethanol, other opioids, and other CNS depressants may increase the risk of adverse outcomes, including death.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Myoclonus and seizures have been reported with high doses; use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction. Hydromorphone may increase biliary tract pressure following spasm in sphincter of Oddi. Use caution in patients with inflammatory or obstructive bowel disorder, acute pancreatitis secondary to biliary tract disease, and patients undergoing biliary surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delirium tremens: Use with caution in patients with delirium tremens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal narrowing: Exalgo&reg; tablets are nondeformable; do not administer to patients with pre-existing severe gastrointestinal narrowing (eg, esophageal motility, small bowel inflammatory disease, short gut syndrome, history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, Meckel&rsquo;s diverticulum); obstruction may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychoses: Use with caution in patients with toxic psychoses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics; use within 14 days of MAO inhibitors is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Controlled release capsules: Should only be used when continuous analgesia is required over an extended period of time. Controlled release products are not to be used on an \"as needed\" (PRN) basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended release tablets: Exalgo&reg;:",
"     <b>",
"      [U.S. Boxed Warning]: For use in opioid tolerant patients only; fatal respiratory depression may occur in patients who are not opioid tolerant. The highest risk of fatal respiratory depression is at initiation and with dose increases. Indicated for the management of moderate-to-severe pain when around the clock pain control is needed for an extended time period. Not for use as an as-needed analgesic or for the management of acute or postoperative pain. Tablets should be swallowed whole; do not crush, break, chew, dissolve or inject; doing so may lead to rapid release and absorption of a potentially fatal dose of hydromorphone.",
"     </b>",
"     Injection of the tablet excipients may be toxic and cause lethal complications.",
"     <b>",
"      Accidental consumption may lead to fatal overdose, especially in children.",
"     </b>",
"     Tablets may be visible on abdominal x-rays, especially when digital enhancing techniques are used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection:",
"     <b>",
"      [U.S. Boxed Warning]: Extreme caution should be taken to avoid confusing the highly-concentrated (Dilaudid-HP&reg;) injection with the less-concentrated (Dilaudid&reg;) injectable product.",
"     </b>",
"     Dilaudid-HP&reg; should only be used in patients who are opioid-tolerant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Vial stoppers of single-dose injectable vials may contain latex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium metabisulfite: Some dosage forms contain trace amounts of sodium metabisulfite which may cause allergic reactions in susceptible individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion:",
"     <b>",
"      [U.S. Boxed Warning]: Hydromorphone has a high potential for abuse;",
"     </b>",
"     healthcare provider should be alert to problems of abuse, misuse, and diversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.M. administration: Variable absorption and a lag time to peak effect may result from I.M. use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy  in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F180602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Gotu kola, valerian, and kava kava may increase CNS depression. Management: Avoid gotu kola, valerian, and kava kava.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F180573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F180588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydromorphone was teratogenic in some, but not all, animal studies; however, maternal toxicity was also reported. Hydromorphone crosses the placenta. Chronic opioid use during pregnancy may lead to a withdrawal syndrome in the neonate. Symptoms include irritability, hyperactivity, loss of sleep pattern, abnormal crying, tremor, vomiting, diarrhea, weight loss, or failure to gain weight.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F180618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F180589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low concentrations of hydromorphone can be found in breast milk. Withdrawal symptoms may be observed in breast-feeding infants when opioid analgesics are discontinued. Breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Dilaudid-5 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (473 mL): $239.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (HYDROmorphone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (473 mL): $189.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dilaudid Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (1 mL): $1.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (1 mL): $1.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/mL (1 mL): $2.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Dilaudid-HP Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (5 mL): $23.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (HYDROmorphone HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (1 mL): $1.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (HYDROmorphone HCl PF Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (1 mL): $2.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (1 mL): $2.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/mL (1 mL): $1.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $3.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Dilaudid-HP Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (1): $114.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (HYDROmorphone HCl Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (6): $73.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Exalgo Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (100): $1234.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg (100): $1852.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16 mg (100): $2469.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32 mg (100): $4939.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dilaudid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $109.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $178.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (100): $324.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (HYDROmorphone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $42.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $63.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (100): $132.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F180575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pain relief, respiratory and mental status, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F180590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dilaudid (AT, AU);",
"     </li>",
"     <li>",
"      Dilid (KP);",
"     </li>",
"     <li>",
"      Dolonovag (AR);",
"     </li>",
"     <li>",
"      Hydal (AT);",
"     </li>",
"     <li>",
"      Jurnista (AT, AU, CZ, DE, DK, EE, ES, HN, IL, IT, NZ, PH, PT, SG);",
"     </li>",
"     <li>",
"      Jurnista IR (KP);",
"     </li>",
"     <li>",
"      Jurnista SR (KP);",
"     </li>",
"     <li>",
"      Liberaxim (MX);",
"     </li>",
"     <li>",
"      Paliadon Retardkaps (DE);",
"     </li>",
"     <li>",
"      Palladon (CH, DK, FI, NL, NO, SE);",
"     </li>",
"     <li>",
"      Palladon OD (SE);",
"     </li>",
"     <li>",
"      Palladon Retard (CH);",
"     </li>",
"     <li>",
"      Palladone (BE, CZ, EE, ES, GB, GR, HN, IE, IL, PT);",
"     </li>",
"     <li>",
"      Palladone SR (GB, IE);",
"     </li>",
"     <li>",
"      Sophidone LP (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F180565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opioid receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; causes cough supression by direct central action in the medulla; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F180584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Analgesic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release formulations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 15-30 minutes; Peak effect: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 5 minutes; Peak effect: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablet: 6 hours; Peak effect: ~9 hours (Angst, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release formulations: Oral, I.V.: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablet: ~13 hours (Angst, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Extended release tablet: Delayed; I.M.: Variable and delayed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~8% to 19%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via glucuronidation; to inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 62%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release formulations: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablets: Apparent half-life: ~11 hours (range: 8-15 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release tablet: &le;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release tablet: 12-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as glucuronide conjugates)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Agency for Health Care Policy and Research, &ldquo;Acute Pain Management in Infants, Children and Adolescents: Operative and Medical Procedures,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 1992, 46(2):469-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/1636563/pubmed\" id=\"1636563\" target=\"_blank\">",
"        1636563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Angst MS, Drover DR, Lotsch J, et al, &ldquo;Pharmacodynamics of Orally Administered Sustained-release Hydromorphone in Humans,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2001, 94(1):63-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/11135723/pubmed\" id=\"11135723\" target=\"_blank\">",
"        11135723",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Leon-Casasola OA and Lema MJ, \"Postoperative Epidural Opioid Analgesia: What Are the Choices?\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1996, 83(4):867-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/8831337/pubmed\" id=\"8831337\" target=\"_blank\">",
"        8831337",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pain,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2000, 42(1085):73-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/10951654/pubmed\" id=\"10951654\" target=\"_blank\">",
"        10951654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferrell BA, &ldquo;Pain Management in Elderly People,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1991, 39(1):64-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/1670940/pubmed\" id=\"1670940\" target=\"_blank\">",
"        1670940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Honigberg IL, and Stewart JT, &ldquo;Radioimmunoassay of Hydromorphone and Hydrocodone in Human Plasma,&rdquo;",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1980, 69(10):1171-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/6158568/pubmed\" id=\"6158568\" target=\"_blank\">",
"        6158568",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Inturrisi CE, &ldquo;Narcotic Drugs,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 1982, 66(5):1061-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/6127453/pubmed\" id=\"6127453\" target=\"_blank\">",
"        6127453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaiko RF, Wallenstein SL, Rogers AG, et al, &ldquo;Narcotics in the Elderly,&rdquo;",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 1982, 66(5):1079-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/7132470/pubmed\" id=\"7132470\" target=\"_blank\">",
"        7132470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy MH, &ldquo;Pharmacologic Treatment of Cancer Pain,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(15):1124-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/8813044/pubmed\" id=\"8813044\" target=\"_blank\">",
"        8813044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu SS, Bieltz M, Wukovits B, et al, \"Prospective Survey of Patient-Controlled Epidural Analgesia With Bupivacaine and Hydromorphone in 3736 Postoperative Orthopedic Patients,\"",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2010, 35(4):351-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/20607876/pubmed\" id=\"20607876\" target=\"_blank\">",
"        20607876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lugo RD and Kern SE, &ldquo;Pharmacokinetics of Opioids,&rdquo;",
"      <i>",
"       Management of Pain",
"      </i>",
"      , Lipman AG ed, Bethesda, MD: ASHP,  2004, 77.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nasraway SA Jr, &ldquo;Use of Sedative Medications in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Sem Resp Crit Care Med",
"      </i>",
"      , 2001, 22(2):165-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/16088671/pubmed\" id=\"16088671\" target=\"_blank\">",
"        16088671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith HS,",
"      <i>",
"       Current Therapy in Pain",
"      </i>",
"      , 1st ed, Philadelphia, PA: Saunders, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2004, 38:1525-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/48/25353/abstract-text/15252190/pubmed\" id=\"15252190\" target=\"_blank\">",
"        15252190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8538 Version 53.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25353=[""].join("\n");
var outline_f24_48_25353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708907\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180607\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180608\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180641\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180611\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180630\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180612\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10169504\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180613\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180578\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950125\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180562\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180643\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11238289\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10168465\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180582\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180649\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180581\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180651\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180639\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180585\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180566\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299481\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180571\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180602\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180573\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180588\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180618\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180589\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989385\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180575\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180590\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180565\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180584\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8538|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/48/14086?source=related_link\">",
"      Hydromorphone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/13/3289?source=related_link\">",
"      Hydromorphone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_48_25354="Inpatient treatment of pneumonia in children";
var content_f24_48_25354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inpatient treatment of pneumonia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/48/25354/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25354/contributors\">",
"     William J Barson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/48/25354/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25354/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25354/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/48/25354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/48/25354/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/48/25354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia. CAP is a common and potentially serious illness with considerable morbidity.",
"   </p>",
"   <p>",
"    The Pediatric Infectious Diseases",
"    <span class=\"nowrap\">",
"     Society/Infectious",
"    </span>",
"    Diseases Society of America and the British Thoracic Society have developed clinical practice guidelines for the treatment of CAP in children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inpatient treatment of pneumonia in children will be reviewed here. The outpatient treatment of CAP is discussed separately, as are the epidemiology, etiology, clinical features, and diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27369?source=see_link\">",
"     \"Outpatient treatment of community-acquired pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=see_link\">",
"     \"Epidemiology, pathogenesis, and etiology of pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HOSPITALIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to hospitalize a child with community-acquired pneumonia (CAP) is individualized based upon age, underlying medical problems, and clinical factors including severity of illness (",
"    <a class=\"graphic graphic_table graphicRef72015 \" href=\"UTD.htm?28/35/29244\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Hospitalization generally is warranted for infants younger than three to six months of age, unless a viral etiology or",
"    <em>",
"     Chlamydia trachomatis",
"    </em>",
"    is suspected and they are normoxemic and relatively asymptomatic. Hospitalization is also warranted for a child of any age whose family cannot provide appropriate care and assure compliance with the management plan. Additional indications for hospitalization include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoxemia (oxygen saturation [SpO",
"      <sub>",
"       2",
"      </sub>",
"      ] &lt;90 percent in room air at sea level)",
"     </li>",
"     <li>",
"      Dehydration, or inability to maintain hydration orally; inability to feed in an infant",
"     </li>",
"     <li>",
"      Moderate to severe respiratory distress: Respiratory rate &gt;70",
"      <span class=\"nowrap\">",
"       breaths/minute",
"      </span>",
"      for infants &lt;12 months of age and &gt;50 breaths per minute for older children; retractions; nasal flaring; difficulty breathing; apnea; grunting",
"     </li>",
"     <li>",
"      Toxic appearance (more common in bacterial pneumonia and may suggest a more severe course) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Underlying conditions that may predispose to a more serious course of pneumonia (eg, cardiopulmonary disease, genetic syndromes, neurocognitive disorders), may be worsened by pneumonia (eg, metabolic disorder) or may adversely affect response to treatment (eg, immunocompromised host)",
"     </li>",
"     <li>",
"      Complications (eg,",
"      <span class=\"nowrap\">",
"       effusion/empyema)",
"      </span>",
"     </li>",
"     <li>",
"      Suspicion or confirmation that CAP is due to a pathogen with increased virulence, such",
"      <em>",
"       as Staphylococcus aureus",
"      </em>",
"      or group A",
"      <em>",
"       streptococcus",
"      </em>",
"     </li>",
"     <li>",
"      Failure of outpatient therapy (worsening or no response in 48 to 72 hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications for intensive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat a child with pneumonia in an intensive care setting is individualized, based upon clinical, laboratory, and radiologic findings. Treatment in an intensive care setting generally is warranted for children who manifest [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The need for ventilatory support beyond that which can be provided outside the intensive care unit (eg, mechanical ventilation, noninvasive positive pressure ventilation, failure to maintain oxygen saturation [SpO",
"      <sub>",
"       2",
"      </sub>",
"      ] &gt;92 percent in FiO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;0.5)",
"     </li>",
"     <li>",
"      Signs of impending respiratory failure (lethargy, increasing work of breathing,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      exhaustion with or without hypercarbia)",
"     </li>",
"     <li>",
"      Recurrent apnea or slow irregular respirations",
"     </li>",
"     <li>",
"      Cardiovascular compromise with progressive tachycardia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension that requires or is refractory to fluid management",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Care in the intensive care unit also may be warranted for children with two or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respiratory rate &gt;70",
"      <span class=\"nowrap\">",
"       breaths/minute",
"      </span>",
"      for infants &lt;12 months of age and &gt;50 breaths per minute for older children",
"     </li>",
"     <li>",
"      Apnea",
"     </li>",
"     <li>",
"      Increased work of breathing (retractions, dyspnea, nasal flaring, grunting)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      ratio &lt;250",
"     </li>",
"     <li>",
"      Multilobar infiltrates",
"     </li>",
"     <li>",
"      Altered mental status",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Pleural effusion",
"     </li>",
"     <li>",
"      Comorbid condition (eg, sickle cell disease, immune deficiency, immunosuppression)",
"     </li>",
"     <li>",
"      Unexplained metabolic acidosis",
"     </li>",
"     <li>",
"      Pediatric Early Warning Score &gt;6 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infection control",
"    </span>",
"    &nbsp;&mdash;&nbsp;CAP can be caused by a variety of microbial agents requiring a variety of infection-control measures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/6\">",
"     6",
"    </a>",
"    ]. If possible, rapid diagnostic tests should be performed at the time of admission, to facilitate decisions regarding appropriate precautions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Rapid diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hand washing is the single most important procedure to prevent the spread of infection. Additional infection control measures depend upon the likely pathogen(s), as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory syncytial and parainfluenza viruses &ndash; gown and gloves (ie, contact precautions)",
"     </li>",
"     <li>",
"      Influenza virus, group A",
"      <em>",
"       streptococcus",
"      </em>",
"      (for the first 24 hours of treatment), methicillin-susceptible",
"      <em>",
"       S. aureus",
"      </em>",
"      ,",
"      <em>",
"       Bordetella pertussis",
"      </em>",
"      (until patient has received five days of effective therapy), and",
"      <em>",
"       Mycoplasma pneumoniae",
"      </em>",
"      &ndash; mask within 3 feet (ie, droplet precautions)",
"     </li>",
"     <li>",
"      Adenovirus &ndash; contact and droplet precautions",
"     </li>",
"     <li>",
"      Methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      &ndash; special organism precautions; contact and droplet precautions and dedicated patient equipment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These precautions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .) Guidelines for hand hygiene in healthcare settings can be accessed through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/handhygiene/\">",
"     Centers for Disease Control and Prevention",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care includes ensuring adequate antipyresis, analgesia, respiratory support, and hydration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antipyresis and analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children hospitalized with pneumonia usually have fever and may have pleuritic chest pain, which can lead to shallow breathing and impaired ability to cough. Administration of antipyretics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    analgesics can be used to keep the child comfortable. Adequate pain control may promote coughing, which facilitates airway clearance. Antitussives should be avoided. Symptomatic treatment of cough is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=see_link&amp;anchor=H15315058#H15315058\">",
"     \"The common cold in children: Treatment and prevention\", section on 'Cough'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Respiratory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children hospitalized with pneumonia should receive ventilatory support as indicated by their clinical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A supported sitting position may help to expand the lungs and improve respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest that children with oxygen saturation [SpO",
"    <sub>",
"     2",
"    </sub>",
"    ] &lt;95 percent in room air be treated with supplemental oxygen to maintain oxygen saturation &ge;95 percent while they are in respiratory distress. Different thresholds for supplemental oxygen are suggested by other experts (eg, the British Thoracic Society guidelines suggest supplemental oxygenation to maintain oxygenation saturation &gt;92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/2\">",
"     2",
"    </a>",
"    ]. Gentle bulb suction of the nares may be helpful in infants and children whose nares are blocked with secretions. Minimal handling seems to reduce oxygen requirements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=see_link\">",
"     \"Continuous oxygen delivery systems for infants, children, and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children who are severely ill, it may be necessary to monitor carbon dioxide tension via blood gas analysis in addition to oxygen saturation (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ) by oximetry. Hypercarbia is an important sign of impending respiratory failure, particularly in the young infant who is tiring but may have preserved oxygenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fluid management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who cannot maintain adequate fluid intake because of breathlessness, fatigue, or risk of aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/7\">",
"     7",
"    </a>",
"    ] may require intravenous fluid therapy. Nasogastric (NG) tubes should be avoided if possible because they may compromise breathing; if necessary, the smallest NG tube possible should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with pneumonia are at risk for inappropriate secretion of antidiuretic hormone (SIADH) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Serum electrolytes should be monitored if there is clinical suspicion of SIADH [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Pulmonary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chest physiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest physiotherapy is not beneficial for children with uncomplicated community-acquired pneumonia (CAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/2\">",
"     2",
"    </a>",
"    ]. In randomized and observational studies in children and adults, chest physiotherapy had no effect on length of hospital stay, duration of fever, or radiographic resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/10-14\">",
"     10-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EMPIRIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment of children who are hospitalized with pneumonia is empiric (",
"    <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"     table 2",
"    </a>",
"    ). Factors that must be considered include the spectrum of likely pathogens, antimicrobial susceptibility, simplicity, tolerability, palatability, safety, and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommendations of most guidelines are based on in vitro susceptibilities of the most likely pathogen or pathogens, rather than evidence of the superiority of one antibiotic over another. Clinical response to empiric therapy and results of microbiologic studies, when available, help to determine whether additional evaluation or changes in therapy are necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Microbiology'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H25\">",
"     'Specific therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H31\">",
"     'Response to therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are few randomized controlled trials to guide the choice of empiric antibiotics in children with community-acquired pneumonia (CAP). Decisions regarding empiric therapy are complicated by the substantial overlap in the clinical presentation of bacterial and nonbacterial pneumonias [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Treatment decisions usually are based upon algorithms that include patient age, epidemiologic and clinical information, and diagnostic laboratory and imaging studies (",
"    <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/4\">",
"     4",
"    </a>",
"    ]. The scope of empiric therapy (ie, narrow or broad) depends upon the severity of illness and presence of complications. Agents other than those suggested in the table may be more appropriate if there are clinical or epidemiologic features strongly suggestive of a specific cause (eg, mediastinal or hilar lymphadenopathy, residence in the central United States, and exposure to caves",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bat guano suggestive of pulmonary histoplasmosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consultation with a specialist in infectious disease may be helpful in children with medication allergies, comorbid conditions, failure of outpatient therapy, or multiple-drug-resistant organisms. Consultation with a pediatric pulmonologist may be helpful in children with recurrent pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27369?source=see_link&amp;anchor=H13#H13\">",
"     \"Outpatient treatment of community-acquired pneumonia in children\", section on 'Treatment failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Etiologic clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain clinical and epidemiologic features can be used to determine the most likely pathogen(s) to aid in decisions regarding empiric therapy. Because these features often overlap, they cannot be used with complete confidence, but are helpful in guiding empiric therapy until results of microbiologic tests are available (",
"    <a class=\"graphic graphic_table graphicRef52021 \" href=\"UTD.htm?22/2/22573\">",
"     table 3",
"    </a>",
"    ). These features are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clues to etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Etiologic clues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of neonatal pneumonia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"     \"Neonatal pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Viral pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children younger than three to five years of age who are admitted to the hospital with pneumonia have viral pneumonia (eg, respiratory syncytial virus). This is particularly true in the absence of lobar (or lobular) infiltrate and pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/4\">",
"     4",
"    </a>",
"    ]. Viral pneumonia does not require antibiotic therapy, unless a mixed infection or secondary bacterial infection is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38327?source=see_link&amp;anchor=H2#H2\">",
"     \"Respiratory syncytial virus infection: Treatment\", section on 'Overview'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link&amp;anchor=H15#H15\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No effective antivirals are available for most viral pneumonias, with the exception of influenza.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H275031\">",
"    <span class=\"h3\">",
"     Influenza pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of antiviral treatment for influenza (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    ) as soon as possible is recommended for children hospitalized with presumed influenza pneumonia; laboratory confirmation should not delay initiation of antiviral therapy. The diagnosis and treatment of influenza in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children with influenza pneumonia in whom secondary bacterial pneumonia is suspected, empiric antibiotic therapy should include coverage for",
"    <em>",
"     S. aureus",
"    </em>",
"    , including methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA). Coinfection with",
"    <em>",
"     S. aureus",
"    </em>",
"    may be particularly severe and rapidly fatal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'S. aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Uncomplicated bacterial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    is the most common bacterial cause of pneumonia in children of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. Other potential bacterial pathogens that may need to be included in empiric therapy for hospitalized children include",
"    <em>",
"     S. aureus",
"    </em>",
"    , including methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA),",
"    <em>",
"     S. pyogenes",
"    </em>",
"    (group A",
"    <em>",
"     streptococcus",
"    </em>",
"    ),",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b (if unimmunized), nontypeable",
"    <em>",
"     H. influenzae",
"    </em>",
"    , and",
"    <em>",
"     Moraxella catarrhalis",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/2,4,20-25\">",
"     2,4,20-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Table provides several suggested parenteral empiric antibiotic regimens for",
"    <strong>",
"     uncomplicated",
"    </strong>",
"    bacterial pneumonia in hospitalized children when",
"    <em>",
"     S. aureus",
"    </em>",
"    is not a consideration (",
"    <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/4,26,27\">",
"     4,26,27",
"    </a>",
"    ]. The treatment of complicated CAP and severe CAP (particularly when",
"    <em>",
"     S. aureus",
"    </em>",
"    is a consideration) are discussed below. (See",
"    <a class=\"local\" href=\"#H96270984\">",
"     'Complicated CAP'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Severe CAP requiring ICU admission'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     Ampicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"     penicillin G",
"    </a>",
"    generally provides adequate coverage for the fully immunized child in communities without substantial prevalence of penicillin-resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1\">",
"     1",
"    </a>",
"    ]. We suggest a third-generation cephalosporin (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) for children younger than 12 months and those who are not fully immunized because third-generation cephalosporins provide coverage for the beta-lactamase producing pathogens (eg,",
"    <em>",
"     H. influenzae",
"    </em>",
"    and",
"    <em>",
"     M. catarrhalis",
"    </em>",
"    ) that may occur in these children. We also suggest third-generation cephalosporins also for children with more severe illness (",
"    <a class=\"graphic graphic_table graphicRef72015 \" href=\"UTD.htm?28/35/29244\">",
"     table 1",
"    </a>",
"    ) because they provide coverage for a broader range of pathogens, including penicillin-resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    , than does ampicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,28,29\">",
"     1,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A macrolide may be added (",
"    <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"     table 2",
"    </a>",
"    ) if",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    , or legionellosis is suspected. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Atypical pneumonia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest that children who require hospitalization for treatment of CAP be treated initially with parenteral antibiotics. However, oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    may be an alternative for children older than six months with uncomplicated pneumonia that is not thought to be due to",
"    <em>",
"     S. aureus",
"    </em>",
"    . In a multicenter randomized trial, treatment with amoxicillin was equivalent to treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/46/14054?source=see_link\">",
"     penicillin G",
"    </a>",
"    in children with CAP who required hospital admission but did not have wheezing, hypotension, chronic pulmonary conditions (other than asthma), immunodeficiency, pleural effusion requiring drainage, or oxygen saturations &lt;85 percent in room air [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/30\">",
"     30",
"    </a>",
"    ]. The British Thoracic Society guidelines suggest that oral antibiotics are safe and effective even for children with severe pneumonia as long as they are able to tolerate oral fluids, are not vomiting, and do not have signs of septicemia or complicated pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Atypical pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical bacterial pathogens include",
"    <em>",
"     C. trachomatis",
"    </em>",
"    in afebrile infants, and",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    and",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    in older children and adolescents. The Table provides several suggested empiric regimens for atypical bacterial pneumonia in hospitalized children (",
"    <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/4,26\">",
"     4,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For children older than four months with presumed atypical bacterial pneumonia,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    or a second- or third-generation cephalosporin may be added if there is strong evidence of a bacterial cause (eg, white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;15,000/microL,",
"    </span>",
"    CRP &gt;35 to 60",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (3.5 to 6",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    chills, no response to outpatient therapy with a macrolide or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/54/12136?source=see_link\">",
"     doxycycline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/4,31\">",
"     4,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluoroquinolones (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/11/33968?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) may be reasonable empiric therapy for the older child and adolescent with suspected atypical pneumonia, who could actually have pneumococcal pneumonia. The fluoroquinolones also may be used in the older child or adolescent who has a type 1 hypersensitivity (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 4",
"    </a>",
"    ) to beta-lactam antibiotics. In addition to their excellent gram-negative spectrum, the fluoroquinolones are active against a number of the pathogens responsible for CAP, including beta-lactam-susceptible and nonsusceptible",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    (including macrolide-resistant",
"    <em>",
"     M. pneumoniae)",
"    </em>",
"    , and",
"    <em>",
"     C. pneumoniae",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/32\">",
"     32",
"    </a>",
"    ]. However,",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    resistant to levofloxacin have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Severe CAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with severe CAP that does not require admission to the intensive care unit (",
"    <a class=\"graphic graphic_table graphicRef72015 \" href=\"UTD.htm?28/35/29244\">",
"     table 1",
"    </a>",
"    ) may benefit from combination empiric therapy with a macrolide and a beta-lactam antibiotic (eg, penicillin or third-generation cephalosporin) (",
"    <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"     table 2",
"    </a>",
"    ). Combination therapy improves coverage for resistant organisms and mixed",
"    <span class=\"nowrap\">",
"     bacterial/atypical",
"    </span>",
"    bacterial infections. Antimicrobial therapy can be adjusted as necessary when results of microbiologic testing become available. Invasive diagnostic testing, including bronchoscopy with bronchoalveolar lavage, may be necessary for specific microbiologic diagnosis. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Uncomplicated bacterial pneumonia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Atypical pneumonia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Invasive studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Severe CAP requiring ICU admission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are admitted to the intensive care unit for serious or life-threatening infections require broad-spectrum empiric coverage that addresses potential beta-lactam resistance and community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA). A suggested regimen for such children may include (",
"    <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses up to a maximum of 4",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      A third-generation cephalosporin (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses up to a maximum of 10",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in two divided doses up to a maximum dose of 4",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/15/35056?source=see_link\">",
"       Azithromycin",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once per day IV for two days (maximum 500",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      followed by 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once per day IV (maximum 250",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      <strong>",
"       and possibly",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"       Nafcillin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses; maximum 12",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      if",
"      <em>",
"       S. aureus",
"      </em>",
"      is likely (methicillin-susceptible",
"      <em>",
"       S. aureus",
"      </em>",
"      is more rapidly killed by nafcillin than by",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      ),",
"      <strong>",
"       and possibly",
"      </strong>",
"     </li>",
"     <li>",
"      Antiviral therapy for influenza, if the child is hospitalized during influenza season; laboratory confirmation of influenza should not delay initiation of antiviral therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"       \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This combination is necessary because of reports of treatment failure resulting from treatment of nonsusceptible",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    with beta-lactams, increasing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    resistance among",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    , and concern for MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/34\">",
"     34",
"    </a>",
"    ]. Virtually all strains of MRSA are susceptible to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When treating with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    , renal function and serum trough levels or dosing to achieve an",
"    <span class=\"nowrap\">",
"     AUC/MIC",
"    </span>",
"    ratio &gt;400 should be monitored in an attempt to assure therapeutic efficacy and limit toxicity. In adults, vancomycin trough levels between 15 and 20",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    have been suggested to improve clinical outcomes for complicated infections due to",
"    <em>",
"     S. aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/52/22345?source=see_link\">",
"     Linezolid",
"    </a>",
"    is an oxazolidinone antibiotic with activity against gram-positive cocci, including beta-lactam-resistant",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    and MRSA. Linezolid could be substituted for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    in the above regimen. The dose for linezolid is 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose (maximum 600 mg); it is administered every eight hours in children younger than 12 years and every 12 hours in children 12 years and older.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96270984\">",
"    <span class=\"h2\">",
"     Complicated CAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complicated CAP (eg, parapneumonic effusion, lung abscess) requires a broader spectrum of antibiotic coverage if etiologies other than",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    are being considered. The expanded spectrum should include coverage for beta-lactam-resistant isolates and community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA). Coverage for anaerobes and gram-negative organisms also may be necessary for children with lung abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39\">",
"     39",
"    </a>",
"    ]. Antimicrobial therapy can be adjusted as necessary when results of microbiologic testing become available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H2294532#H2294532\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=see_link\">",
"     \"Management and prognosis of parapneumonic effusion and empyema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complicated CAP requires a prolonged course of antimicrobial therapy, usually initiated parenterally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/19\">",
"     19",
"    </a>",
"    ]. Appropriate regimens may include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously (IV) in two divided doses up to a maximum dose of 4",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      OR",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses up to a maximum of 10",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      <strong>",
"       PLUS",
"      </strong>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in three or four divided doses to a maximum of 1 to 2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      <em>",
"       if S. aureus",
"      </em>",
"      or anaerobes are a consideration.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      40 to 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in three or four divided doses up to a maximum of 4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      is an alternative to clindamycin if the patient is allergic to clindamycin. When treating with vancomycin, renal function and serum trough levels or dosing to achieve an",
"      <span class=\"nowrap\">",
"       AUC/MIC",
"      </span>",
"      ratio of &gt;400 should be monitored in an attempt assure therapeutic efficacy and limit toxicity. In adults, vancomycin trough levels between 15 and 20",
"      <span class=\"nowrap\">",
"       microgram/mL",
"      </span>",
"      have been suggested to improve clinical outcomes for complicated infections due to",
"      <em>",
"       S. aureus",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'MRSA infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/3/29750?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      150 to 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      component IV in four divided doses; maximum 12",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      alone may be effective if a lung abscess is thought to be secondary to an aspiration event. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Aspiration pneumonia'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of therapy and other considerations in the management of complicated pneumonia depend upon the type of complication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Parapneumonic",
"       <span class=\"nowrap\">",
"        effusion/empyema",
"       </span>",
"      </strong>",
"      &ndash; The treatment of parapneumonic effusion and empyema is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=see_link\">",
"       \"Management and prognosis of parapneumonic effusion and empyema in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Necrotizing pneumonia",
"      </strong>",
"      &ndash; Treatment of necrotizing pneumonia requires a prolonged course of antibiotic therapy. The duration is determined by the clinical response but is usually a total of four weeks or two weeks after the patient is afebrile and has improved clinically. Interventional procedures (eg, percutaneous drainage catheter placement) should be performed cautiously in children with necrotizing pneumonia; such procedures increase the risk of complications, such as the development of bronchopleural fistulae [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39-42\">",
"       39-42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Lung abscess",
"      </strong>",
"      &ndash; Treatment of lung abscess requires a prolonged course of antibiotic therapy. The duration is determined by the clinical response, but is usually a total of four weeks or two weeks after the patient is afebrile and has clinical improvement. The average duration of fever is four to eight days [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/19\">",
"       19",
"      </a>",
"      ]. Eighty to 90 percent of lung abscesses in children resolve with antibiotic therapy alone and spontaneous drainage through the tracheobronchial tree, provided that bronchial obstruction is removed [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/43\">",
"       43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In cases that fail to resolve with antibiotics alone, needle aspiration or percutaneous catheter drainage may provide diagnostic information and therapeutic benefit without the increased risk of complications that occurs in children with necrotizing pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39,40,44,45\">",
"       39,40,44,45",
"      </a>",
"      ]. Percutaneous drainage may be warranted in children with lung abscess whose condition fails to improve or worsens after 72 hours of antibiotic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39\">",
"       39",
"      </a>",
"      ]. At least three weeks of IV antibiotic therapy should be delivered before lobectomy is considered for treatment failure [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pneumatocele",
"      </strong>",
"      &ndash; Most pneumatoceles involute spontaneously [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. However, on occasion, pneumatoceles result in pneumothorax [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nosocomial pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric treatment of nosocomial (hospital-acquired) pneumonia should include coverage for",
"    <em>",
"     S. aureus",
"    </em>",
"    , Enterobacteriaceae,",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    , and anaerobes. Acceptable broad spectrum regimens usually include an aminoglycoside (for gram-negative pathogens) and another agent to address gram-positive pathogens and anaerobes (",
"    <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aminoglycoside (usually",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      if extended spectrum or Amp C beta-lactamase producing gram-negative rods are possible etiologies)",
"      <strong>",
"       plus",
"      </strong>",
"      :",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/6/35941?source=see_link\">",
"       Ticarcillin-clavulanate",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses up to a maximum of 24",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses up to a maximum of 12",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       Meropenem",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in three divided doses, up to a maximum of 6",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      if extended-spectrum or Amp C beta-lactamase-producing gram-negative rods are possible etiologies,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      125 to 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses; maximum of 6",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/9/12438?source=see_link\">",
"       Cefepime",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses; maximum of 4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/43/12984?source=see_link\">",
"     amikacin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"     meropenem",
"    </a>",
"    should be used if extended-spectrum or Amp C beta-lactamase-producing gram-negative rods are possible etiologies. The",
"    <span class=\"nowrap\">",
"     cephalosporin/aminoglycoside",
"    </span>",
"    combination lacks anaerobic coverage so should NOT be used when aspiration pneumonia is a possibility. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Aspiration pneumonia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    should be added to the empiric regimen if methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    is a consideration.",
"   </p>",
"   <p>",
"    Patients with true beta-lactam hypersensitivity (ie, type 1 hypersensitivity reaction) (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 4",
"    </a>",
"    ) can be treated with a combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    and an aminoglycoside.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Aspiration pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antibiotic regimens for community-acquired aspiration pneumonia must cover oral anaerobes. Appropriate antibiotic regimens for hospitalized children include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/3/29750?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      150 to 200",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      component IV in four divided doses; maximum 12",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       Clindamycin",
"      </a>",
"      30 to 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in three or four divided doses to a maximum of 1 to 2",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      if MRSA etiology is suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Pneumonia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In neurologically compromised older adolescents prone to aspiration events, empiric treatment for CAP with a fluoroquinolone like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    (400 mg once daily) may be reasonable. Moxifloxacin has activity against anaerobic bacteria, as well as the usual treatable causes of CAP (",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     M. pneumoniae",
"    </em>",
"    , and",
"    <em>",
"     C. pneumoniae)",
"    </em>",
"    .",
"   </p>",
"   <p>",
"    Appropriate antibiotic regimens for children with nosocomial aspiration who are known to be colonized with unusual gram-negative pathogens (eg,",
"    <em>",
"     Klebsiella pneumoniae",
"    </em>",
"    ) include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/6/35941?source=see_link\">",
"       Ticarcillin-clavulanate",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses up to a maximum of 24",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/27/28086?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      300",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in four divided doses up to a maximum of 12",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/24/2439?source=see_link\">",
"       Meropenem",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day IV in three divided doses, up to a maximum of 6",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    should be added to the empiric regime if methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) is a consideration.",
"   </p>",
"   <p>",
"    Patients with true beta-lactam hypersensitivity (ie, type 1 hypersensitivity reaction) (",
"    <a class=\"graphic graphic_table graphicRef80466 \" href=\"UTD.htm?13/11/13500\">",
"     table 4",
"    </a>",
"    ) can be treated with a combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    and an aminoglycoside.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Immunocompromised host",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric treatment for pneumonia in immunocompromised hosts also requires broad-spectrum gram-positive and gram-negative coverage, similar to that required for nosocomial pneumonia, with the addition of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    if methicillin-resistant",
"    <em>",
"     staphylococcus",
"    </em>",
"    is considered, and possibly",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    for",
"    <em>",
"     Pneumocystis jirovecii",
"    </em>",
"    (formerly",
"    <em>",
"     P. carinii",
"    </em>",
"    ). Empiric regimens may need to be modified once results of cultures and antibiotic susceptibility testing are available. Invasive testing may be required to obtain a satisfactory specimen in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Invasive studies'",
"    </a>",
"    .) Treatment of CAP in the immunocompromised host should occur in consultation with an infectious disease specialist.",
"   </p>",
"   <p>",
"    An aggressive approach to specific microbial diagnosis is indicated in immunocompromised hosts with clinically significant pneumonias. For patients with an endotracheal tube in place, specific microbial diagnosis may involve early flexible bronchoscopy for bronchoalveolar lavage with viral, fungal, and bacterial cultures. Although the protected specimen brush technique has been utilized in some settings, quantitative bacterial cultures are more commonly used to differentiate colonization from true lower respiratory tract infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link&amp;anchor=H2756495#H2756495\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SPECIFIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once results of microbiologic tests are available, antimicrobial therapy can be directed toward the responsible pathogen or pathogens. Specific antibiotic therapy for bacterial CAP is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef57150 \" href=\"UTD.htm?30/51/31550\">",
"     table 5",
"    </a>",
"    ). Specific antimicrobial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supportive therapy for the pathogens that commonly cause CAP in children is discussed in the topic reviews listed below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=see_link&amp;anchor=H15#H15\">",
"       \"Pneumococcal pneumonia in children\", section on 'Specific therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <em>",
"       M. pneumoniae",
"      </em>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H21#H21\">",
"       \"Mycoplasma pneumoniae infection in children\", section on 'Treatment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <em>",
"       C. pneumoniae",
"      </em>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=see_link\">",
"       \"Pneumonia caused by Chlamydophila (Chlamydia) species in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Methicillin-sensitive",
"      <em>",
"       S. aureus",
"      </em>",
"      &ndash; Methicillin-susceptible",
"      <em>",
"       S. aureus",
"      </em>",
"      pneumonia may be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"       cefazolin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,4\">",
"       1,4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      (MRSA) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Definitive therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Respiratory syncytial virus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38327?source=see_link\">",
"       \"Respiratory syncytial virus infection: Treatment\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Influenza (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"       \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parainfluenza (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=see_link&amp;anchor=H12#H12\">",
"       \"Parainfluenza viruses in children\", section on 'Treatment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adenovirus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=see_link&amp;anchor=H16#H16\">",
"       \"Diagnosis and treatment of adenovirus infection\", section on 'Treatment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Human metapneumovirus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link&amp;anchor=H19#H19\">",
"       \"Human metapneumovirus infections\", section on 'Treatment'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DURATION OF TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Parenteral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data to guide decisions about the duration of parenteral therapy for community-acquired pneumonia (CAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/2\">",
"     2",
"    </a>",
"    ]. It is common to switch to oral therapy in patients who have received parenteral antibiotics when the patient has become afebrile for 24 to 48 hours and is not having emesis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Total duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few randomized controlled trials to guide decisions about the appropriate duration of antimicrobial therapy for radiographically confirmed childhood pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/2\">",
"     2",
"    </a>",
"    ]. Current practice assigns duration of therapy according to the host, causative agent, and severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Uncomplicated cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual duration of combined parenteral and oral therapy for uncomplicated pneumonia is 7 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some authorities suggest continuing oral therapy at least one week beyond resolution of fever; others suggest treating until the erythrocyte sedimentation rate falls below 20",
"    <span class=\"nowrap\">",
"     mm/hour.",
"    </span>",
"    Some data from trials in adults suggest that a shorter course may be equivalent to a 7- to 10-day course, but additional controlled studies are necessary before this practice can be recommended routinely for children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39,52,53\">",
"     39,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Complicated cases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of complications, such as necrotizing pneumonia and lung abscess, requires a prolonged course of antibiotic therapy, usually initiated parenterally. The duration is determined by the clinical response, but usually is either a total of four weeks or a total of two weeks after the patient is afebrile and has improved clinically. (See",
"    <a class=\"local\" href=\"#H96270984\">",
"     'Complicated CAP'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following clinical parameters can be monitored to assess response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Temperature",
"     </li>",
"     <li>",
"      Respiratory rate",
"     </li>",
"     <li>",
"      Heart rate",
"     </li>",
"     <li>",
"      Oxygen saturation (SpO",
"      <sub>",
"       2",
"      </sub>",
"      )",
"     </li>",
"     <li>",
"      Work of breathing (eg, retractions, nasal flaring, grunting)",
"     </li>",
"     <li>",
"      Chest examination (extent of abnormal or absent breath sounds; extent of dullness to percussion)",
"     </li>",
"     <li>",
"      Mental status",
"     </li>",
"     <li>",
"      Ability to maintain oral intake and hydration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of monitoring depends upon the severity of illness. In patients who are receiving oxygen supplementation, oxygen saturation should be evaluated regularly. Evaluation for hypercarbia may be necessary in children with severe respiratory distress, as oxygenation may be preserved.",
"   </p>",
"   <p>",
"    The respiratory status of children with community-acquired pneumonia (CAP) who are appropriately treated should improve within 48 to 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1\">",
"     1",
"    </a>",
"    ]. However, fevers may persist for several days after initiation of appropriate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children who fail to improve as anticipated, the following possibilities must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,2,54,55\">",
"     1,2,54,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternative or coincident diagnoses (eg, foreign body aspiration) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H33#H33\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Differential diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Ineffective antibiotic coverage (lack of coverage for the actual etiology or resistant organism)",
"     </li>",
"     <li>",
"      Development of complications (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H2294532#H2294532\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Complications'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Underlying immunodeficiency condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history should be reviewed with special attention to the possibility of foreign body aspiration and geographic or environmental exposures associated with pathogens not treated by the empiric regimen (",
"    <a class=\"graphic graphic_table graphicRef52510 \" href=\"UTD.htm?8/59/9149\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Changes in laboratory parameters (eg, peripheral white blood cell count, inflammatory markers (if obtained initially)) may provide information about disease progression. Repeat radiographs or additional imaging studies can help to assess the degree of parenchymal involvement and evaluate for complications or anatomic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H2294532#H2294532\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology, pathogenesis, and etiology of pneumonia in children\", section on 'Etiologic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending upon the severity of illness, more aggressive attempts may need to be made to establish a microbiologic diagnosis (eg, induced sputum [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/56\">",
"     56",
"    </a>",
"    ], bronchoscopy with bronchoalveolar lavage, percutaneous needle aspiration, or lung biopsy). In children with lung abscess whose condition fails to improve or worsens after 72 hours of antibiotic therapy, needle aspiration or percutaneous catheter drainage may provide diagnostic information and therapeutic benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39,40,44,45\">",
"     39,40,44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Invasive studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     DISCHARGE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discharge criteria for children who have been admitted to the hospital with community-acquired pneumonia (CAP) have not been standardized, but typically include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/1,39\">",
"     1,39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improvement of vital signs",
"     </li>",
"     <li>",
"      Ability to maintain adequate fluid and nutrition orally",
"     </li>",
"     <li>",
"      Ability to maintain oxygen saturation &ge;90 percent in room air",
"     </li>",
"     <li>",
"      Improvement in respiratory distress (tachypnea, retractions, nasal flaring, use of accessory muscles)",
"     </li>",
"     <li>",
"      Overall clinical improvement including level of activity, appetite, and decreased fever for at least 12 to 24 hours",
"     </li>",
"     <li>",
"      Stable",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      baseline mental status",
"     </li>",
"     <li>",
"      Parents&rsquo; ability to administer and child&rsquo;s ability to comply with home antibiotic regimen",
"     </li>",
"     <li>",
"      Safe and compliant home environment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Outpatient parenteral antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatient parenteral antimicrobial therapy (OPAT) is an option for selected patients who require prolonged treatment (usually for complicated CAP that for some reason cannot be treated with an oral antibiotic) and have stabilized clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39,57,58\">",
"     39,57,58",
"    </a>",
"    ]. Eligibility for OPAT requires a suitable home environment and a pharmacologic agent with a reasonable dosing schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/59\">",
"     59",
"    </a>",
"    ]. Decisions regarding OPAT should involve the caregivers, an infectious disease specialist (or clinician knowledgeable about the use of antimicrobial agents in OPAT), a hospital pharmacist, and the primary care provider. The services of a visiting nurse may be required for home visits, education and observation of caregiver administration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obtaining blood samples for therapeutic monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with pneumonia should be seen by their primary care provider soon after discharge to ensure that clinical improvement continues and antibiotic therapy is being taken as prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39\">",
"     39",
"    </a>",
"    ]. Decisions regarding the timing of clinical follow-up should involve the child's primary care provider and the clinical status of the child at the time of discharge.",
"   </p>",
"   <p>",
"    Children who are appropriately treated for pneumonia should gradually improve with time. Cough may persist for as long as three to four months after viral pneumonia or pertussis. Children who are recovering from typical or atypical bacterial pneumonia may continue to cough for several weeks and have moderate dyspnea on exertion for two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/60\">",
"     60",
"    </a>",
"    ]. Symptomatic treatment of cough is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=see_link&amp;anchor=H15315058#H15315058\">",
"     \"The common cold in children: Treatment and prevention\", section on 'Cough'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up radiographs are not necessary in asymptomatic children with uncomplicated community-acquired pneumonia (CAP). However, in children with complicated community-acquired pneumonia or CAP that required intervention, follow-up radiographs help to ensure resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/2,61\">",
"     2,61",
"    </a>",
"    ]. Follow-up radiographs also may be helpful in children with recurrent pneumonia, persistent symptoms, severe atelectasis, unusually located infiltrates, or round pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/2,39,62\">",
"     2,39,62",
"    </a>",
"    ]. Conditions that must be considered if a round pneumonia fails to resolve on follow-up imaging include congenital lung sequestration, metastatic Wilms tumor, cavitary necrosis, pleural pseudocyst, and primary lung carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. When follow-up radiographs are indicated, they should be obtained two to three weeks after hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39,67\">",
"     39,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have evaluated the utility of follow-up radiographs in cohorts of children with acute radiologically proven CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/68-73\">",
"     68-73",
"    </a>",
"    ]. Three of the studies included clinical as well as radiologic follow-up at three to seven weeks after initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. In each of these studies, follow-up radiographs were normal or improved in asymptomatic children. Residual findings, even when present, did not result in additional therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most otherwise healthy children with pneumonia recover without sequelae, even if the pneumonia is complicated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/39,41,42,74\">",
"     39,41,42,74",
"    </a>",
"    ]. Although some data suggest that nearly one-half of children who are hospitalized for viral pneumonia have symptoms of asthma five years after hospitalization, it is not clear whether this is related to unrecognized asthma at the time of presentation with pneumonia or a tendency to develop asthma after viral community-acquired pneumonia (CAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall pneumonia mortality rate in developed countries is &lt;1 per 1000 per year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/77\">",
"     77",
"    </a>",
"    ]. Pneumococcal pneumonia case fatality rates (not adjusted for comorbid conditions) for children in the United States were estimated to be 4 percent in children younger than two years and 2 percent in children 2 to 17 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/48/25354/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=see_link\">",
"       \"Patient information: Pneumonia in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision to hospitalize a child with community-acquired pneumonia (CAP) must be individualized and is based upon age, underlying medical problems, and severity of illness (",
"      <a class=\"graphic graphic_table graphicRef72015 \" href=\"UTD.htm?28/35/29244\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CAP can be caused by a variety of microbial agents requiring a variety of infection-control measures. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive care for children hospitalized with pneumonia includes provision of adequate respiratory support, hydration, antipyresis, and analgesia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with CAP who are hospitalized are treated empirically until information from the microbiologic evaluation is available to direct therapy toward a specific pathogen. Decisions regarding empiric antimicrobial therapy for CAP in children are usually based upon age unless there are other overriding epidemiologic or clinical factors to suggest a specific etiologic agent (",
"      <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=see_link&amp;anchor=H14#H14\">",
"       \"Epidemiology, pathogenesis, and etiology of pneumonia in children\", section on 'Etiologic agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that empiric antibiotic therapy for presumed bacterial pneumonia in hospitalized children include coverage for",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      (",
"      <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Uncomplicated bacterial pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extended empiric coverage may be indicated for children with complicated or severe pneumonia, particularly those who require admission to an intensive care unit (",
"      <a class=\"graphic graphic_table graphicRef56260 \" href=\"UTD.htm?1/18/1327\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H96270984\">",
"       'Complicated CAP'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Severe CAP requiring ICU admission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When results of microbiologic tests are available, antibiotic therapy can be directed toward the specific pathogen recovered (",
"      <a class=\"graphic graphic_table graphicRef57150 \" href=\"UTD.htm?30/51/31550\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Specific therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral therapy typically is initiated when the patient has been afebrile for 24 to 48 hours and can tolerate oral intake. The total duration of antibiotic therapy is usually 7 to 10 days for uncomplicated CAP and up to four weeks in complicated CAP. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The respiratory status of children receiving appropriate therapy for CAP should improve within 48 to 72 hours. Children who fail to improve as anticipated may be receiving inadequate antibiotic therapy, have developed complications, or have an alternative or coincident diagnosis. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Treatment failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children recovering from CAP may continue to have cough for several weeks to four months, depending upon the etiology. Those recovering from typical or atypical bacterial pneumonia may have moderate dyspnea on exertion for two to three months. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Follow-up radiographs are not necessary in asymptomatic children with uncomplicated CAP. However, in children with complicated CAP or CAP that required intervention, follow-up radiographs help to ensure resolution. Follow-up radiographs two to three weeks after completion of therapy may be helpful in children with recurrent pneumonia, persistent symptoms, severe atelectasis, round pneumonia, or unusually located infiltrates. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most otherwise healthy children who develop pneumonia recover without any long-term sequelae. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/1\">",
"      Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/2\">",
"      Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/3\">",
"      Russell G. Community acquired pneumonia. Arch Dis Child 2001; 85:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/4\">",
"      McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/5\">",
"      Duncan H, Hutchison J, Parshuram CS. The Pediatric Early Warning System score: a severity of illness score to predict urgent medical need in hospitalized children. J Crit Care 2006; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. file://www.cdc.gov/hicpac/2007ip/2007isolationprecautions.html (Accessed on September 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/7\">",
"      Khoshoo V, Edell D. Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis. Pediatrics 1999; 104:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/8\">",
"      Singhi S, Dhawan A. Frequency and significance of electrolyte abnormalities in pneumonia. Indian Pediatr 1992; 29:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/9\">",
"      Dhawan A, Narang A, Singhi S. Hyponatraemia and the inappropriate ADH syndrome in pneumonia. Ann Trop Paediatr 1992; 12:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/10\">",
"      Britton S, Bejstedt M, Vedin L. Chest physiotherapy in primary pneumonia. Br Med J (Clin Res Ed) 1985; 290:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/11\">",
"      Levine A. Chest physical therapy for children with pneumonia. J Am Osteopath Assoc 1978; 78:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/12\">",
"      Stapleton T. Chest physiotherapy in primary pneumonia. Br Med J (Clin Res Ed) 1985; 291:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/13\">",
"      Paludo C, Zhang L, Lincho CS, et al. Chest physical therapy for children hospitalised with acute pneumonia: a randomised controlled trial. Thorax 2008; 63:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/14\">",
"      Lukrafka JL, Fuchs SC, Fischer GB, et al. Chest physiotherapy in paediatric patients hospitalised with community-acquired pneumonia: a randomised clinical trial. Arch Dis Child 2012; 97:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/15\">",
"      Low DE, Pichichero ME, Schaad UB. Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance. Clin Pediatr (Phila) 2004; 43:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/16\">",
"      Friis B, Andersen P, Bren&oslash;e E, et al. Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study. Arch Dis Child 1984; 59:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/17\">",
"      Esposito S, Bosis S, Cavagna R, et al. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. Clin Infect Dis 2002; 35:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/18\">",
"      Virkki R, Juven T, Rikalainen H, et al. Differentiation of bacterial and viral pneumonia in children. Thorax 2002; 57:438.",
"     </a>",
"    </li>",
"    <li>",
"     Mani CS, Murray DL. Acute pneumonia and its complications. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.235.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/20\">",
"      Pelton SI, Hammerschlag MR. Overcoming current obstacles in the management of bacterial community-acquired pneumonia in ambulatory children. Clin Pediatr (Phila) 2005; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/21\">",
"      Juv&eacute;n T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000; 19:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/22\">",
"      Korppi M, Heiskanen-Kosma T, Jalonen E, et al. Aetiology of community-acquired pneumonia in children treated in hospital. Eur J Pediatr 1993; 152:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/23\">",
"      Heiskanen-Kosma T, Korppi M, Jokinen C, et al. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J 1998; 17:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/24\">",
"      Trujillo M, McCracken GH Jr. Prolonged morbidity in children with group A beta-hemolytic streptococcal pneumonia. Pediatr Infect Dis J 1994; 13:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/25\">",
"      Drummond P, Clark J, Wheeler J, et al. Community acquired pneumonia--a prospective UK study. Arch Dis Child 2000; 83:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/26\">",
"      Bradley JS. Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. Pediatr Infect Dis J 2002; 21:592.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.799.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/28\">",
"      Buckingham SC, Brown SP, Joaquin VH. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr 1998; 132:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/29\">",
"      Dowell SF, Smith T, Leversedge K, Snitzer J. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis 1999; 29:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/30\">",
"      Atkinson M, Lakhanpaul M, Smyth A, et al. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. Thorax 2007; 62:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/31\">",
"      Flood RG, Badik J, Aronoff SC. The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children. Pediatr Infect Dis J 2008; 27:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/32\">",
"      Yamada M, Buller R, Bledsoe S, Storch GA. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr Infect Dis J 2012; 31:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/33\">",
"      Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/34\">",
"      Kaplan SL, Mason EO Jr, Barson WJ, et al. Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriazone in children treated with beta-lactam antibiotics. Pediatr Infect Dis J 2001; 20:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/35\">",
"      Bradley JS. Old and new antibiotics for pediatric pneumonia. Semin Respir Infect 2002; 17:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/36\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/37\">",
"      Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/38\">",
"      McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr 2011; 158:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/39\">",
"      Sandora TJ, Harper MB. Pneumonia in hospitalized children. Pediatr Clin North Am 2005; 52:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/40\">",
"      Hoffer FA, Bloom DA, Colin AA, Fishman SJ. Lung abscess versus necrotizing pneumonia: implications for interventional therapy. Pediatr Radiol 1999; 29:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/41\">",
"      Kerem E, Bar Ziv Y, Rudenski B, et al. Bacteremic necrotizing pneumococcal pneumonia in children. Am J Respir Crit Care Med 1994; 149:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/42\">",
"      McCarthy VP, Patamasucon P, Gaines T, Lucas MA. Necrotizing pneumococcal pneumonia in childhood. Pediatr Pulmonol 1999; 28:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/43\">",
"      Tan TQ, Seilheimer DK, Kaplan SL. Pediatric lung abscess: clinical management and outcome. Pediatr Infect Dis J 1995; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/44\">",
"      Rice TW, Ginsberg RJ, Todd TR. Tube drainage of lung abscesses. Ann Thorac Surg 1987; 44:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/45\">",
"      Zuhdi MK, Spear RM, Worthen HM, Peterson BM. Percutaneous catheter drainage of tension pneumatocele, secondarily infected pneumatocele, and lung abscess in children. Crit Care Med 1996; 24:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/46\">",
"      Emanuel B, Shulman ST. Lung abscess in infants and children. Clin Pediatr (Phila) 1995; 34:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/47\">",
"      Kunyoshi V, Cataneo DC, Cataneo AJ. Complicated pneumonias with empyema and/or pneumatocele in children. Pediatr Surg Int 2006; 22:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/48\">",
"      Ceruti E, Contreras J, Neira M. Staphylococcal pneumonia in childhood. Long-term follow-up including pulmonary function studies. Am J Dis Child 1971; 122:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/49\">",
"      Soto M, Demis T, Landau LI. Pulmonary function following staphylococcal pneumonia in children. Aust Paediatr J 1983; 19:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/50\">",
"      Amitai I, Mogle P, Godfrey S, Aviad I. Pneumatocele in infants and children. Report of 12 cases. Clin Pediatr (Phila) 1983; 22:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/51\">",
"      Dagan R, Syrogiannopoulos G, Ashkenazi S, et al. Parenteral-oral switch in the management of paediatric pneumonia. Drugs 1994; 47 Suppl 3:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/52\">",
"      Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/53\">",
"      Mandell LA, File TM Jr. Short-course treatment of community-acquired pneumonia. Clin Infect Dis 2003; 37:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/54\">",
"      Alves dos Santos JW, Torres A, Michel GT, et al. Non-infectious and unusual infectious mimics of community-acquired pneumonia. Respir Med 2004; 98:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/55\">",
"      Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/56\">",
"      Lahti E, Peltola V, Waris M, et al. Induced sputum in the diagnosis of childhood community-acquired pneumonia. Thorax 2009; 64:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/57\">",
"      Morales JO, Snead H. Efficacy and safety of intravenous cefotaxime for treating pneumonia in outpatients. Am J Med 1994; 97:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/58\">",
"      Esposito S. Treatment of lower respiratory tract infections in Italy: the role of outpatient parenteral antibiotic therapy. Chemotherapy 2001; 47 Suppl 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/59\">",
"      Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004; 38:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/60\">",
"      Gaston B. Pneumonia. Pediatr Rev 2002; 23:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/61\">",
"      Jadavji T, Law B, Lebel MH, et al. A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ 1997; 156:S703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/62\">",
"      Griscom NT. Pneumonia in children and some of its variants. Radiology 1988; 167:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/63\">",
"      McLennan MK. Radiology rounds. Round pneumonia. Can Fam Physician 1998; 44:751, 757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/64\">",
"      Kim YW, Donnelly LF. Round pneumonia: imaging findings in a large series of children. Pediatr Radiol 2007; 37:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/65\">",
"      Eggli KD, Newman B. Nodules, masses, and pseudomasses in the pediatric lung. Radiol Clin North Am 1993; 31:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/66\">",
"      Rose RW, Ward BH. Spherical pneumonias in children simulating pulmonary and mediastinal masses. Radiology 1973; 106:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/67\">",
"      Donnelly LF. Maximizing the usefulness of imaging in children with community-acquired pneumonia. AJR Am J Roentgenol 1999; 172:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/68\">",
"      Grossman LK, Wald ER, Nair P, Papiez J. Roentgenographic follow-up of acute pneumonia in children. Pediatrics 1979; 63:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/69\">",
"      Virkki R, Juven T, Mertsola J, Ruuskanen O. Radiographic follow-up of pneumonia in children. Pediatr Pulmonol 2005; 40:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/70\">",
"      Gibson NA, Hollman AS, Paton JY. Value of radiological follow up of childhood pneumonia. BMJ 1993; 307:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/71\">",
"      Heaton P, Arthur K. The utility of chest radiography in the follow-up of pneumonia. N Z Med J 1998; 111:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/72\">",
"      Wacogne I, Negrine RJ. Are follow up chest x ray examinations helpful in the management of children recovering from pneumonia? Arch Dis Child 2003; 88:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/73\">",
"      Sur&eacute;n P, Try K, Eriksson J, et al. Radiographic follow-up of community-acquired pneumonia in children. Acta Paediatr 2008; 97:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/74\">",
"      Bruckheimer E, Dolberg S, Shlesinger Y, et al. Primary lung abscess in infancy. Pediatr Pulmonol 1995; 19:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/75\">",
"      Clark CE, Coote JM, Silver DA, Halpin DM. Asthma after childhood pneumonia: six year follow up study. BMJ 2000; 320:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/76\">",
"      Eastham KM, Hammal DM, Parker L, Spencer DA. A follow-up study of children hospitalised with community-acquired pneumonia. Arch Dis Child 2008; 93:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/77\">",
"      Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/48/25354/abstract/78\">",
"      Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6054 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25354=[""].join("\n");
var outline_f24_48_25354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HOSPITALIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications for intensive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antipyresis and analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Respiratory support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fluid management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chest physiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EMPIRIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Etiologic clues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Viral pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H275031\">",
"      - Influenza pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Uncomplicated bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Atypical pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Severe CAP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Severe CAP requiring ICU admission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H96270984\">",
"      Complicated CAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nosocomial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Aspiration pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Immunocompromised host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SPECIFIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DURATION OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Parenteral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Total duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Uncomplicated cases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Complicated cases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      DISCHARGE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Outpatient parenteral antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Radiographs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6054\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6054|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/35/29244\" title=\"table 1\">",
"      Severity of pneumonia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/18/1327\" title=\"table 2\">",
"      Empiric IV rx pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/2/22573\" title=\"table 3\">",
"      Etiologic clues to pediatric pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/11/13500\" title=\"table 4\">",
"      Types allergic reactions SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/51/31550\" title=\"table 5\">",
"      Specific rx pneumonia children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/59/9149\" title=\"table 6\">",
"      Pediatric pneumonia history",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=related_link\">",
"      Continuous oxygen delivery systems for infants, children, and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/40/37513?source=related_link\">",
"      Diagnosis and treatment of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/55/2938?source=related_link\">",
"      Epidemiology, pathogenesis, and etiology of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=related_link\">",
"      Management and prognosis of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27369?source=related_link\">",
"      Outpatient treatment of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/17/14611?source=related_link\">",
"      Patient information: Pneumonia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=related_link\">",
"      Pneumococcal pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33062?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) species in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38327?source=related_link\">",
"      Respiratory syncytial virus infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13146?source=related_link\">",
"      The common cold in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_48_25355="NSAID dosing in recurrent pericarditis";
var content_f24_48_25355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NSAID dosing in recurrent pericarditis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Attack dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment length",
"       </td>",
"       <td class=\"subtitle1\">",
"        Monitoring",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tapering*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibuprofen",
"       </td>",
"       <td>",
"        600 to 800 mg three times daily",
"       </td>",
"       <td>",
"        1 to 2 weeks*",
"       </td>",
"       <td>",
"        Blood cell count, CRP",
"       </td>",
"       <td>",
"        Decrease the dose every 1 to 2 weeks once CRP has normalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indomethacin",
"       </td>",
"       <td>",
"        50 mg three times daily",
"       </td>",
"       <td>",
"        1 to 2 weeks*",
"       </td>",
"       <td>",
"        Blood cell count, CRP",
"       </td>",
"       <td>",
"        Decrease the total daily dose by 25 mg every 1 to 2 weeks once CRP has normalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin",
"       </td>",
"       <td>",
"        650 to 1000 mg three times daily",
"       </td>",
"       <td>",
"        1 to 2 weeks*",
"       </td>",
"       <td>",
"        Blood cell count, CRP",
"       </td>",
"       <td>",
"        Decrease the dose every 1 to 2 weeks once CRP has normalized",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CRP: C-reactive protein.",
"     <br>",
"      * Therapy should be tailored according to symptoms, markers of inflammation elevation.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25355=[""].join("\n");
var outline_f24_48_25355=null;
var title_f24_48_25356="Cyst malformations";
var content_f24_48_25356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Malformative disorders associated with renal cyst formation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main extrarenal manifestations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehlers-Danlos",
"       </td>",
"       <td>",
"        Joint hyperextensibility, increased stretchability of skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elejalde",
"       </td>",
"       <td>",
"        Acrocephalopolydactylous dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ellis-van Creveld",
"       </td>",
"       <td>",
"        Chondroectodermal dysplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Geominne",
"       </td>",
"       <td>",
"        Torticollis, multiple keloids, cryptorchidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goldston",
"       </td>",
"       <td>",
"        Dandy-Walker malformation, cerebellar malformations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ivemark",
"       </td>",
"       <td>",
"        Spleen agenesis, cyanotic heart disease, gut malrotation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jeune",
"       </td>",
"       <td>",
"        Asphyxiating thoracic dystrophy, short limb dwarfism, hypoplastic iliac wings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laurence-Moon-Bardet-Biedl",
"       </td>",
"       <td>",
"        Mental retardation, obesity, polydactyly, retinopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meckel-Gruber",
"       </td>",
"       <td>",
"        Posterior encephalocoele, cleft palate, polydactyly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melnick-Fraser",
"       </td>",
"       <td>",
"        Branchial fistulas, preauricular pits, hearing loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papillon-Leage-Psaume",
"       </td>",
"       <td>",
"        Oral frenula, cleft tongue, digital malformations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Passarge",
"       </td>",
"       <td>",
"        Hypotonia, abnormal ears, hepatomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Roberts",
"       </td>",
"       <td>",
"        Tetraphocomelia, cleft lip, genital hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trisomy 13 (Patau)",
"       </td>",
"       <td>",
"        Microcephaly, cleft lip, digital anomalies, mental retardation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trisomy 18 (Edwards)",
"       </td>",
"       <td>",
"        Overlapping fingers, foot deformities, muscular hypertonicity, neonatal hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trisomy 21 (Down)",
"       </td>",
"       <td>",
"        Brachycephaly, epicanthal folds, hypotonia, congenital heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zellweger",
"       </td>",
"       <td>",
"        Brain malformations, craniofacial dysmorphism, limb deformities, metabolic defect",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Extrarenal manifestations of the major malformative syndromes associated with renal cyst formation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25356=[""].join("\n");
var outline_f24_48_25356=null;
var title_f24_48_25357="Treatment of TB in children";
var content_f24_48_25357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of tuberculosis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnostic category",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Regimen",
"        <br/>",
"        (daily or three times weekly)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        New cases",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Intensive phase",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Continuation phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         New smear-positive pulmonary TB",
"        </p>",
"        <p>",
"         New smear-negative pulmonary TB with extensive parenchymal involvement",
"        </p>",
"        <p>",
"         Severe forms of extrapulmonary TB (not including meningitis or osteoarticular disease)",
"        </p>",
"        <p>",
"         Severe concomitant HIV disease",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         INH",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        <p>",
"         PZA",
"        </p>",
"        <p>",
"         EMB",
"        </p>",
"        <p>",
"         (2 months)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         INH",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        <p>",
"         (4 months)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TB meningitis (see text)",
"       </td>",
"       <td>",
"        <p>",
"         INH",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        <p>",
"         PZA",
"        </p>",
"        <p>",
"         SM or AM or Eto",
"        </p>",
"        <p>",
"         (2 months)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         INH",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        <p>",
"         (7 to 10 months)",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Osteoarticular TB",
"       </td>",
"       <td>",
"        <p>",
"         INH",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        <p>",
"         PZA",
"        </p>",
"        <p>",
"         EMB",
"        </p>",
"        (2 months)",
"       </td>",
"       <td>",
"        <p>",
"         INH",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        (7 to 10 months)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         New smear-negative pulmonary TB (other than above categories)",
"        </p>",
"        <p>",
"         Less severe forms of extrapulmonary TB",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         INH",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        <p>",
"         PZA",
"        </p>",
"        <p>",
"         (2 months)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         INH",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        <p>",
"         (4 months)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Previously treated cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Smear-positive pulmonary TB",
"        <br/>",
"        <ul>",
"         <li>",
"          Relapse",
"         </li>",
"         <li>",
"          Treatment after interruption",
"         </li>",
"         <li>",
"          Treatment failure",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         INH",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        <p>",
"         PZA",
"        </p>",
"        <p>",
"         EMB",
"        </p>",
"        <p>",
"         SM",
"        </p>",
"        <p>",
"         (2 months)",
"        </p>",
"        <hr/>",
"        <p>",
"         <strong>",
"          Followed by",
"         </strong>",
"        </p>",
"        <p>",
"         INH",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        <p>",
"         PZA",
"        </p>",
"        <p>",
"         EMB",
"        </p>",
"        <p>",
"         (1 month)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         INH",
"        </p>",
"        <p>",
"         RIF",
"        </p>",
"        <p>",
"         EMB",
"        </p>",
"        <p>",
"         (5 months)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic and MDR-TB",
"       </td>",
"       <td colspan=\"2\">",
"        Individualized regimens",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TB: tuberculosis; INH: isoniazid; RIF: rifampin (rifampicin); PZA: pyrazinamide; EMB: ethambutol; SM: streptomycin; AM: amikacin; Eto: ethionomide; HIV: human immunodeficiency virus; MDR-TB: multidrug resistant TB.",
"     <br/>",
"     * Direct observation of drug administration is recommended. Intermittent therapy (two or three times weekly) is not recommended for children with HIV infection.",
"     <br/>",
"     &Delta; For treatment of meningitis, EMB is replaced by SM or Am or Eto. The decision about which drug to use may be guided by drug susceptibility data of the index case if available, or country-level rates of specific drug resistance.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     EMB may be omitted during the initial phase of treatment for patients in the following categories:",
"     <br/>",
"     <ul>",
"      <li>",
"       Patients with non-cavitary, smear-negative pulmonary TB and known to be HIV-negative",
"      </li>",
"      <li>",
"       Patients known to be infected with fully drug-susceptible bacilli",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Rapid Advice: Treatment of tuberculosis in children. World Health Organization, Geneva, 2010. (WHO/HTM/TB/2010.13).",
"      </li>",
"     </ol>",
"     <br/>",
"     Reproduced with permission from: World Health Organization, Childhood TB Subgroup. Guidance for national tuberculosis programmes on the management of tuberculosis in children, Geneva. Available at file://whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf. Copyright &copy; 2006 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25357=[""].join("\n");
var outline_f24_48_25357=null;
var title_f24_48_25358="Etiology cardiomyopathy outcome";
var content_f24_48_25358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Outcome with a cardiomyopathy is related to the etiology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 329px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 1230 patients with a cardiomyopathy of various etiologies, the adjusted Kaplan-Meier estimates of survival is related to the underlying cause of cardiomyopathy; only idiopathic cardiomyopathy and cardiomyopathy due to causes for which survival was significantly different from that in patients with idiopathic cardiomyopathy are shown. The best outcome is in those with a peripartum cardiomyopathy and the worst outcome is in those with an infiltrative cardiomyopathy or that due to HIV infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Felker, CM, Thompson, RE, Hare, JM, et al. N Engl J Med 2000; 342:1077.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25358=[""].join("\n");
var outline_f24_48_25358=null;
var title_f24_48_25359="MUNE statistical method";
var content_f24_48_25359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Motor unit number estimation (MUNE) by the statistical method",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 444px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Recordings from a normal patient (left) and a patient with denervating disease (right). For each patient, a series of 30 progressively more intense stimuli (x axis) are plotted against the size of the waveforms, expressed as a percentage of the full compound motor action potential (CMAP) area (y axis). The superimposed waveforms resulting from the 30 stimuli appear above each graph. The smooth progression of small incremental steps in the normal patient (left) contrasts markedly with the curve of the patient with denervating disease, which is interrupted by numerous large increments corresponding with larger, reinnervated single motor unit action potentials (S-MUAPs).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Daube JR. Estimating the number of motor units in a muscle. J Clin Neurophysiol 1995; 12:585. Copyright &copy; 1995 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_48_25359=[""].join("\n");
var outline_f24_48_25359=null;
